PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16769988-0	2006	Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?	Epirubicin	102-112	colony stimulating factor 3	Homo sapiens	5-42
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	Epirubicin	160-170	colony stimulating factor 3	Homo sapiens	37-74
16769988-1	2006	PURPOSE: We report on the effects of granulocyte colony-stimulating factor (G-CSF) on hemoglobin (Hb) value in early breast cancer patients receiving high-dose epirubicin and cyclophosphamide (EC) adjuvant treatment.	Epirubicin	160-170	colony stimulating factor 3	Homo sapiens	76-81
16357174-6	2005	In vivo therapy studies in a series of xenograft models featuring overexpression of EGFR and/or EGFRvIII showed the superiority of immunoliposomal delivery of encapsulated drugs, which included doxorubicin, epirubicin, and vinorelbine.	Epirubicin	207-217	epidermal growth factor receptor	Homo sapiens	84-88
16444429-0	2006	The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer.	Epirubicin	35-45	carboxypeptidase B2	Homo sapiens	79-83
16444429-0	2006	The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer.	Epirubicin	35-45	serpin family E member 1	Homo sapiens	88-93
17318948-6	2006	FAC (5 fluorouracil/doxorubicin/cyclophosphamide/methotrexate/5 fluorouracil), higher doses of epirubicin in FE(100)C are twice as high compared with FAC.	Epirubicin	95-105	FA complementation group C	Homo sapiens	0-3
16640345-3	2006	Effective concentrations for overcoming mdr have been demonstrated in competition studies with the P-gp substrate epirubicin.	Epirubicin	114-124	ATP binding cassette subfamily B member 1	Homo sapiens	99-103
16331277-4	2006	Conversely, restoration of procaspase-3 sensitizes MCF-7 cells to chemotherapeutics including epirubicine, etoposide and taxol.	Epirubicin	94-105	caspase 3	Homo sapiens	27-39
16628497-6	2006	We have demonstrated that the selection by epirubicin actually elevated the level of the multidrug resistance-associated protein (MRP1) gene.	Epirubicin	43-53	ATP binding cassette subfamily C member 1	Homo sapiens	89-134
16137437-0	2005	HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.	Epirubicin	134-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
16334129-1	2005	BACKGROUND: Epirubicin (EPX) has been found to be active in hormone-refractory prostate cancer (HRPC) patients.	Epirubicin	12-22	eosinophil peroxidase	Homo sapiens	24-27
16234514-1	2005	PURPOSE: The aim of the study was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients.	Epirubicin	134-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-74
16234514-1	2005	PURPOSE: The aim of the study was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients.	Epirubicin	134-144	DNA topoisomerase II alpha	Homo sapiens	107-112
16234514-8	2005	CONCLUSION: TOP2A amplification-and possibly deletion-seems to be predictive markers for the effect of adjuvant epirubicin containing therapy in primary breast cancer, but a final conclusion has to await a confirmative study or a meta-analysis.	Epirubicin	112-122	DNA topoisomerase II alpha	Homo sapiens	12-17
16234551-0	2005	Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.	Epirubicin	53-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	68-73
16026610-6	2005	RESULTS: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp.	Epirubicin	134-144	ATP binding cassette subfamily B member 1	Homo sapiens	88-116
16109560-1	2005	OBJECTIVE: To observe the expression of Bcl-2 and Bax proteins and cell apoptosis induced by preoperative lymphatic chemotherapy with epirubicin-activated carbon suspension (Epi-CH) in the cells of axillary metastatic lymph node of breast cancer and investigate the mechanism.	Epirubicin	134-144	BCL2 apoptosis regulator	Homo sapiens	40-45
16109560-1	2005	OBJECTIVE: To observe the expression of Bcl-2 and Bax proteins and cell apoptosis induced by preoperative lymphatic chemotherapy with epirubicin-activated carbon suspension (Epi-CH) in the cells of axillary metastatic lymph node of breast cancer and investigate the mechanism.	Epirubicin	134-144	BCL2 associated X, apoptosis regulator	Homo sapiens	50-53
16026610-6	2005	RESULTS: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp.	Epirubicin	134-144	ATP binding cassette subfamily B member 1	Homo sapiens	118-122
16026610-6	2005	RESULTS: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp.	Epirubicin	134-144	ATP binding cassette subfamily B member 1	Homo sapiens	249-254
16026610-6	2005	RESULTS: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp.	Epirubicin	134-144	phosphoglycolate phosphatase	Homo sapiens	272-276
15273737-3	2004	TNFalpha pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide.	Epirubicin	106-116	tumor necrosis factor	Homo sapiens	0-8
15738535-0	2005	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.	Epirubicin	116-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	180-214
15865083-3	2005	G-CSF was administered during epirubicin-vinorelbine treatment.	Epirubicin	30-40	colony stimulating factor 3	Homo sapiens	0-5
15685822-1	2004	The tAnGo trial is a randomized, open-label, multicenter phase III trial examining adjuvant treatment with epirubicin (Ellence)/cyclophosphamide (Cytoxan, Neosar) for four cycles followed by paclitaxel alone or combined with gemcitabine (Gemzar) for four cycles in patients with early-stage breast cancer.	Epirubicin	107-117	MIA SH3 domain ER export factor 3	Homo sapiens	4-9
15685822-1	2004	The tAnGo trial is a randomized, open-label, multicenter phase III trial examining adjuvant treatment with epirubicin (Ellence)/cyclophosphamide (Cytoxan, Neosar) for four cycles followed by paclitaxel alone or combined with gemcitabine (Gemzar) for four cycles in patients with early-stage breast cancer.	Epirubicin	119-126	MIA SH3 domain ER export factor 3	Homo sapiens	4-9
15970926-9	2005	Our data suggest a potential role of HER-2 overexpression in predicting the efficacy of dose-dense epirubicin-containing chemotherapy and the need to confirm this hypothesis in future prospective studies.	Epirubicin	99-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-42
15864700-6	2005	MEC (methotrexate, epirubicin, and cisplatin) chemotherapy had efficacy similar to that of the MVAC regimen.	Epirubicin	19-29	C-C motif chemokine ligand 28	Homo sapiens	0-3
15685835-3	2004	With the addition of granulocyte colony-stimulating factor (G-CSF [Neupogen]) to the regimen, patients received epirubicin at clinically relevant doses after dose-escalation.	Epirubicin	112-122	colony stimulating factor 3	Homo sapiens	21-58
15685835-3	2004	With the addition of granulocyte colony-stimulating factor (G-CSF [Neupogen]) to the regimen, patients received epirubicin at clinically relevant doses after dose-escalation.	Epirubicin	112-122	colony stimulating factor 3	Homo sapiens	60-65
15467752-9	2004	Stable overexpression of Bak in DU145 sensitized for epirubicin-induced apoptosis but failed to confer synergy between TRAIL and 5-FU.	Epirubicin	53-63	BCL2 antagonist/killer 1	Homo sapiens	25-28
15273737-3	2004	TNFalpha pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide.	Epirubicin	106-116	caspase 3	Homo sapiens	68-77
15193230-1	2004	AIM: To detect the expression and status of extracellular regulatory kinase 1 and 2 (ERK1/2) and its upstream kinase MEK1/2 proteins in four breast cancer cell lines MCF-7, Bcap-37, SK-BR-3 and T47D and study the effects of cyclophosphamide and epirubicin on the growth of the cell lines and on the expression and status of the signaling molecules.	Epirubicin	245-255	mitogen-activated protein kinase 3	Homo sapiens	85-91
15685929-1	2004	Accumulating evidence suggests the concept that epirubicin and lymphokine-activated killer (LAK) cells cytotoxicity may be mediated by free radicals generation and P-glycoprotein-positive (Pg-p+) cancer cells are more sensitive for LAK cells than their drug-sensitive parental lines.	Epirubicin	48-58	ATP binding cassette subfamily B member 1	Homo sapiens	164-178
15685929-10	2004	The resistance of MCF-7 EPI(R) cells to epirubicin appears to be associated with a developed tolerance to superoxide, most likely because of a tree-fold increase in superoxide dismutase (SOD) activity and 13-fold augmented selenium dependent glutathione peroxidase (GSH-Px) activity.	Epirubicin	40-50	superoxide dismutase 1	Homo sapiens	187-190
15685929-12	2004	The addition of SOD decreased cytotoxicity of epirubicin and LAK cells.	Epirubicin	46-56	superoxide dismutase 1	Homo sapiens	16-19
15292386-2	2004	In this retrospective subset analysis of patients with metastatic breast cancer enrolled in a randomized treatment trial, we investigated the response of patients with known HER-2/neu status to treatment with taxane-based epirubicin-paclitaxel (ET) chemotherapy compared with treatment with epirubicin-cyclophosphamide (EC) chemotherapy.	Epirubicin	222-232	erb-b2 receptor tyrosine kinase 2	Homo sapiens	174-183
15520498-7	2004	The mechanism of cytotoxicity of epirubicin HCl (IC(50) value of 1.6 mug/ml within 24 h) appeared to involve a production of free radical species since activities of free radical scavenging enzymes (SOD, catalase, Se-dependent GPx) were increased.	Epirubicin	33-47	superoxide dismutase 1	Homo sapiens	199-202
15520498-7	2004	The mechanism of cytotoxicity of epirubicin HCl (IC(50) value of 1.6 mug/ml within 24 h) appeared to involve a production of free radical species since activities of free radical scavenging enzymes (SOD, catalase, Se-dependent GPx) were increased.	Epirubicin	33-47	catalase	Homo sapiens	204-212
15520498-8	2004	Addition of SOD prevented cytotoxicity of epirubicin HCl, and also counteracted the apoptosis.	Epirubicin	42-56	superoxide dismutase 1	Homo sapiens	12-15
15093573-2	2004	HER2-positive patients received standard-dose trastuzumab plus epirubicin (60 or 90 mg/m(2))/cyclophosphamide (600 mg/m(2)) 3-weekly (EC60+H, n=26; EC90+H, n=25), for four to six cycles; 23 HER2-negative patients received EC alone (90/600 mg/m(2)) 3-weekly for six cycles (EC90).	Epirubicin	63-73	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
15173086-9	2004	In contrast, patients with high (99m)Tc-MIBI accumulation show a higher response rate (41.7%) to chemotherapy with epirubicin, which is known to be a substrate of P-gp transporter.	Epirubicin	115-125	ATP binding cassette subfamily B member 1	Homo sapiens	163-167
15274385-3	2004	In a previous multicenter phase I study, we recommended two schedules of epirubicin-docetaxel combination for MBC: 1) epirubicin 75 mg/m2, docetaxel 80 mg/m2 every 3 weeks without G-CSF; 2) epirubicin 90 mg/m2 plus docetaxel 90 mg/m2 every 3 weeks, with G-CSF support.	Epirubicin	73-83	coiled-coil domain containing 112	Homo sapiens	110-116
15193230-8	2004	The inhibitory effect of cyclophosphamide and epirubicin on proliferation of the breast cancer cells may be by means of inhibiting expression and phosphorylation of MEK and ERK.	Epirubicin	46-56	mitogen-activated protein kinase kinase 7	Homo sapiens	165-168
15193230-8	2004	The inhibitory effect of cyclophosphamide and epirubicin on proliferation of the breast cancer cells may be by means of inhibiting expression and phosphorylation of MEK and ERK.	Epirubicin	46-56	mitogen-activated protein kinase 1	Homo sapiens	173-176
14754410-4	2004	Over-expression of ABCG2 in cell lines confers resistance on a wide variety of anticancer drugs including mitoxantrone, daunorubicin, doxorubicin, topotecan and epirubicin.	Epirubicin	161-171	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	19-24
15161039-12	2004	A synergistic interaction between epirubicin and the silicon-substituted resistance modifiers was found only in MDR1-mediated MDR in the case of colo-320/MDR1-LRP cells and mouse lymphoma cells transfected with the human MDR1 gene.	Epirubicin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
15161039-12	2004	A synergistic interaction between epirubicin and the silicon-substituted resistance modifiers was found only in MDR1-mediated MDR in the case of colo-320/MDR1-LRP cells and mouse lymphoma cells transfected with the human MDR1 gene.	Epirubicin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	154-158
15161039-12	2004	A synergistic interaction between epirubicin and the silicon-substituted resistance modifiers was found only in MDR1-mediated MDR in the case of colo-320/MDR1-LRP cells and mouse lymphoma cells transfected with the human MDR1 gene.	Epirubicin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	154-158
15009365-6	2004	RESULTS: Treatment of ACHN and Caki-1 human RCC lines with TRAIL, in combination with subtoxic concentrations of epirubicin (EPI) or pirarubicin (THP), enhanced induction of apoptosis and cytotoxicity.	Epirubicin	113-123	TNF superfamily member 10	Homo sapiens	59-64
14557375-3	2003	Treatment with doxorubicin or epirubicin resulted in increased phospho-p44/42-MAPK levels in a time- and concentration-dependent manner.	Epirubicin	30-40	interferon induced protein 44	Homo sapiens	71-74
15110186-4	2004	Studies from our laboratory have also shown that TRAIL-resistant renal cell carcinoma, prostate gland cancer, and bladder cancer cells are sensitized by subtoxic concentrations of chemotherapeutic drugs including doxorubicin, epirubicin, pirarubicin, and cisplatin.	Epirubicin	226-236	TNF superfamily member 10	Homo sapiens	49-54
14703068-0	2003	Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.	Epirubicin	38-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
14703068-0	2003	Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.	Epirubicin	38-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-92
14703068-2	2003	Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu.	Epirubicin	36-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	230-238
14532987-6	2003	We show that p53-deficient cells were 2 to 3-fold resistant to treatment with doxorubicin, epirubicin, cisplatin, and docetaxel as compared to wild-type cells.	Epirubicin	91-101	transformation related protein 53, pseudogene	Mus musculus	13-16
14612912-5	2003	Cells transfected with mutant ABCG2 were 13- to 71- fold resistant to the P-glycoprotein substrates doxorubicin, daunorubicin, epirubicin, bisantrene, and rhodamine 123 compared to cells transfected with wild-type ABCG2, which were only three- to four-fold resistant to these compounds.	Epirubicin	127-137	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35
14532987-7	2003	We further demonstrate that the additional loss of DNA-PKcs function in p53-deficient cells resulted in a 2-fold increase in sensitivity to doxorubicin and epirubicin as documented by the MTT assay, clonogenic assay, and trypan blue exclusion.	Epirubicin	156-166	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	51-59
12852361-0	2003	[A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab].	Epirubicin	179-189	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
14532987-7	2003	We further demonstrate that the additional loss of DNA-PKcs function in p53-deficient cells resulted in a 2-fold increase in sensitivity to doxorubicin and epirubicin as documented by the MTT assay, clonogenic assay, and trypan blue exclusion.	Epirubicin	156-166	transformation related protein 53, pseudogene	Mus musculus	72-75
14522926-6	2003	The degree of iPLA(2) inhibition by equimolar concentrations of epirubicin and idarubicin was significantly less than that of doxorubicin or daunorubicin, which correlates with the reported in vivo cardiotoxicity of these drugs.	Epirubicin	64-74	phospholipase A2 group VI	Rattus norvegicus	14-21
14680568-3	2003	An orthotopic mdr1 hepatoma was produced by implanting the tumor fragment subserosally to the mice liver, and intermittent chemotherapy with Pharmorubicin given to induce drug resistance.	Epirubicin	141-154	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-18
14680568-8	2003	The expressions of mdr1-mRNA and p-gp in the Pharmorubicin group were 23 folds and 13 folds of the control group, respectively.	Epirubicin	45-58	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-23
14680568-8	2003	The expressions of mdr1-mRNA and p-gp in the Pharmorubicin group were 23 folds and 13 folds of the control group, respectively.	Epirubicin	45-58	phosphoglycolate phosphatase	Mus musculus	33-37
12796033-6	2003	Loss of ATM function did not result in increased apoptosis, but resulted in increased Trypan Blue staining in response to epirubicin, suggesting that processes other than apoptosis may mediate cytotoxicity.	Epirubicin	122-132	ataxia telangiectasia mutated	Mus musculus	8-11
12576456-10	2003	For lung resistance-related protein, this association was limited to 5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide.	Epirubicin	96-106	major vault protein	Homo sapiens	4-35
12926135-0	2003	Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.	Epirubicin	14-24	colony stimulating factor 3	Homo sapiens	38-75
12820428-3	2003	The present study was undertaken to determine if there is a correlation between the expression of CD40 in spindle-cell sarcomas and the response to epirubicin and ifosfamide chemotherapy.	Epirubicin	148-158	CD40 molecule	Homo sapiens	98-102
12419756-8	2002	The highest administered dose level with G-CSF was docetaxel 85 mg/m(2) and epirubicin 105 mg/m(2) with DLTs in five of six patients.	Epirubicin	76-86	colony stimulating factor 3	Homo sapiens	41-46
12899502-13	2003	In line with the observations of others conducting phase II first-line trials combining vinorelbine and epirubicin, it is concluded that the NEF regimen is effective in metastatic breast cancer.	Epirubicin	104-114	S100 calcium binding protein B	Homo sapiens	141-144
12576456-8	2003	However, in the subgroup of patients treated with anthracycline-based chemotherapy (5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide), a correlation between response and the expression of BCRP and MRP1 (only PFS) was found, whereas such an association was not present in the cyclophosphamide, methotrexate, and 5-fluorouracil-treated group of patients.	Epirubicin	111-121	BCR pseudogene 1	Homo sapiens	199-203
12576456-8	2003	However, in the subgroup of patients treated with anthracycline-based chemotherapy (5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide), a correlation between response and the expression of BCRP and MRP1 (only PFS) was found, whereas such an association was not present in the cyclophosphamide, methotrexate, and 5-fluorouracil-treated group of patients.	Epirubicin	111-121	ATP binding cassette subfamily C member 1	Homo sapiens	208-212
12589037-11	2003	Resistance to doxorubicin and its analogue, epirubicin, were positively correlated with topoisomerase II beta expression, whereas it negatively correlated with expression of carboxypeptidases A3 and Z.	Epirubicin	44-54	DNA topoisomerase II beta	Homo sapiens	88-109
12613518-0	2002	Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.	Epirubicin	15-25	DNA damage inducible transcript 3	Homo sapiens	46-50
12297834-4	2002	Epirubicin-selected HB8065/R cells were used as MDR1-P-glycoprotein-overexpressing cells.	Epirubicin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
12297834-4	2002	Epirubicin-selected HB8065/R cells were used as MDR1-P-glycoprotein-overexpressing cells.	Epirubicin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
12297834-6	2002	AFP promoter-driven anti-MDR1 ribozymes reduced the IC(50) 30-fold for epirubicin in HCC cells, whereas human colorectal cancer cells were unaffected.	Epirubicin	71-81	alpha fetoprotein	Homo sapiens	0-3
12297834-6	2002	AFP promoter-driven anti-MDR1 ribozymes reduced the IC(50) 30-fold for epirubicin in HCC cells, whereas human colorectal cancer cells were unaffected.	Epirubicin	71-81	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
12297834-8	2002	Adenoviral delivery of CMV promoter-driven anti-MDR1 ribozymes resulted in a reduced IC(50) for epirubicin and doxorubicin (60- and 20-fold, respectively).	Epirubicin	96-106	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
12039931-12	2002	CONCLUSION: The epirubicin-vinorelbine combination with G-CSF support has been shown in this study to be highly active as first-line treatment of metastatic breast cancer patients, with significant although transient toxicity.	Epirubicin	16-26	colony stimulating factor 3	Homo sapiens	56-61
12174947-3	2002	After administration of chemotherapy consisting of 5-fluorouracil (4000 mg) and epirubicin (280 mg), the pulmonary metastases disappeared and this was associated with a decrease of serum CEA levels and tumor size.	Epirubicin	80-90	CEA cell adhesion molecule 3	Homo sapiens	187-190
11956588-8	2002	Synergistic cytotoxicity was also obtained even when the exposure time was shortened from 24 to 8 or 2 h. A similar effect was achieved with TRAIL in combination with epirubicin, pirarubicin, or amrubicin.	Epirubicin	167-177	TNF superfamily member 10	Homo sapiens	141-146
11466674-8	2001	CONCLUSIONS: T/N(d) ratios determined by (99m)Tc-MIBI scintigraphy are useful in the prediction of response to chemotherapy with epirubicin and cyclophosphamide or docetaxel as well as in the in vivo evaluation of P-gp expression status in tumors in patients with locally advanced or recurrent breast carcinoma.	Epirubicin	129-139	phosphoglycolate phosphatase	Homo sapiens	214-218
12209450-2	2002	The tested catechols were found to reduce the light emission accompanying oxidation of farmorubicin by Co(II) + H2O2 and Cu(II) + H2O2 mixtures.	Epirubicin	87-99	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	103-109
11762812-0	2001	A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.	Epirubicin	20-30	ECT	Homo sapiens	84-87
11759828-2	2001	It was the purpose of this in vitro study to define the association between HER-2/neu overexpression and the sensitivity to the chemotherapeutic drug combinations of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and 5-fluorouracil, epirubicin and cyclophosphamide (FEC) of breast cancer cells derived from 140 chemotherapy-naive patients at the time of primary surgery.	Epirubicin	242-252	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-85
11477562-5	2001	Loss of either MSH2 or MLH1 function resulted in resistance to the topoisomerase II poisons doxorubicin, epirubicin and mitoxantrone, whereas only loss of MLH1 function was associated with low-level resistance to the topoisomerase I poisons camptothecin and topotecan.	Epirubicin	105-115	mutS homolog 2	Homo sapiens	15-19
11477562-5	2001	Loss of either MSH2 or MLH1 function resulted in resistance to the topoisomerase II poisons doxorubicin, epirubicin and mitoxantrone, whereas only loss of MLH1 function was associated with low-level resistance to the topoisomerase I poisons camptothecin and topotecan.	Epirubicin	105-115	mutL homolog 1	Homo sapiens	23-27
11583189-0	2001	HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.	Epirubicin	149-159	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-32
11583189-11	2001	CONCLUSIONS: This study suggests that in node-positive breast cancer patients randomly treated with CMF or an epirubicin-based regimen, the predictive value of HER-2 may vary according to the Abs used in the immunohistochemistry assay.	Epirubicin	110-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	160-165
11583191-9	2001	At the third step (epirubicin 90 mg/m2) G-CSF allowed a safe escalation of docetaxel up to 90 mg/m2.	Epirubicin	19-29	colony stimulating factor 3	Homo sapiens	40-45
12432274-6	2002	The results showed that epirubicin damaged tumor microvessels when the drug was given as a single dose, whereas epirubicin lost its vascular toxicity when the drug was given continuously for seven days, accompanied by higher levels of VEGF in tumor tissues.	Epirubicin	112-122	vascular endothelial growth factor A	Homo sapiens	235-239
11935300-6	2002	RESULTS: Ex vivo chemosensitivity testing showed that tumors with p53 mutations were significantly more resistant to the cyclophosphamide/etoposide/epirubicin regimen than with normal p53 gene ( P = 0.012).	Epirubicin	148-158	tumor protein p53	Homo sapiens	66-69
11818250-1	2002	P-glycoprotein (P-GP) is known to be a multidrug resistant 1 gene product and to exhibit resistance to a broad range of drugs including anticancer drugs such as epirubicin.	Epirubicin	161-171	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
11818250-1	2002	P-glycoprotein (P-GP) is known to be a multidrug resistant 1 gene product and to exhibit resistance to a broad range of drugs including anticancer drugs such as epirubicin.	Epirubicin	161-171	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-20
11803466-5	2002	Moreover, we show that both apoptosis-promoters, Nbk/Bik and Bak, antagonize acquired chemoresistance for epirubicin-mediated apoptosis in MT3-Adr breast cancer cells.	Epirubicin	106-116	BCL2 interacting killer	Homo sapiens	49-52
11803466-5	2002	Moreover, we show that both apoptosis-promoters, Nbk/Bik and Bak, antagonize acquired chemoresistance for epirubicin-mediated apoptosis in MT3-Adr breast cancer cells.	Epirubicin	106-116	BCL2 interacting killer	Homo sapiens	53-56
11803466-5	2002	Moreover, we show that both apoptosis-promoters, Nbk/Bik and Bak, antagonize acquired chemoresistance for epirubicin-mediated apoptosis in MT3-Adr breast cancer cells.	Epirubicin	106-116	BCL2 antagonist/killer 1	Homo sapiens	61-64
11720428-0	2001	Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.	Epirubicin	36-46	colony stimulating factor 3	Homo sapiens	52-57
11720428-11	2001	None of the patients encountered dose-limiting toxicity in the first course, which confirmed that epirubicin 135 mg m(-2) could be combined with cisplatin 60 mg m(-2) and accelerated by G-CSF support to a 14-day-schedule.	Epirubicin	98-108	colony stimulating factor 3	Homo sapiens	186-191
11720428-20	2001	Accelerated cisplatin and high-dose epirubicin with G-CSF support is a feasible and promising regimen in relapsed NSCLC.	Epirubicin	36-46	colony stimulating factor 3	Homo sapiens	52-57
11545522-1	2001	The enhanced generation of singlet oxygen (1O2) during oxidation of farmorubicin in the Co(II) + H2O2 system was studied using chemiluminescent, fluorescent and spectrophotometic techniques.	Epirubicin	68-80	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	88-94
11408917-9	2001	Epirubicin and pirarubicin, compounds closely related to ADR, also respectively enhanced 4.2-fold (p = 0.0052) and 2.8-fold (p = 0.0147) caspase-3 activity in ACHN cells.	Epirubicin	0-10	caspase 3	Homo sapiens	137-146
11222383-1	2001	The activation of caspase-8, a crucial upstream mediator of death receptor signaling, was investigated in epirubicin- and Taxol-induced apoptosis of B-lymphoma cells.	Epirubicin	106-116	caspase 8	Homo sapiens	18-27
11302935-0	2001	Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.	Epirubicin	0-10	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	49-80
11302935-10	2001	We screened commercially available UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 for epirubicin glucuronidation.	Epirubicin	99-109	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	35-41
11302935-10	2001	We screened commercially available UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 for epirubicin glucuronidation.	Epirubicin	99-109	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	59-65
11302935-10	2001	We screened commercially available UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 for epirubicin glucuronidation.	Epirubicin	99-109	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	67-73
11302935-10	2001	We screened commercially available UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 for epirubicin glucuronidation.	Epirubicin	99-109	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	87-94
11302935-11	2001	Only UGT2B7 converted epirubicin to its glucuronide.	Epirubicin	22-32	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	5-11
11302935-13	2001	Catalytic efficiency (V(max)/K(m)) of epirubicin glucuronidation was 1.4 microl/min/mg, a value higher than that observed for morphine, a substrate of UGT2B7.	Epirubicin	38-48	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	151-157
11302935-16	2001	UGT2B7 is the major human UGT catalyzing epirubicin glucuronidation, and UGT2B7 is the candidate gene for this phenotype.	Epirubicin	41-51	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	0-6
11302935-16	2001	UGT2B7 is the major human UGT catalyzing epirubicin glucuronidation, and UGT2B7 is the candidate gene for this phenotype.	Epirubicin	41-51	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	0-3
11302935-16	2001	UGT2B7 is the major human UGT catalyzing epirubicin glucuronidation, and UGT2B7 is the candidate gene for this phenotype.	Epirubicin	41-51	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	73-79
11304774-1	2001	PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients.	Epirubicin	74-84	colony stimulating factor 3	Homo sapiens	150-187
11283936-11	2001	Aminotriazole inhibition of catalase had a marginal effect on the toxicity caused by epirubicin.	Epirubicin	85-95	catalase	Homo sapiens	28-36
11222383-3	2001	Indeed, active caspase-8 was readily detected after treatment of mature and immature B-lymphoid cells with epirubicin or Taxol.	Epirubicin	107-117	caspase 8	Homo sapiens	15-24
15959941-5	2000	An ongoing German study is evaluating epirubicin/cyclophosphamide in combination with trastuzumab as first-line therapy of metastatic breast cancer in patients whose tumors overexpress HER2/neu protein.	Epirubicin	38-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-193
10962437-9	2000	Our cell line experiments indicated that cells expressing high MnSOD levels were more resistant to apoptosis and showed lower proliferation when exposed to epirubicin in vitro.	Epirubicin	156-166	superoxide dismutase 2	Homo sapiens	63-68
11167651-5	2001	RESULTS: MDR-1 and -3 were significantly and equally overexpressed in MGHU-1R, and associated with a dramatic increase in the 50% inhibitory drug concentration (P < 0.001) for mitomycin C and epirubicin against controls.	Epirubicin	195-205	ATP binding cassette subfamily B member 1	Homo sapiens	9-21
11123976-3	2000	A decrease in the level of alcohol metabolite formation was observed by replacing DOX with epirubicin (EPI), a less cardiotoxic analogue characterized by an axial-to-equatorial epimerization of the hydroxyl group at C-4 in the amino sugar bound to the tetracyclic ring (daunosamine).	Epirubicin	91-101	complement C4A (Rodgers blood group)	Homo sapiens	216-219
11008132-9	2000	The study suggests that inhibition of P-gp or other transporter proteins located in the intestines may be partially involved in the reduction of epirubicin efflux.	Epirubicin	145-155	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
11016746-0	2000	Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer.	Epirubicin	10-20	colony stimulating factor 3	Homo sapiens	59-64
10996485-2	2000	Amongst anthracycline antibiotics, we have found daunorubicin and epirubicin able to acutely stimulate prolactin (PRL) secretion both in vivo, in the rat, and in vitro, from rat anterior pituitary cell cultures.	Epirubicin	66-76	prolactin	Rattus norvegicus	103-112
10996485-2	2000	Amongst anthracycline antibiotics, we have found daunorubicin and epirubicin able to acutely stimulate prolactin (PRL) secretion both in vivo, in the rat, and in vitro, from rat anterior pituitary cell cultures.	Epirubicin	66-76	prolactin	Rattus norvegicus	114-117
10749746-3	2000	We investigated the levels of manganese superoxide dismutase (Mn SOD), its inducibility, and its protective role against tumor necrosis factor-alpha and cytotoxic drugs (cisplatin, epirubicin, methotrexate, and vindesin) in human pleural mesothelioma (M14K) and pulmonary adenocarcinoma (A549) cells.	Epirubicin	181-191	superoxide dismutase 2	Homo sapiens	30-60
10914720-8	2000	p53 was a significant predictor for poor cCR in the subset submitted to epirubicin (3.6 versus 25.5%; P < 0.02; in patients with p53+ and p53- BC, respectively); by contrast, only a trend toward lower cCR has been observed in patients with p53+ tumors receiving CMF +/- tamoxifen with respect to p53- ones.	Epirubicin	72-82	tumor protein p53	Homo sapiens	0-3
10914720-8	2000	p53 was a significant predictor for poor cCR in the subset submitted to epirubicin (3.6 versus 25.5%; P < 0.02; in patients with p53+ and p53- BC, respectively); by contrast, only a trend toward lower cCR has been observed in patients with p53+ tumors receiving CMF +/- tamoxifen with respect to p53- ones.	Epirubicin	72-82	tumor protein p53	Homo sapiens	132-135
10914720-8	2000	p53 was a significant predictor for poor cCR in the subset submitted to epirubicin (3.6 versus 25.5%; P < 0.02; in patients with p53+ and p53- BC, respectively); by contrast, only a trend toward lower cCR has been observed in patients with p53+ tumors receiving CMF +/- tamoxifen with respect to p53- ones.	Epirubicin	72-82	tumor protein p53	Homo sapiens	132-135
10914720-8	2000	p53 was a significant predictor for poor cCR in the subset submitted to epirubicin (3.6 versus 25.5%; P < 0.02; in patients with p53+ and p53- BC, respectively); by contrast, only a trend toward lower cCR has been observed in patients with p53+ tumors receiving CMF +/- tamoxifen with respect to p53- ones.	Epirubicin	72-82	tumor protein p53	Homo sapiens	132-135
10914720-8	2000	p53 was a significant predictor for poor cCR in the subset submitted to epirubicin (3.6 versus 25.5%; P < 0.02; in patients with p53+ and p53- BC, respectively); by contrast, only a trend toward lower cCR has been observed in patients with p53+ tumors receiving CMF +/- tamoxifen with respect to p53- ones.	Epirubicin	72-82	tumor protein p53	Homo sapiens	132-135
10914720-13	2000	The role of mutated p53 in preventing response is more evident in patients submitted to epirubicin, and this may be caused by the up-regulation of multidrug resistance gene expression by p53 inactivation.	Epirubicin	88-98	tumor protein p53	Homo sapiens	20-23
10914720-13	2000	The role of mutated p53 in preventing response is more evident in patients submitted to epirubicin, and this may be caused by the up-regulation of multidrug resistance gene expression by p53 inactivation.	Epirubicin	88-98	tumor protein p53	Homo sapiens	187-190
10698706-2	2000	In the present study, cleavage of D4-GDI (Rho-GDI 2), an abundant haemopoietic-cell GDP dissociation inhibitor for the Ras-related Rho family GTPases, was demonstrated after treatment of BJAB Burkitt-like lymphoma cells with taxol or epirubicin.	Epirubicin	234-244	Rho GDP dissociation inhibitor beta	Homo sapiens	42-51
10677583-6	2000	The co-presence of verapamil, one typical P-glycoprotein (P-gp) substrate, and Deo-Na or Cap-Na demonstrated further reduction of epirubicin efflux.	Epirubicin	130-140	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
10677583-6	2000	The co-presence of verapamil, one typical P-glycoprotein (P-gp) substrate, and Deo-Na or Cap-Na demonstrated further reduction of epirubicin efflux.	Epirubicin	130-140	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
10516673-2	1999	We have previously reported that G-IVE (G-CSF, ifosphamide, VP-16, epirubicin) improves the yield of CD34+ cells mobilised in patients with lymphoproliferative disorders compared with cyclophosphamide 3 g/m2 and G-CSF (G/CYCLO).	Epirubicin	67-77	CD34 molecule	Homo sapiens	101-105
10677583-7	2000	The study suggests that inhibition of P-gp or other transporter proteins located in the intestines may be involved, at least partially, in the reduction of epirubicin efflux.	Epirubicin	156-166	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
10793559-1	2000	We devised a new epirubicin-based combination chemotherapy (Epi-COP) regimen for the patients with elderly non-Hodgkin"s lymphoma and have treated 30 patients aged 66 years and older who had measurable diseases.	Epirubicin	17-27	caspase recruitment domain family member 16	Homo sapiens	64-67
10606239-7	1999	In addition to topotecan and SN-38, MXR-overexpressing cells are highly resistant to mitoxantrone and epirubicin.	Epirubicin	102-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	36-39
10600046-5	1999	In patients with metastatic disease, epirubicin- and doxorubicin-containing regimens (with cyclophosphamide and fluorouracil; FEC and FAC) are therapeutically equivalent.	Epirubicin	37-47	FA complementation group C	Homo sapiens	134-137
10516673-2	1999	We have previously reported that G-IVE (G-CSF, ifosphamide, VP-16, epirubicin) improves the yield of CD34+ cells mobilised in patients with lymphoproliferative disorders compared with cyclophosphamide 3 g/m2 and G-CSF (G/CYCLO).	Epirubicin	67-77	colony stimulating factor 3	Homo sapiens	212-217
10428874-6	1999	However, only those in which the COOH-terminal third of mrp had been replaced with the corresponding region of MRP-conferred resistance to the anthracyclines, doxorubicin, and epirubicin.	Epirubicin	176-186	ATP binding cassette subfamily C member 1	Homo sapiens	56-59
10428874-6	1999	However, only those in which the COOH-terminal third of mrp had been replaced with the corresponding region of MRP-conferred resistance to the anthracyclines, doxorubicin, and epirubicin.	Epirubicin	176-186	ATP binding cassette subfamily C member 1	Homo sapiens	111-114
10188617-2	1999	We examined the distribution of iNOS and evaluated the effects of anticancer drugs, 4"-epi-doxorubicin (EPI-DXR) and mitomycin C (MMC), on iNOS induction by lipopolysaccharide in rats.	Epirubicin	84-102	nitric oxide synthase 2	Rattus norvegicus	139-143
10402245-22	1999	Rapidly alternating or sequential cycles of epirubicin and cyclophosphamide with CSF support is a feasible strategy that allows a higher increase of dose-intensity of the single drugs.	Epirubicin	44-54	colony stimulating factor 2	Homo sapiens	81-84
10220572-12	1999	Human MRP2 overexpressed in HEK-293 cells enhanced the resistance to etoposide (4-fold), cisplatin (10-fold), doxorubicin (7.8-fold), and epirubicin (5-fold).	Epirubicin	138-148	ATP binding cassette subfamily C member 2	Homo sapiens	6-10
10561191-0	1999	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.	Epirubicin	170-180	erythropoietin	Homo sapiens	0-14
10561191-0	1999	Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.	Epirubicin	170-180	colony stimulating factor 3	Homo sapiens	27-64
10509151-1	1999	BACKGROUND: To define a maximum tolerated dose (MTD) for the combination of epirubicin and cyclophosphamide with filgrastim (r-met-HuG-CSF) in patients with advanced solid tumors and non-Hodgkin"s lymphoma (NHL).	Epirubicin	76-86	colony stimulating factor 2	Homo sapiens	135-138
10470143-14	1999	Therefore, it can be concluded, that in the xenografted breast cancer cell lines a regulation of CD44 isoforms by farmorubicine, cyclophosphamide, estradiol, progesterone or tamoxifen could not be found, while serum levels were influenced in some cases probably due to tumour cell kill and shedding of surface proteins into blood stream.	Epirubicin	114-127	CD44 molecule (Indian blood group)	Homo sapiens	97-101
9439427-0	1997	Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional cell bladder tumours.	Epirubicin	45-55	pre T cell antigen receptor alpha	Homo sapiens	119-122
10378632-0	1999	A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.	Epirubicin	46-56	colony stimulating factor 3	Homo sapiens	133-170
9569045-0	1998	Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity.	Epirubicin	127-137	glutathione S-transferase kappa 1	Homo sapiens	35-60
9569045-10	1998	In addition to the high MnSOD activity, hydrogen peroxide scavenging antioxidant enzymes, glutathione and GST can partly explain the high hydrogen peroxide and epirubicin resistance of these cells in vitro.	Epirubicin	160-170	superoxide dismutase 2	Homo sapiens	24-29
9569045-10	1998	In addition to the high MnSOD activity, hydrogen peroxide scavenging antioxidant enzymes, glutathione and GST can partly explain the high hydrogen peroxide and epirubicin resistance of these cells in vitro.	Epirubicin	160-170	glutathione S-transferase kappa 1	Homo sapiens	106-109
9543613-2	1998	Therefore, drugs such as cimetidine, which inhibit the cytochrome P-450 enzyme system or reduce liver blood flow, may reduce the plasma clearance of epirubicin.	Epirubicin	149-159	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-71
9892204-4	1999	The 3" end of the MRP6 protein was found to be almost identical with the anthracycline resistance associated (ARA) protein identified previously in epirubicin-selected leukemia cells.	Epirubicin	148-158	ATP binding cassette subfamily C member 6	Homo sapiens	18-22
9892204-4	1999	The 3" end of the MRP6 protein was found to be almost identical with the anthracycline resistance associated (ARA) protein identified previously in epirubicin-selected leukemia cells.	Epirubicin	148-158	ATP binding cassette subfamily C member 6	Homo sapiens	110-113
9720473-0	1998	A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer.	Epirubicin	44-58	colony stimulating factor 3	Homo sapiens	107-112
9713500-1	1998	P-glycoprotein (P-gp) actively pumps out a number of anticancer drugs, such as epirubicin, from tumor cells.	Epirubicin	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
9713500-1	1998	P-glycoprotein (P-gp) actively pumps out a number of anticancer drugs, such as epirubicin, from tumor cells.	Epirubicin	79-89	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
9649144-14	1998	Among the prognostic biomarkers, overexpression of c-erbB2 oncogene and negative ER may have predictive value in epirubicin therapy in patients with advanced breast cancer.	Epirubicin	113-123	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-58
9610729-4	1998	Treatment of the H82 cells for 1 hr with 69 nM epirubicin increased MRP1-mRNA expression within 4 hr and this was associated with an increase in the resistance to epirubicin, chlorambucil, cisplatin and paclitaxel.	Epirubicin	47-57	ATP binding cassette subfamily C member 1	Homo sapiens	68-72
9491796-6	1998	However, the expression of caspase-1 but not of caspase-2 or -3 enhanced chemosensitivity toward cytotoxic anticancer drugs such as aclarubicin, epirubicin, adriamycin, nimustine and ifosfamide.	Epirubicin	145-155	caspase 1	Mus musculus	27-36
9439427-0	1997	Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional cell bladder tumours.	Epirubicin	45-55	zinc finger protein 77	Homo sapiens	127-130
9390210-0	1997	A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.	Epirubicin	30-40	colony stimulating factor 3	Homo sapiens	80-85
9415415-5	1997	MCF-7 cells showed a block in the G1 phase after treatment with 50 nM epirubicin for 24 hours, in agreement with the actions of p53 at the G1 checkpoint.	Epirubicin	70-80	tumor protein p53	Homo sapiens	128-131
9415415-8	1997	A dramatic increase in the level of p21 mRNA was seen in epirubicin-treated MCF-7 cells, while no such increase was seen in SK-BR-3 cells.	Epirubicin	57-67	H3 histone pseudogene 16	Homo sapiens	36-39
9093707-0	1997	Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.	Epirubicin	64-74	vasoactive intestinal peptide	Homo sapiens	76-79
9446257-5	1997	In a randomized study by Ardizzoni et al., the administration of GM-CSF at the dose of 10 micrograms/kg following CEF program (cyclophosphamide, epirubicin and fluorouracil) was effective in reducing from 20 to 16 days the time interval among cycles.	Epirubicin	145-155	colony stimulating factor 2	Homo sapiens	65-71
9186325-13	1997	For pT1 tumors recurrence rates in arms 1 to 4 were 26.3, 17.8, 39.3 and 70.9%, respectively, which were significantly lower in the chemotherapy group than in controls (p < 0.001) and in the epirubicin groups than in the doxorubicin group (p = 0.01).	Epirubicin	194-204	zinc finger protein 77	Homo sapiens	4-7
9158511-0	1997	Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study.	Epirubicin	45-55	pre T cell antigen receptor alpha	Homo sapiens	119-122
9158511-0	1997	Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study.	Epirubicin	45-55	zinc finger protein 77	Homo sapiens	127-130
9151912-2	1997	One report showed intra-arterial administration of epirubicin to be effective in the treatment of nonresectable HCC.	Epirubicin	51-61	HCC	Homo sapiens	112-115
9167749-0	1997	Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.	Epirubicin	47-57	colony stimulating factor 2	Homo sapiens	63-69
9167749-10	1997	This study has demonstrated that epirubicin can be safely administered at 2 week intervals with GM-CSF at a dose of 90 mg/m2, equivalent to the previously reported maximum tolerated dose intensity of 45 mg/m2/week.	Epirubicin	33-43	colony stimulating factor 2	Homo sapiens	96-102
9093708-0	1997	Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.	Epirubicin	64-74	vasoactive intestinal peptide	Homo sapiens	76-79
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Epirubicin	200-214	colony stimulating factor 3	Homo sapiens	47-84
8690514-5	1996	Induction of bax-alpha expression did not affect viability by itself but strongly increased chemosensitivity to epirubicin.	Epirubicin	112-122	BCL2 associated X, apoptosis regulator	Homo sapiens	13-16
8605104-1	1996	Expression of the MRP gene has been demonstrated in vitro to be a casual factor in non-P-glycoprotein-mediated multidrug resistance, and is implicated in resistance to a number of the chemotherapeutic agents currently used in the treatment of high-grade transitional cell carcinoma (TCC) of the bladder (doxorubicin, epirubicin and vinblastine).	Epirubicin	317-327	ATP binding cassette subfamily C member 3	Homo sapiens	18-21
8605104-1	1996	Expression of the MRP gene has been demonstrated in vitro to be a casual factor in non-P-glycoprotein-mediated multidrug resistance, and is implicated in resistance to a number of the chemotherapeutic agents currently used in the treatment of high-grade transitional cell carcinoma (TCC) of the bladder (doxorubicin, epirubicin and vinblastine).	Epirubicin	317-327	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
9020952-3	1997	After arterial infusion chemotherapy consisting of CDDP, epirubicin and 5-FU, the tumor size and serum level of CEA were significantly decreased.	Epirubicin	57-67	CEA cell adhesion molecule 3	Homo sapiens	112-115
9304408-12	1996	Pretreatment with 4"-epi-doxorubicin in vivo also prevented the induction of inducible NO synthase by lipopolysaccharide in rat thoracic aorta and lung.	Epirubicin	18-36	nitric oxide synthase 2	Rattus norvegicus	77-98
8751810-0	1996	[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP].	Epirubicin	97-107	alpha fetoprotein	Homo sapiens	11-14
8751810-0	1996	[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP].	Epirubicin	97-107	alpha fetoprotein	Homo sapiens	16-33
8645591-1	1996	We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer.	Epirubicin	85-99	colony stimulating factor 3	Homo sapiens	180-185
9816222-1	1996	We have previously demonstrated that within 24 h of exposure of the CEM/A7R cell line to epirubicin (EPI), MDR1 gene expression is induced.	Epirubicin	89-99	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
8569365-0	1996	Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.	Epirubicin	59-69	angiotensin I converting enzyme	Homo sapiens	15-44
8742097-1	1996	It was our intention to verify if increases of granulocyte colony stimulating factor (G-CSF) dose were able to reduce treatment delays due to leukopenia in our weekly regimen of cisplatin (40 mg/m2), epidoxorubicin (35 mg/m2), 6S-leucovorin (250 mg/m2) and 5-fluorouracil (500 mg/m2), usually supported by G-CSF at a dose of 5 mu g/kg.	Epirubicin	200-214	colony stimulating factor 3	Homo sapiens	86-91
7577476-0	1995	Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).	Epirubicin	76-86	colony stimulating factor 3	Homo sapiens	92-129
8823488-0	1996	Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.	Epirubicin	127-141	erythropoietin	Homo sapiens	0-14
8823488-0	1996	Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.	Epirubicin	127-141	colony stimulating factor 2	Homo sapiens	19-67
8823488-1	1996	To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study.	Epirubicin	202-216	colony stimulating factor 2	Homo sapiens	37-85
8823488-1	1996	To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study.	Epirubicin	202-216	colony stimulating factor 2	Homo sapiens	87-93
8823488-1	1996	To verify whether the association of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) would allow both the acceleration and the dose escalation of the cyclophosphamide/epidoxorubicin/5-fluorouracil (CEF) regimen as first-line therapy in advanced breast cancer patients, we conducted a dose-finding study.	Epirubicin	202-216	erythropoietin	Homo sapiens	99-113
7577476-19	1995	Use of G-CSF allows epirubicin dosage to be increased up to 120 mg m-2 cycle-1, but its use may be linked to the occurrence of sometimes severe cumulative haematological toxicity.	Epirubicin	20-30	colony stimulating factor 3	Homo sapiens	7-12
8620409-14	1995	CONCLUSION: The MTD of epirubicin for this regimen with DVPM and GM-CSF was 120 mg/m2 every 3 weeks.	Epirubicin	23-33	colony stimulating factor 2	Homo sapiens	65-71
7579561-3	1995	The intracellular concentrations of epirubicin (EPIR), daunomycin (DM), adriamycin (ADM) and THP-adriamycin (THP) were increased by the addition of CsA or FK506 in VJ-300, but not in KB cells.	Epirubicin	36-46	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	148-151
7574817-5	1995	Treatment with 5-FU (iv; once a week) and epirubicin (20 mg/body once every 2 weeks iv) resulted in disappearance of the pulmonary metastases and a marked decrease in the AFP level.	Epirubicin	42-52	alpha fetoprotein	Homo sapiens	171-174
7579561-3	1995	The intracellular concentrations of epirubicin (EPIR), daunomycin (DM), adriamycin (ADM) and THP-adriamycin (THP) were increased by the addition of CsA or FK506 in VJ-300, but not in KB cells.	Epirubicin	48-52	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	148-151
8542509-1	1995	A case of primarily inoperable hepatoid adenocarcinoma of the stomach is reported, which, after chemotherapy with farmorubicin, 5-fluorouracil and leucovorin, showed an impressive regression resulting in an improvement of the overall condition of the patient and a decrease of the serum AFP level from initially 79.120 ng/ml to 3.728 ng/ml.	Epirubicin	114-126	alpha fetoprotein	Homo sapiens	287-290
7670142-3	1995	The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide.	Epirubicin	119-129	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
7734315-2	1995	The induction of mdr1 RNA expression by three anthracyclines, (doxorubicin, daunorubicin, epirubicin), VP-16 and two vinca alkaloids (vincristine, vinblastine) was semiquantitatively assessed by scanning Northern blots on a phosphorimager.	Epirubicin	90-100	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
7734315-4	1995	A significant increase (P < 0.02) in expression of mdr1 was noted within 4 hrs of exposure to 1.5 micrograms ml-1 daunorubicin or epirubicin.	Epirubicin	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
7734315-6	1995	With increasing concentrations of daunorubicin or epirubicin in a fixed 24 h time period, mdr1 expression increased, although a biphasic response was seen.	Epirubicin	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
7734315-7	1995	Based on MRK 16 binding, an increase in P-gp levels was seen in the CEM/A7R line after a 24 h exposure to 1 microgram ml-1 daunorubicin or epirubicin.	Epirubicin	139-149	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
7734315-8	1995	The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours.	Epirubicin	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
7734315-8	1995	The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours.	Epirubicin	103-113	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
7587708-9	1995	By dual parameter flow cytometry it was shown that Pgp expression in viable cells may be assessed together with uptake of epirubicin, which was low in cells expressing high levels of Pgp and vice versa.	Epirubicin	122-132	ATP binding cassette subfamily B member 1	Homo sapiens	183-186
7590500-1	1995	BACKGROUND: The purpose of our cooperative trial was to investigate whether epirubicin (EPI) at 90 mg/m2 in a CHOP-like combination (called CEOP) could increase complete response (CR) and survival rates in non-Hodgkin lymphoma (NHL) patients while maintaining a tolerable degree of toxicity.	Epirubicin	76-86	DNA damage inducible transcript 3	Homo sapiens	110-114
7882276-8	1995	In the group treated with the W/O/W containing a high dose (40 mg or more) of epirubicin, even though the gelatin-sponge particles were not used, tumor size was reduced in six of seven patients, and a 50% or greater decrease of initial alpha-fetoprotein (AFP) levels within 14 days was observed in all four patients who showed abnormal levels of serum AFP before treatment.	Epirubicin	78-88	alpha fetoprotein	Homo sapiens	236-253
7752673-0	1995	Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line.	Epirubicin	61-71	ATP binding cassette subfamily C member 1	Homo sapiens	31-34
7752673-4	1995	Treatment with 100-1000 ng/ml epirubicin produced sublines with increased expression of the mrp gene, increased resistance to the anthracyclines and etoposide, additional cross resistance to vincristine and colchicine, decreased drug accumulation and reversal of resistance by verapamil and by buthionine sulphoximine (BSO; an inhibitor of glutathione synthesis).	Epirubicin	30-40	ATP binding cassette subfamily C member 1	Homo sapiens	92-95
7882276-8	1995	In the group treated with the W/O/W containing a high dose (40 mg or more) of epirubicin, even though the gelatin-sponge particles were not used, tumor size was reduced in six of seven patients, and a 50% or greater decrease of initial alpha-fetoprotein (AFP) levels within 14 days was observed in all four patients who showed abnormal levels of serum AFP before treatment.	Epirubicin	78-88	alpha fetoprotein	Homo sapiens	255-258
7882276-8	1995	In the group treated with the W/O/W containing a high dose (40 mg or more) of epirubicin, even though the gelatin-sponge particles were not used, tumor size was reduced in six of seven patients, and a 50% or greater decrease of initial alpha-fetoprotein (AFP) levels within 14 days was observed in all four patients who showed abnormal levels of serum AFP before treatment.	Epirubicin	78-88	alpha fetoprotein	Homo sapiens	352-355
7526143-15	1995	The present study shows that the prophylactic use of r-met-hu G-CSF allows the administration of high-dose epirubicin every 4 weeks with minimal morbidity and an improved quality of life.	Epirubicin	107-117	colony stimulating factor 3	Homo sapiens	62-67
7533518-0	1995	The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.	Epirubicin	90-100	colony stimulating factor 3	Homo sapiens	11-48
7741078-1	1995	We report a case of lung metastasis from bladder cancer effectively responding to a combination chemotherapy using methotrexate, epirubicin and cisplatin (MEC therapy).	Epirubicin	129-139	C-C motif chemokine ligand 28	Homo sapiens	155-158
7656812-7	1995	However, the resistances of K562/Dox cells to epirubicin and daunorubicin still remained for about 5.6 and > 6.6 folds, respectively, even at verapamil concentration of 6 mumol/L, suggesting at least a relatively big fraction of drug resistance was not directly related to the altered cellular pharmacokinetics associated with overexpression of P-glycoprotein.	Epirubicin	46-56	ATP binding cassette subfamily B member 1	Homo sapiens	348-362
7710452-1	1995	The influence of interferon-alpha-2b (CAS 99210-65-8, IFN) on the pharmacokinetics of epirubicin (CAS 56420-45-2, EPR) was investigated in 10 patients (4 male, 6 female).	Epirubicin	86-96	interferon alpha 2	Homo sapiens	17-36
7710452-1	1995	The influence of interferon-alpha-2b (CAS 99210-65-8, IFN) on the pharmacokinetics of epirubicin (CAS 56420-45-2, EPR) was investigated in 10 patients (4 male, 6 female).	Epirubicin	86-96	interferon alpha 1	Homo sapiens	54-57
8698741-11	1995	The recommended dose of epirubicin for this regimen with dexverapamil and GM-CSF is 120 mg/m2 every 3 weeks.	Epirubicin	24-34	colony stimulating factor 2	Homo sapiens	74-80
7526143-2	1995	Concurrent administration of G-CSF probably allows the administration of epirubicin on schedule with minimal morbidity.	Epirubicin	73-83	colony stimulating factor 3	Homo sapiens	29-34
7538704-0	1995	Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF.	Epirubicin	100-115	colony stimulating factor 3	Homo sapiens	167-172
7847819-3	1994	Treatment of OVCAR-3 cells with cisplatin, etoposide or epirubicin for two hours resulted in a marked augmentation of EGF-R expression and growth inhibition, on the other hand, incubation with substances blocking RNA or protein synthesis, actinomycin-D and cycloheximide, resulted in a reduction of both EGF-R expression and growth rate.	Epirubicin	56-66	epidermal growth factor receptor	Homo sapiens	118-123
7847819-3	1994	Treatment of OVCAR-3 cells with cisplatin, etoposide or epirubicin for two hours resulted in a marked augmentation of EGF-R expression and growth inhibition, on the other hand, incubation with substances blocking RNA or protein synthesis, actinomycin-D and cycloheximide, resulted in a reduction of both EGF-R expression and growth rate.	Epirubicin	56-66	epidermal growth factor receptor	Homo sapiens	304-309
7520769-0	1994	Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.	Epirubicin	194-204	CD34 molecule	Homo sapiens	37-41
8083699-1	1994	PURPOSE: To evaluate the effect of quinidine, a putative modulator of P-glycoprotein-mediated drug resistance, on the response rate and toxicity profile of epirubicin in patients with advanced breast cancer.	Epirubicin	156-166	ATP binding cassette subfamily B member 1	Homo sapiens	70-84
7863813-2	1994	On this basis, we have evaluated the influence of low-dose IL-2 on lymphocyte and NK cell numbers in cancer patients treated with the anthracycline drug, epirubicin.	Epirubicin	154-164	interleukin 2	Homo sapiens	59-63
7908215-1	1994	Overexpression of the multidrug resistance (mdr1) gene has been implicated in resistance to a number of the chemotherapeutic agents currently used in the treatment of bladder cancer (doxorubicin, vincristine and epirubicin).	Epirubicin	212-222	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
8153657-0	1994	Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.	Epirubicin	21-31	colony stimulating factor 2	Homo sapiens	78-126
8435362-6	1993	Twenty-six were treated with epirubicin (EPI) 120 mg/m2 i.v.	Epirubicin	29-39	tissue factor pathway inhibitor	Homo sapiens	41-44
8070007-3	1994	Epirubicin clearance correlated with serum aspartate aminotransferase (AST), albumin and bilirubin values in patients treated intravenously or intraarterially.	Epirubicin	0-10	solute carrier family 17 member 5	Homo sapiens	43-69
8070007-3	1994	Epirubicin clearance correlated with serum aspartate aminotransferase (AST), albumin and bilirubin values in patients treated intravenously or intraarterially.	Epirubicin	0-10	solute carrier family 17 member 5	Homo sapiens	71-74
8070007-8	1994	These data confirm that although current recommended dose adjustments are based primarily on serum bilirubin levels, altered epirubicin pharmacokinetics correlate more strongly with AST and albumin values than with serum bilirubin concentrations.	Epirubicin	125-135	solute carrier family 17 member 5	Homo sapiens	182-185
8347160-1	1993	The purpose of this study was to investigate in rats the effects of three anthracyclines, pirarubicin, doxorubicin and epirubicin on gastric prostaglandin E2 (PGE2) metabolism and phospholipase A2 (PLA2, EC 3.1.1.4) activity.	Epirubicin	119-129	phospholipase A2 group IB	Rattus norvegicus	198-202
8347160-4	1993	Pirarubicin does not give rise to any changes in these activities but doxorubicin and epirubicin decreased PGE2 production and the activities of PLA2, LPase and ACLAT.	Epirubicin	86-96	phospholipase A2 group IB	Rattus norvegicus	145-149
8251651-3	1993	mdr1-RNA was never detected in 29 primary breast tumors including 5 samples from patients previously treated by 6 courses of 5-fluorouracil, epirubicin, cyclophosphamide (FEC).	Epirubicin	141-151	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
7691117-8	1993	These results would indicate the usefulness of a phase II study with epirubicin at the dose of 90 mg/m2 in association with conventional dose of vinorelbine with the support of G-CSF in advanced NSCLC.	Epirubicin	69-79	colony stimulating factor 3	Homo sapiens	177-182
1511613-5	1992	Chlorpromazine augmentation of epirubicin cytotoxicity, including plasma membrane and DNA damage, may be due to its calmodulin antagonistic action and related to the maintenance integrity.	Epirubicin	31-41	LOC100759184	Cricetulus griseus	116-126
8279093-3	1993	Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24h after epirubicin instillation.	Epirubicin	143-153	interferon alpha 2	Homo sapiens	113-132
1353119-3	1992	The KK47/ADM exhibited cross-resistance to doxorubicin derivatives (pirarubicin, epirubicin), vinca alkaloids (vinblastine, vincristine) and etoposide, but not to cisplatin, carboplatin, mitomycin C, peplomycin and methotrexate.	Epirubicin	81-91	adrenomedullin	Homo sapiens	9-12
1419619-6	1992	Epirubicin clearance was significantly reduced in the patients with a raised AST, whether their serum bilirubin was normal (22 patients) or elevated (eight patients).	Epirubicin	0-10	solute carrier family 17 member 5	Homo sapiens	77-80
1419619-7	1992	In the 30 patients with a raised AST +/- raised bilirubin, epirubicin clearance correlated strongly with the level of AST (r = -0.72) but not with serum bilirubin, alkaline phosphatase, albumin or creatinine.	Epirubicin	59-69	solute carrier family 17 member 5	Homo sapiens	33-36
1419619-7	1992	In the 30 patients with a raised AST +/- raised bilirubin, epirubicin clearance correlated strongly with the level of AST (r = -0.72) but not with serum bilirubin, alkaline phosphatase, albumin or creatinine.	Epirubicin	59-69	solute carrier family 17 member 5	Homo sapiens	118-121
1419619-8	1992	Using a multiple regression analysis, AST was the only one of these biochemical variables predictive of epirubicin clearance (r2 = 0.47, P = 0.0006).	Epirubicin	104-114	solute carrier family 17 member 5	Homo sapiens	38-41
1419619-9	1992	We conclude that a raised serum AST is a more sensitive and reliable measure of abnormal epirubicin pharmacokinetics than increased bilirubin.	Epirubicin	89-99	solute carrier family 17 member 5	Homo sapiens	32-35
1433946-0	1992	[Effective treatment of CMMoL with F-COP (epirubicine, cyclophosphamide, vincristine, prednisolone) therapy].	Epirubicin	42-53	caspase recruitment domain family member 16	Homo sapiens	37-40
1433946-7	1992	Treatment with F-COP (epirubicine, cyclophosphamide, vincristine, prednisolone) therapy, resulted in a dramatic improvement of her condition.	Epirubicin	22-33	caspase recruitment domain family member 16	Homo sapiens	17-20
1403081-10	1992	The results of this study show that a dose escalation to 50 mg/m2 for cisplatin, epirubicin and methotrexate in the PEM regimen results in an increase in overall response (OR) (19/40 = 47.5%) with respect to a historical control using the same drugs at doses of 40 mg/m2 (12/35 = 34%).	Epirubicin	81-91	mucin 1, cell surface associated	Homo sapiens	116-119
1337040-1	1992	The present study reports findings on the disposition of epirubicin after an intrahepato-arterial administration of the Lipiodol-drug complex, prepared by mixing the drug-aqueous phase with the iodized oil by ultra-sonification, in 14 patients with histologically proven hepatoma or hepatomegaly with serum alpha-fetoprotein level above 500 micrograms.l-1.	Epirubicin	57-67	alpha fetoprotein	Homo sapiens	307-324
22504700-5	2012	As a second choice of treatment, transarterial chemo-embolization(TACE)using epirubicin hydrochloride and Lipiodol was performed because it was reported to have a high efficacy.	Epirubicin	77-101	ADAM metallopeptidase domain 17	Homo sapiens	66-70
1952960-4	1991	WEHI-3B-MIT-R cell line, which have a capacity of G-CSF-induced differentiation, was cross-resistance to 4"-epi-adriamycin.	Epirubicin	105-122	colony stimulating factor 3 (granulocyte)	Mus musculus	50-55
1952960-5	1991	These results suggest that the mechanism of action differs from that of the induction of differentiation by G-CSF (which is known to show the activity by the secondary autoinduction of differentiation) and the differentiation induction is due to the direct action of 4"-epi-adriamycin.	Epirubicin	267-284	colony stimulating factor 3 (granulocyte)	Mus musculus	108-113
1831809-7	1991	Epidx administration was limited at a cumulative dose ranging between 840 and 1200 mg/m2 because of a 25% decrease in LVEF and due to a progressive rising in ANF plasma levels.	Epirubicin	0-5	natriuretic peptide A	Homo sapiens	158-161
33818020-1	2021	PURPOSE: This study aimed to investigate the changes in microRNA-130a (miR-130a) and its correlation with cardiotoxicity during epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D+T) adjuvant chemotherapy in human epidermal growth factor receptor-2-positive (HER2+) breast cancer patients.	Epirubicin	128-138	microRNA 130a	Homo sapiens	56-69
33818020-1	2021	PURPOSE: This study aimed to investigate the changes in microRNA-130a (miR-130a) and its correlation with cardiotoxicity during epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D+T) adjuvant chemotherapy in human epidermal growth factor receptor-2-positive (HER2+) breast cancer patients.	Epirubicin	128-138	microRNA 130a	Homo sapiens	71-79
26516361-0	2015	High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.	Epirubicin	77-87	pyruvate kinase M1/2	Homo sapiens	19-37
26516361-5	2015	RESULTS: We found high PKM2 expression was significantly associated with in vitro chemosensitivity to epirubicin (EPI) (P=0.019) and 5-fluorouracil (5-Fu) (P=0.009) in breast cancer patients.	Epirubicin	102-112	pyruvate kinase M1/2	Homo sapiens	23-27
23815443-0	2013	Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.	Epirubicin	21-31	immunoglobulin kappa variable 6D-21 (non-functional)	Homo sapiens	61-64
23815443-3	2013	In this work, A10 (Apt), an aptamer for prostate-specific membrane anytigen (PSMA), was applied for targeted delivery of Epirubicin (Epi) to LNCaP cells (PSMA(+)).	Epirubicin	121-131	immunoglobulin kappa variable 6D-21 (non-functional)	Homo sapiens	14-17
23815443-3	2013	In this work, A10 (Apt), an aptamer for prostate-specific membrane anytigen (PSMA), was applied for targeted delivery of Epirubicin (Epi) to LNCaP cells (PSMA(+)).	Epirubicin	121-131	folate hydrolase 1	Homo sapiens	40-75
23815443-3	2013	In this work, A10 (Apt), an aptamer for prostate-specific membrane anytigen (PSMA), was applied for targeted delivery of Epirubicin (Epi) to LNCaP cells (PSMA(+)).	Epirubicin	121-131	folate hydrolase 1	Homo sapiens	77-81
23815443-3	2013	In this work, A10 (Apt), an aptamer for prostate-specific membrane anytigen (PSMA), was applied for targeted delivery of Epirubicin (Epi) to LNCaP cells (PSMA(+)).	Epirubicin	121-131	folate hydrolase 1	Homo sapiens	154-158
34312098-2	2022	The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).	Epirubicin	175-185	erb-b2 receptor tyrosine kinase 2	Homo sapiens	285-319
34312098-2	2022	The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).	Epirubicin	175-185	erb-b2 receptor tyrosine kinase 2	Homo sapiens	330-334
34592784-1	2022	AIM: To explore the effect of TEC chemotherapy regimen (Docetaxel + Epirubicin + Cyclophosphamide) on traditional cardiovascular risk factors, atherosclerotic cardiovascular disease and cardiac electrical activity.	Epirubicin	68-78	tec protein tyrosine kinase	Homo sapiens	30-33
34654351-0	2021	Orosomucoid 1 Promotes Epirubicin Resistance in Breast Cancer by Upregulating the Expression of matrix metalloproteinases 2 and 9.	Epirubicin	23-33	orosomucoid 1	Homo sapiens	0-13
34848465-7	2021	EPI served as a substrate of P-glycoprotein and multidrug associated protein (MRP) 1 and MRP2 similarly to DOX, but the efflux efficiency of each transporter was markedly different between EPI and DOX.	Epirubicin	189-192	ATP binding cassette subfamily B member 1	Homo sapiens	29-43
34848465-7	2021	EPI served as a substrate of P-glycoprotein and multidrug associated protein (MRP) 1 and MRP2 similarly to DOX, but the efflux efficiency of each transporter was markedly different between EPI and DOX.	Epirubicin	189-192	ATP binding cassette subfamily C member 1	Homo sapiens	48-84
34654351-0	2021	Orosomucoid 1 Promotes Epirubicin Resistance in Breast Cancer by Upregulating the Expression of matrix metalloproteinases 2 and 9.	Epirubicin	23-33	matrix metallopeptidase 2	Homo sapiens	96-129
34848465-7	2021	EPI served as a substrate of P-glycoprotein and multidrug associated protein (MRP) 1 and MRP2 similarly to DOX, but the efflux efficiency of each transporter was markedly different between EPI and DOX.	Epirubicin	189-192	ATP binding cassette subfamily C member 2	Homo sapiens	89-93
34654351-8	2021	Therefore, ORM1 may represent a potential therapeutic target for breast cancer and promote epirubicin resistance by regulating the expression of MMP-2 and MMP-9, as well as activating the AKT/ERK signaling pathway.	Epirubicin	91-101	orosomucoid 1	Homo sapiens	11-15
34654351-8	2021	Therefore, ORM1 may represent a potential therapeutic target for breast cancer and promote epirubicin resistance by regulating the expression of MMP-2 and MMP-9, as well as activating the AKT/ERK signaling pathway.	Epirubicin	91-101	matrix metallopeptidase 2	Homo sapiens	145-150
34654351-8	2021	Therefore, ORM1 may represent a potential therapeutic target for breast cancer and promote epirubicin resistance by regulating the expression of MMP-2 and MMP-9, as well as activating the AKT/ERK signaling pathway.	Epirubicin	91-101	matrix metallopeptidase 9	Homo sapiens	155-160
34654351-8	2021	Therefore, ORM1 may represent a potential therapeutic target for breast cancer and promote epirubicin resistance by regulating the expression of MMP-2 and MMP-9, as well as activating the AKT/ERK signaling pathway.	Epirubicin	91-101	mitogen-activated protein kinase 1	Homo sapiens	192-195
34849208-3	2021	GPR120 gene knockdown in breast cancer studies revealed a role of GPR120-induced chemoresistance in epirubicin and cisplatin-induced DNA damage in tumour cells.	Epirubicin	100-110	free fatty acid receptor 4	Homo sapiens	0-6
34834357-0	2021	POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients.	Epirubicin	60-70	RNA polymerase mitochondrial	Homo sapiens	0-6
34834357-9	2021	Individuals harbouring the risk allele had a decreased expression of POLRMT in heart tissue that may cause an impaired capacity to maintain a healthy mitochondrial population in cardiomyocytes under stressful conditions, as is treatment with epirubicin.	Epirubicin	242-252	RNA polymerase mitochondrial	Homo sapiens	69-75
34720803-3	2021	Methods: IGKC expression was immunohistochemically analyzed in 193 breast cancer patients who were treated with adjuvant chemotherapy, either with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) between 1993 and 2001 with a median follow-up of 11 years.	Epirubicin	223-233	immunoglobulin kappa constant	Homo sapiens	9-13
34294886-0	2022	Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.	Epirubicin	93-103	cofilin 1	Homo sapiens	117-124
34294886-7	2022	Moreover, we revealed that co-administration of CEP and epirubicin markedly increased the generation of mitochondrial superoxide, resulting in oxidation of the actin-remodeling protein cofilin, which promoted formation of an intramolecular disulfide bridge between Cys39 and Cys80 as well as Ser3 dephosphorylation, leading to mitochondria translocation of cofilin, thus causing mitochondrial fission and apoptosis.	Epirubicin	56-66	cofilin 1	Homo sapiens	185-192
34294886-7	2022	Moreover, we revealed that co-administration of CEP and epirubicin markedly increased the generation of mitochondrial superoxide, resulting in oxidation of the actin-remodeling protein cofilin, which promoted formation of an intramolecular disulfide bridge between Cys39 and Cys80 as well as Ser3 dephosphorylation, leading to mitochondria translocation of cofilin, thus causing mitochondrial fission and apoptosis.	Epirubicin	56-66	cofilin 1	Homo sapiens	357-364
34849208-3	2021	GPR120 gene knockdown in breast cancer studies revealed a role of GPR120-induced chemoresistance in epirubicin and cisplatin-induced DNA damage in tumour cells.	Epirubicin	100-110	free fatty acid receptor 4	Homo sapiens	66-72
34323910-5	2021	Multifunctional nanoparticles modified with pH-sensitive epidermal growth factor receptor (EGFR)-targeting and nucleus-directed peptides were designed for the efficient delivery of HuR CRISPR and epirubicin to human tongue squamous carcinoma SAS cells and SAS tumor-bearing mice.	Epirubicin	196-206	epidermal growth factor receptor	Homo sapiens	57-89
34323910-5	2021	Multifunctional nanoparticles modified with pH-sensitive epidermal growth factor receptor (EGFR)-targeting and nucleus-directed peptides were designed for the efficient delivery of HuR CRISPR and epirubicin to human tongue squamous carcinoma SAS cells and SAS tumor-bearing mice.	Epirubicin	196-206	epidermal growth factor receptor	Homo sapiens	91-95
34323910-12	2021	In combination with HuR CRISPR nanoparticles, the efficacy and safety of epirubicin nanoparticles against cancer in SAS tumor-bearing mice improved significantly.	Epirubicin	73-83	ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R)	Mus musculus	20-23
34437536-6	2021	The NAD(P)H quinone dehydrogenase 1 (NQO1) gene was found to be associated with the dose-response of arsenic trioxide, erlotinib, trametinib, and a combination treatment of paclitaxel + epirubicin.	Epirubicin	186-196	NAD(P)H quinone dehydrogenase 1	Homo sapiens	4-35
34658346-3	2021	MTT assay was used to assess the proliferation of BON-ELF4 cells and BON-Vector cells, and the cell apoptosis induced by treatment with epirubicin (0.1 mumol/L for 24 h) was analyzed by detecting the expressions of cleaved caspase-8, caspase-9, and PARP using Western blotting.	Epirubicin	136-146	caspase 8	Homo sapiens	223-232
34658346-3	2021	MTT assay was used to assess the proliferation of BON-ELF4 cells and BON-Vector cells, and the cell apoptosis induced by treatment with epirubicin (0.1 mumol/L for 24 h) was analyzed by detecting the expressions of cleaved caspase-8, caspase-9, and PARP using Western blotting.	Epirubicin	136-146	caspase 9	Homo sapiens	234-243
34658346-3	2021	MTT assay was used to assess the proliferation of BON-ELF4 cells and BON-Vector cells, and the cell apoptosis induced by treatment with epirubicin (0.1 mumol/L for 24 h) was analyzed by detecting the expressions of cleaved caspase-8, caspase-9, and PARP using Western blotting.	Epirubicin	136-146	poly(ADP-ribose) polymerase 1	Homo sapiens	249-253
34658346-7	2021	ELF4 overexpression significantly promoted the proliferation (P < 0.05) and obviously suppressed epirubicin- induced apoptosis in BON cells, resulting also in significantly reduced expressions of cleaved caspase-8, caspase-9 and PARP (P < 0.05).	Epirubicin	97-107	E74 like ETS transcription factor 4	Homo sapiens	0-4
34437536-6	2021	The NAD(P)H quinone dehydrogenase 1 (NQO1) gene was found to be associated with the dose-response of arsenic trioxide, erlotinib, trametinib, and a combination treatment of paclitaxel + epirubicin.	Epirubicin	186-196	NAD(P)H quinone dehydrogenase 1	Homo sapiens	37-41
34437536-7	2021	NQO1 has previously been shown as a biomarker of epirubicin response, but our results reveal novel associations with these additional treatments.	Epirubicin	49-59	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-4
35618186-5	2022	Herein, based on the statistically different NQO1 expression between cancerous and normal bladder tissues, the reactive oxygen species (ROS) activatable epirubicin prodrug and highly potent NQO1 substrate, KP372-1, was co-delivered using a GSH-responsive mucoadhesive nanocarrier.	Epirubicin	153-163	NAD(P)H quinone dehydrogenase 1	Homo sapiens	45-49
34262130-5	2021	Here we found that CRIP1 downregulation causes HR repair deficiency with concomitant increase in cell sensitivity to cisplatin, epirubicin, and the poly ADP-ribose polymerase (PARP) inhibitor olaparib in gastric cancer cells.	Epirubicin	128-138	cysteine rich protein 1	Homo sapiens	19-24
34694666-0	2021	Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation.	Epirubicin	47-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	61-65
34991424-4	2022	This study aims to evaluate targeted delivery of epirubicin (Epi) to colon cancer cells using ferritin nanoparticles (Ft NPs) and MUC1 aptamer (Apt) and formation of Apt-Epi Ft NPs.	Epirubicin	49-59	mucin 1, cell surface associated	Homo sapiens	130-134
34893156-7	2021	The polymorphism rs1695 of the GSTP1 gene has been associated with the effectiveness and toxicity of fluorouracil, cyclophosphamide and epirubicin therapy.	Epirubicin	136-146	glutathione S-transferase pi 1	Homo sapiens	31-36
34116668-11	2021	Among the 94 obtained drugs, only 12 drugs were reported in studies, of which 7 drugs (e.g., epirubicin) were found to target TOP2A.	Epirubicin	93-103	DNA topoisomerase II alpha	Homo sapiens	126-131
34178646-3	2021	The chemotherapeutics such as epirubicin (EPI) could increase Nrf2 expression, while Camptothecin (CPT) could inhibit tumor growth by down-regulating the key molecule of antioxidant stress signal-Nrf2.	Epirubicin	30-40	nuclear factor, erythroid derived 2, like 2	Mus musculus	62-66
34178646-3	2021	The chemotherapeutics such as epirubicin (EPI) could increase Nrf2 expression, while Camptothecin (CPT) could inhibit tumor growth by down-regulating the key molecule of antioxidant stress signal-Nrf2.	Epirubicin	30-40	nuclear factor, erythroid derived 2, like 2	Mus musculus	196-200
34178646-3	2021	The chemotherapeutics such as epirubicin (EPI) could increase Nrf2 expression, while Camptothecin (CPT) could inhibit tumor growth by down-regulating the key molecule of antioxidant stress signal-Nrf2.	Epirubicin	42-45	nuclear factor, erythroid derived 2, like 2	Mus musculus	62-66
34178646-3	2021	The chemotherapeutics such as epirubicin (EPI) could increase Nrf2 expression, while Camptothecin (CPT) could inhibit tumor growth by down-regulating the key molecule of antioxidant stress signal-Nrf2.	Epirubicin	42-45	nuclear factor, erythroid derived 2, like 2	Mus musculus	196-200
34178646-6	2021	In Huh7 cells, Nrf2 expression and ROS level were found increased after incubation with EPI by western blot and flow cytometry assay.	Epirubicin	88-91	NFE2 like bZIP transcription factor 2	Homo sapiens	15-19
34178646-10	2021	The combination of EPI and CPT could inhibit Nrf2 expression but demonstrated more suppressing effect of tumor growth than EPI.	Epirubicin	19-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	45-49
35618186-6	2022	After endocytosis, epirubicin could be promptly activated by the NQO1-dependent ROS production caused by KP372-1, thus specifically inhibiting the proliferation of bladder cancer cells.	Epirubicin	19-29	NAD(P)H quinone dehydrogenase 1	Homo sapiens	65-69
35597840-2	2022	The current study aims to identify and validate reliable markers that can predict pathological complete response (pCR) in fluorouracil, epirubicin, and cyclophosphamide (FEC)-based neoadjuvant therapy with (NACT/RT) and without concurrent radiation (NACT).	Epirubicin	136-146	solute carrier family 13 member 5	Homo sapiens	207-211
35507797-0	2022	Recombinant Human Lactoferrin Augments Epirubicin Chemotherapy in Solid Ehrlich Carcinoma Bearing Mice.	Epirubicin	39-49	lactotransferrin	Mus musculus	18-29
35364609-5	2022	Talpha-1 combined with epirubicin chemotherapy markedly suppressed tumor growth in an in vivo breast cancer model by reducing macrophage-derived IL-10 and enhancing the number and function of tumor-infiltrating CD4+ and CD8+ T cells.	Epirubicin	23-33	interleukin 10	Homo sapiens	145-150
35364609-5	2022	Talpha-1 combined with epirubicin chemotherapy markedly suppressed tumor growth in an in vivo breast cancer model by reducing macrophage-derived IL-10 and enhancing the number and function of tumor-infiltrating CD4+ and CD8+ T cells.	Epirubicin	23-33	CD4 molecule	Homo sapiens	211-214
35364609-5	2022	Talpha-1 combined with epirubicin chemotherapy markedly suppressed tumor growth in an in vivo breast cancer model by reducing macrophage-derived IL-10 and enhancing the number and function of tumor-infiltrating CD4+ and CD8+ T cells.	Epirubicin	23-33	CD8a molecule	Homo sapiens	220-223
35615155-10	2022	Moreover, MEOX2 expression was significantly elevated in breast cancer cells after treatment with cisplatin (DDP) and epirubicin (EPI).	Epirubicin	118-128	mesenchyme homeobox 2	Homo sapiens	10-15
35615155-10	2022	Moreover, MEOX2 expression was significantly elevated in breast cancer cells after treatment with cisplatin (DDP) and epirubicin (EPI).	Epirubicin	130-133	mesenchyme homeobox 2	Homo sapiens	10-15
35499687-3	2022	Moreover, PI3K/AKT pathway participates in the process of myocardial injury induced by a number of substances such as H2O2, Mercury, lipopolysaccharides, adriamycin, doxorubicin and epirubicin.	Epirubicin	182-192	AKT serine/threonine kinase 1	Homo sapiens	15-18
35507797-9	2022	Moreover, the combined treatment with rhLF and EPI elevated IL-18 level in the intestinal mucosa compared to other experimental groups with a possible immune-enhancing effect.	Epirubicin	47-50	interleukin 18	Mus musculus	60-65
35154422-0	2022	Erratum: RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells.	Epirubicin	79-89	transient receptor potential cation channel subfamily M member 8	Homo sapiens	48-53
35173139-9	2022	Moreover, locoregional chemotherapy can be achieved with TACE and HAIC (possibly involving FOLFOX, DOX, mitomycin C, cisplatin, epirubicin, etc.).	Epirubicin	128-138	ADAM metallopeptidase domain 17	Homo sapiens	57-61
35145370-9	2022	Finally, low concentrations of CTX and EPI induce gamma-H2AX, and EPI induces cytokine release, NO production and Iba-1 overexpression.	Epirubicin	39-42	allograft inflammatory factor 1	Homo sapiens	114-119
35096395-6	2022	She received six cycles R-CHOP chemotherapy (rituximab, cyclophosphamide, epirubicin, vincristine, and prednisone) with complete resolution of the mass.	Epirubicin	74-84	DNA damage inducible transcript 3	Homo sapiens	26-30
35127582-6	2022	Conclusion: Gemcitabine and L-OHP + EPI + irinotecan + 5-FU, L-OHP + EPI, and L-OHP + irinotecan + EPI were more effective against AFP-positive compared with AFP-negative liver cancer cells according to in vitro high-throughput drug sensitivity screening.	Epirubicin	99-102	alpha fetoprotein	Homo sapiens	158-161
35145370-9	2022	Finally, low concentrations of CTX and EPI induce gamma-H2AX, and EPI induces cytokine release, NO production and Iba-1 overexpression.	Epirubicin	66-69	allograft inflammatory factor 1	Homo sapiens	114-119
33753200-0	2021	A novel nuclear localization region in SIPA1 determines protein nuclear distribution and epirubicin-sensitivity of breast cancer cells.	Epirubicin	89-99	signal-induced proliferation-associated 1	Homo sapiens	39-44
35070996-4	2021	In addition, miR-1301 is related to the anti-tumor effect of epirubicin on osteosarcoma and imatinib on chronic myeloid leukemia(CML) and can enhance the cisplatin sensitivity of ovarian cancer.	Epirubicin	61-71	microRNA 1301	Homo sapiens	13-21
3163942-0	1988	Morphological changes and catalase activity in the hearts of CD 1 mice following acute starvation or single doses of doxorubicin, epirubicin or mitoxantrone.	Epirubicin	130-140	CD1 antigen complex	Mus musculus	61-65
3163942-10	1988	Catalase specific activity increased by 119.9% in the doxorubicin animals, by 73% in the epirubicin mice and by 30.3% in the mitoxantrone ones.	Epirubicin	89-99	catalase	Mus musculus	0-8
33753200-6	2021	Furthermore, we found that a high expression of SIPA1 upregulated the expression of ABCB1, encoding multi-drug resistance protein MDR1, and promoted the resistance to epirubicin in breast cancer cells, while this effect was largely abolished in the cells with the expression of NLR-deleted SIPA1.	Epirubicin	167-177	signal-induced proliferation-associated 1	Homo sapiens	48-53
33753200-7	2021	This study overall, identified a nuclear localization-dependent region determining the nuclear distribution of SIPA1 and its regulation on epirubicin-sensitivity in breast cancer cells, which could be a potential drug target to facilitate the development of breast cancer chemotherapy.	Epirubicin	139-149	signal-induced proliferation-associated 1	Homo sapiens	111-116
33755863-1	2021	BACKGROUND: Zolbetuximab plus first-line EOX (epirubicin, oxaliplatin, capecitabine; ZOL/EOX) significantly prolonged progression-free survival and overall survival in the FAST trial vs EOX alone.	Epirubicin	46-56	Fas activated serine/threonine kinase	Homo sapiens	172-176
34009568-6	2021	We aimed to analyze NKG2DLs expression profiles in response to chemotherapeutic drugs and increased MHC class I polypeptide-related sequence A (MICA) expression, which is related to favorable prognosis in CRC, using low doses of bortezomib and epirubicin combination without causing direct cytotoxicity.	Epirubicin	244-254	killer cell lectin like receptor C1	Homo sapiens	20-27
34009568-6	2021	We aimed to analyze NKG2DLs expression profiles in response to chemotherapeutic drugs and increased MHC class I polypeptide-related sequence A (MICA) expression, which is related to favorable prognosis in CRC, using low doses of bortezomib and epirubicin combination without causing direct cytotoxicity.	Epirubicin	244-254	MHC class I polypeptide-related sequence A	Homo sapiens	100-142
34009568-6	2021	We aimed to analyze NKG2DLs expression profiles in response to chemotherapeutic drugs and increased MHC class I polypeptide-related sequence A (MICA) expression, which is related to favorable prognosis in CRC, using low doses of bortezomib and epirubicin combination without causing direct cytotoxicity.	Epirubicin	244-254	MHC class I polypeptide-related sequence A	Homo sapiens	144-148
34009568-10	2021	Overall, the analyzed data showed that NKG2DLs demonstrate different expression profiles in response to chemotherapeutic agents and a combination of low-dose bortezomib and epirubicin slightly increased MICA mRNA expression in CRC cell lines.	Epirubicin	173-183	killer cell lectin like receptor C1	Homo sapiens	39-46
34009568-10	2021	Overall, the analyzed data showed that NKG2DLs demonstrate different expression profiles in response to chemotherapeutic agents and a combination of low-dose bortezomib and epirubicin slightly increased MICA mRNA expression in CRC cell lines.	Epirubicin	173-183	MHC class I polypeptide-related sequence A	Homo sapiens	203-207
34045966-3	2021	We show that the drug of fluorouracil (5FU), epirubicin (EPI) and gemcitabine (GEM) can induce ROS generation, activate Ets2 and promote CD13 expression.	Epirubicin	45-55	ETS proto-oncogene 2, transcription factor	Homo sapiens	120-124
34045966-3	2021	We show that the drug of fluorouracil (5FU), epirubicin (EPI) and gemcitabine (GEM) can induce ROS generation, activate Ets2 and promote CD13 expression.	Epirubicin	45-55	alanyl aminopeptidase, membrane	Homo sapiens	137-141
34045966-3	2021	We show that the drug of fluorouracil (5FU), epirubicin (EPI) and gemcitabine (GEM) can induce ROS generation, activate Ets2 and promote CD13 expression.	Epirubicin	57-60	ETS proto-oncogene 2, transcription factor	Homo sapiens	120-124
34045966-3	2021	We show that the drug of fluorouracil (5FU), epirubicin (EPI) and gemcitabine (GEM) can induce ROS generation, activate Ets2 and promote CD13 expression.	Epirubicin	57-60	alanyl aminopeptidase, membrane	Homo sapiens	137-141
33832852-1	2021	BACKGROUND: Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7).	Epirubicin	12-22	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	78-84
33162555-8	2021	Furthermore, we found that CRSP8 regulated the sensitivity of thyroid cancer cells to chemotherapeutics, including cisplatin and epirubicin.	Epirubicin	129-139	mediator complex subunit 27	Homo sapiens	27-32
33703900-0	2021	Thermal Reversibility and Structural Stability in Lysozyme Induced by Epirubicin Hydrochloride.	Epirubicin	70-94	lysozyme	Homo sapiens	50-58
33703900-1	2021	Herein we report the binding interactions between lysozyme (Lyz) and an anthracycline drug, epirubicin hydrochloride (EPR), through an extensive spectroscopic approach at both ensemble average and single molecular resolution.	Epirubicin	92-116	lysozyme	Homo sapiens	50-58
33703900-1	2021	Herein we report the binding interactions between lysozyme (Lyz) and an anthracycline drug, epirubicin hydrochloride (EPR), through an extensive spectroscopic approach at both ensemble average and single molecular resolution.	Epirubicin	92-116	lysozyme	Homo sapiens	60-63
33703900-1	2021	Herein we report the binding interactions between lysozyme (Lyz) and an anthracycline drug, epirubicin hydrochloride (EPR), through an extensive spectroscopic approach at both ensemble average and single molecular resolution.	Epirubicin	118-121	lysozyme	Homo sapiens	50-58
33703900-1	2021	Herein we report the binding interactions between lysozyme (Lyz) and an anthracycline drug, epirubicin hydrochloride (EPR), through an extensive spectroscopic approach at both ensemble average and single molecular resolution.	Epirubicin	118-121	lysozyme	Homo sapiens	60-63
33842631-13	2021	After epirubicin therapy, the proportion of early apoptotic cells decreased among cells with PIK3CA mutation.	Epirubicin	6-16	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	93-99
33747911-0	2021	Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression.	Epirubicin	40-50	integrin subunit beta 1	Homo sapiens	109-114
33747911-8	2021	Our study demonstrates that novel lnc005620 promotes TNBC progression and chemoresistance to epirubicin via integrin beta1 both in vitro and in vivo and provides a promising therapeutic target for TNBC patients in terms of enhancing the benefits of epirubicin treatment.	Epirubicin	93-103	integrin subunit beta 1	Homo sapiens	108-122
33747911-8	2021	Our study demonstrates that novel lnc005620 promotes TNBC progression and chemoresistance to epirubicin via integrin beta1 both in vitro and in vivo and provides a promising therapeutic target for TNBC patients in terms of enhancing the benefits of epirubicin treatment.	Epirubicin	249-259	integrin subunit beta 1	Homo sapiens	108-122
33586348-7	2021	Inhibition of EphA2 by AWL-II-41-27, EphA2-specific tyrosine kinase inhibitor, or knock-down of EphA2 decreased mRNA and protein expression of cyclin-dependent kinase (CDK) 6 in CC cells, which increased cellular susceptibility to epirubicin (EPI), an anti-cancer chemotherapy drug.	Epirubicin	231-241	Eph receptor A2	Mus musculus	14-19
33586348-7	2021	Inhibition of EphA2 by AWL-II-41-27, EphA2-specific tyrosine kinase inhibitor, or knock-down of EphA2 decreased mRNA and protein expression of cyclin-dependent kinase (CDK) 6 in CC cells, which increased cellular susceptibility to epirubicin (EPI), an anti-cancer chemotherapy drug.	Epirubicin	231-241	cyclin dependent kinase 6	Homo sapiens	143-174
33586348-7	2021	Inhibition of EphA2 by AWL-II-41-27, EphA2-specific tyrosine kinase inhibitor, or knock-down of EphA2 decreased mRNA and protein expression of cyclin-dependent kinase (CDK) 6 in CC cells, which increased cellular susceptibility to epirubicin (EPI), an anti-cancer chemotherapy drug.	Epirubicin	243-246	Eph receptor A2	Mus musculus	14-19
33586348-7	2021	Inhibition of EphA2 by AWL-II-41-27, EphA2-specific tyrosine kinase inhibitor, or knock-down of EphA2 decreased mRNA and protein expression of cyclin-dependent kinase (CDK) 6 in CC cells, which increased cellular susceptibility to epirubicin (EPI), an anti-cancer chemotherapy drug.	Epirubicin	243-246	cyclin dependent kinase 6	Homo sapiens	143-174
33572239-0	2021	Initial Identification of UDP-Glucose Dehydrogenase as a Prognostic Marker in Breast Cancer Patients, Which Facilitates Epirubicin Resistance and Regulates Hyaluronan Synthesis in MDA-MB-231 Cells.	Epirubicin	120-130	UDP-glucose 6-dehydrogenase	Homo sapiens	26-51
33572239-3	2021	This work aimed to evaluate the effect of UGDH knockdown on epirubicin response and hyaluronan metabolism in MDA-MB-231 breast cancer cells.	Epirubicin	60-70	UDP-glucose 6-dehydrogenase	Homo sapiens	42-46
33572239-11	2021	Epirubicin accumulation increased and apoptosis decreased during UGDH knockdown.	Epirubicin	0-10	UDP-glucose 6-dehydrogenase	Homo sapiens	65-69
33572239-15	2021	However, UGDH knockdown contributes to epirubicin resistance, which might be associated with increases in the expression, deposition and catabolism of hyaluronan.	Epirubicin	39-49	UDP-glucose 6-dehydrogenase	Homo sapiens	9-13
33572239-16	2021	The results obtained allowed us to propose UGDH as a new prognostic marker in breast cancer, positively associated with development of epirubicin resistance and modulation of extracellular matrix.	Epirubicin	135-145	UDP-glucose 6-dehydrogenase	Homo sapiens	43-47
33007707-0	2021	Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-kappaB pathway.	Epirubicin	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
33462219-0	2021	MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.	Epirubicin	53-63	mesenteric estrogen dependent adipogenesis	Homo sapiens	0-5
33462219-0	2021	MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.	Epirubicin	53-63	AKT serine/threonine kinase 1	Homo sapiens	88-91
33462219-0	2021	MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.	Epirubicin	53-63	mechanistic target of rapamycin kinase	Homo sapiens	97-101
33462219-6	2021	MEDAG knockdown inhibited cell proliferation, invasion, and migration; triggered epithelial-to-mesenchymal transition (EMT); and enhanced epirubicin sensitivity in vitro.	Epirubicin	138-148	mesenteric estrogen dependent adipogenesis	Homo sapiens	0-5
33007707-0	2021	Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-kappaB pathway.	Epirubicin	83-93	nuclear factor kappa B subunit 1	Homo sapiens	142-151
33007707-1	2021	BACKGROUND: Epirubicin is a first-line chemotherapeutic drug for the clinical treatment of diffuse large B cell lymphoma (DLBCL), but the overexpression of multidrug resistance (MDR) transporter proteins, especially P-glycoprotein (P-gp), renders epirubicin ineffective.	Epirubicin	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	216-230
33007707-1	2021	BACKGROUND: Epirubicin is a first-line chemotherapeutic drug for the clinical treatment of diffuse large B cell lymphoma (DLBCL), but the overexpression of multidrug resistance (MDR) transporter proteins, especially P-glycoprotein (P-gp), renders epirubicin ineffective.	Epirubicin	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	232-236
33007707-8	2021	Further, melatonin synergized with epirubicin to promote the activation of the mitochondria-mediated apoptosis pathway and increased the accumulation of epirubicin in DLBCL cells by inhibiting the expression and function of P-gp.	Epirubicin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	224-228
33007707-10	2021	Epirubicin was subsequently discovered to upregulate the expression of P-gp by activating the NF-kappaB pathway in the DLBCL cells.	Epirubicin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
33007707-10	2021	Epirubicin was subsequently discovered to upregulate the expression of P-gp by activating the NF-kappaB pathway in the DLBCL cells.	Epirubicin	0-10	nuclear factor kappa B subunit 1	Homo sapiens	94-103
33281951-9	2020	Depletion of PARPBP increased breast cancer cell apoptosis and DNA damage caused by epirubicin.	Epirubicin	84-94	PARP1 binding protein	Homo sapiens	13-19
33007707-12	2021	CONCLUSIONS: Our results demonstrated that melatonin inactivates the NF-kappaB pathway and downregulates the expression of P-gp, ultimately sensitizing DLBCL cells to the epirubicin that suppresses their growth.	Epirubicin	171-181	nuclear factor kappa B subunit 1	Homo sapiens	69-78
33007707-12	2021	CONCLUSIONS: Our results demonstrated that melatonin inactivates the NF-kappaB pathway and downregulates the expression of P-gp, ultimately sensitizing DLBCL cells to the epirubicin that suppresses their growth.	Epirubicin	171-181	ATP binding cassette subfamily B member 1	Homo sapiens	123-127
33299650-8	2020	The basal-like and HER2+ breast cancer primary cells showed chemosensitivities to paclitaxel and epirubicin with significant differences compared with luminal breast cancer primary cells (P < 0.05).	Epirubicin	97-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	19-23
33199443-8	2021	Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR-amplified aGEA.	Epirubicin	59-69	epidermal growth factor receptor	Homo sapiens	17-21
33199443-8	2021	Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR-amplified aGEA.	Epirubicin	59-69	cyclin dependent kinase inhibitor 1A	Homo sapiens	195-198
33199443-8	2021	Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR-amplified aGEA.	Epirubicin	59-69	cyclin B1	Homo sapiens	203-212
33199443-8	2021	Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR-amplified aGEA.	Epirubicin	59-69	cyclin E1	Homo sapiens	232-241
33199443-8	2021	Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR-amplified aGEA.	Epirubicin	59-69	epidermal growth factor receptor	Homo sapiens	286-290
32974345-9	2020	Epirubicin exposure also impaired endothelial function with delayed wound closure, reduced angiogenic potential and increased monolayer permeability downstream of VE-cadherin internalization.	Epirubicin	0-10	cadherin 5	Homo sapiens	163-174
32937248-11	2020	The pro-angiogenic miRNAs let-7f, miR-20a, miR-126 and miR-210 were significantly down-regulated in epirubicin-cardiotoxicity when compared to the non-cardiotoxicity group.	Epirubicin	100-110	microRNA 20a	Homo sapiens	34-41
32937248-11	2020	The pro-angiogenic miRNAs let-7f, miR-20a, miR-126 and miR-210 were significantly down-regulated in epirubicin-cardiotoxicity when compared to the non-cardiotoxicity group.	Epirubicin	100-110	microRNA 126	Homo sapiens	43-50
32937248-11	2020	The pro-angiogenic miRNAs let-7f, miR-20a, miR-126 and miR-210 were significantly down-regulated in epirubicin-cardiotoxicity when compared to the non-cardiotoxicity group.	Epirubicin	100-110	microRNA 210	Homo sapiens	55-62
31894362-1	2020	The chemotherapeutic drug epirubicin increases the exosomal export of miR-503 in endothelial cells.	Epirubicin	26-36	microRNA 503	Homo sapiens	70-77
31894362-5	2020	Using knock-down systems combined with pull-down analysis, we determined that epirubicin mediates the export of miR-503 by disrupting the interaction between hnRNPA2B1 and miR-503.	Epirubicin	78-88	microRNA 503	Homo sapiens	112-119
31894362-5	2020	Using knock-down systems combined with pull-down analysis, we determined that epirubicin mediates the export of miR-503 by disrupting the interaction between hnRNPA2B1 and miR-503.	Epirubicin	78-88	heterogeneous nuclear ribonucleoprotein A2/B1	Homo sapiens	158-167
31894362-5	2020	Using knock-down systems combined with pull-down analysis, we determined that epirubicin mediates the export of miR-503 by disrupting the interaction between hnRNPA2B1 and miR-503.	Epirubicin	78-88	microRNA 503	Homo sapiens	172-179
32806051-3	2020	Here, we applied pH-sensitive epirubicin-loaded micellar nanomedicines, which are under clinical evaluation, to synergize the efficacy of anti-PD1antibodies (aPD1) against PTEN-positive and PTEN-negative orthotopic GBM, the latter with a large subpopulation of CSCs.	Epirubicin	30-40	phosphatase and tensin homolog	Homo sapiens	172-176
32806051-3	2020	Here, we applied pH-sensitive epirubicin-loaded micellar nanomedicines, which are under clinical evaluation, to synergize the efficacy of anti-PD1antibodies (aPD1) against PTEN-positive and PTEN-negative orthotopic GBM, the latter with a large subpopulation of CSCs.	Epirubicin	30-40	phosphatase and tensin homolog	Homo sapiens	190-194
32806051-4	2020	The combination of epirubicin-loaded micelles (Epi/m) with aPD1 overcame GBM resistance to ICIs by transforming cold GBM into hot tumors with high infiltration of antitumor immune cells through the induction of immunogenic cell death (ICD), elimination of immunosuppressive myeloid-derived suppressor cells (MSDCs), and reduction of PD-L1 expression on tumor cells.	Epirubicin	19-29	tissue factor pathway inhibitor	Homo sapiens	47-50
32806051-4	2020	The combination of epirubicin-loaded micelles (Epi/m) with aPD1 overcame GBM resistance to ICIs by transforming cold GBM into hot tumors with high infiltration of antitumor immune cells through the induction of immunogenic cell death (ICD), elimination of immunosuppressive myeloid-derived suppressor cells (MSDCs), and reduction of PD-L1 expression on tumor cells.	Epirubicin	19-29	CD274 molecule	Homo sapiens	333-338
32811806-8	2020	Finally, DNER protects BC cells from epirubicin-induced growth inhibition and apoptosis via the Wnt/beta-catenin pathway.	Epirubicin	37-47	delta/notch like EGF repeat containing	Homo sapiens	9-13
33102228-0	2020	ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer.	Epirubicin	41-51	ankyrin repeat and BTB domain containing 2	Homo sapiens	0-5
33102228-12	2020	Subsequent biological assays illustrated that upregulation of ABTB2 significantly reduced the apoptosis rate of breast cancer cells and enhanced the chemo-resistance to epirubicin.	Epirubicin	169-179	ankyrin repeat and BTB domain containing 2	Homo sapiens	62-67
33102228-13	2020	Conclusions: Our study demonstrated rs6484711 polymorphism regulating ABTB2 expression might predict efficacy to epirubicin based NAC in luminal A breast cancer patients.	Epirubicin	113-123	ankyrin repeat and BTB domain containing 2	Homo sapiens	70-75
32615282-3	2020	Consistently, GCN2 knockdown severely impaired the clonal survival of parental and resistant MCF-7 cells and sensitised them to epirubicin and paclitaxel treatment.	Epirubicin	128-138	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	14-18
32615282-6	2020	In agreement, we also showed that the perk-/- MEFs, expressing elevated levels of P-JNK, JNK, GCN2 and reduced levels of P-AKT and P-FOXO3, have lower clonogenicity and are more sensitive to epirubicin compared to wild-type MEFs.	Epirubicin	191-201	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	38-42
32615282-7	2020	Similarly, gcn2-/- MEFs expressing augmented levels of P-JNK, JNK, P-PERK, PERK and lower levels of P-AKT and P-FOXO3 also had lower clonogenicity and were more sensitive to epirubicin and PERK-inhibition.	Epirubicin	174-184	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	11-15
32811806-8	2020	Finally, DNER protects BC cells from epirubicin-induced growth inhibition and apoptosis via the Wnt/beta-catenin pathway.	Epirubicin	37-47	catenin beta 1	Homo sapiens	100-112
32711251-6	2020	FINDINGS: Effective low-dose epirubicin treatment resulted in substantial downregulation of the sphingosine 1-phosphate (S1P) degrading enzyme S1P lyase (SPL).	Epirubicin	29-39	sphingosine-1-phosphate lyase 1	Homo sapiens	154-157
31187680-3	2020	DEB-TACE was performed using polyvinyl alcohol-based hydrogel microspheres loaded with epirubicin.	Epirubicin	87-97	ADAM metallopeptidase domain 17	Homo sapiens	4-8
32923587-6	2020	Last, EGFR-targeted nanoengagers can augment both NK-activating agents and chemotherapy (epirubicin) as highly effective anticancer agents, providing robust chemoimmunotherapy.	Epirubicin	89-99	epidermal growth factor receptor	Homo sapiens	6-10
32196840-0	2020	Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway.	Epirubicin	47-57	tripartite motif containing 25	Homo sapiens	0-27
32922605-6	2020	The relationship between FOSL1 and chemotherapy sensitivity was analyzed by a one-way of variance analysis and Pearson"s chi-square test among a total of 50 patients with stage II and III breast cancer before and after they received epirubicin-based neoadjuvant chemotherapy (NCT) between 2012 and 2017.	Epirubicin	233-243	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	25-30
32196840-0	2020	Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway.	Epirubicin	47-57	phosphatase and tensin homolog	Homo sapiens	118-122
32196840-0	2020	Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway.	Epirubicin	47-57	AKT serine/threonine kinase 1	Homo sapiens	123-126
32196840-3	2020	Knockdown of TRIM25 increased the sensitivity of HCC HepG2 cells to epirubicin (EPI), as indicated by reduced cell viability, enhanced cell apoptosis, and downregulated P-glycoprotein (P-gp) and multiple drug-resistance protein 1 (MRP1).	Epirubicin	68-78	tripartite motif containing 25	Homo sapiens	13-19
32196840-3	2020	Knockdown of TRIM25 increased the sensitivity of HCC HepG2 cells to epirubicin (EPI), as indicated by reduced cell viability, enhanced cell apoptosis, and downregulated P-glycoprotein (P-gp) and multiple drug-resistance protein 1 (MRP1).	Epirubicin	80-83	tripartite motif containing 25	Homo sapiens	13-19
32196840-3	2020	Knockdown of TRIM25 increased the sensitivity of HCC HepG2 cells to epirubicin (EPI), as indicated by reduced cell viability, enhanced cell apoptosis, and downregulated P-glycoprotein (P-gp) and multiple drug-resistance protein 1 (MRP1).	Epirubicin	80-83	ATP binding cassette subfamily B member 1	Homo sapiens	185-189
32196840-3	2020	Knockdown of TRIM25 increased the sensitivity of HCC HepG2 cells to epirubicin (EPI), as indicated by reduced cell viability, enhanced cell apoptosis, and downregulated P-glycoprotein (P-gp) and multiple drug-resistance protein 1 (MRP1).	Epirubicin	80-83	ATP binding cassette subfamily C member 1	Homo sapiens	195-229
32196840-3	2020	Knockdown of TRIM25 increased the sensitivity of HCC HepG2 cells to epirubicin (EPI), as indicated by reduced cell viability, enhanced cell apoptosis, and downregulated P-glycoprotein (P-gp) and multiple drug-resistance protein 1 (MRP1).	Epirubicin	80-83	ATP binding cassette subfamily C member 1	Homo sapiens	231-235
32461977-2	2020	This study is aimed at evaluating the efficacy of epirubicin/cyclophosphamide with weekly paclitaxel-trastuzumab as neoadjuvant chemotherapies in HER2+ BC patients.	Epirubicin	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
32162602-5	2020	Here, we hypothesize that a combination treatment of bortezomib and epirubicin will induce immunogenic cell death in colorectal cancer cells by increasing expression of death receptors such as Fas, which will make these cancer cells more susceptible to Fas/FasL mediated tumor cell killing.	Epirubicin	68-78	Fas ligand	Homo sapiens	257-261
32580684-7	2021	The results have shown that Doxorubicin, Neratinib maleate, Epirubicin, and Lapatinib Ditosylate have good interaction with GPR116 binding site.	Epirubicin	60-70	adhesion G protein-coupled receptor F5	Homo sapiens	124-130
31776320-0	2020	Neoadjuvant chemotherapy of capecitabine + epirubicin + cyclophosphamide combination therapy ( "CEX" therapy) for HER-2 negative breast cancer, as retrospective study in our institute.	Epirubicin	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
31776320-1	2020	BACKGROUND: We have modified and performed neoadjuvant chemotherapy (NAC) using capecitabine + epirubicin + cyclophosphamide combination therapy ( "CEX" ) for HER-2 negative breast cancer.	Epirubicin	95-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	159-164
32196840-9	2020	Collectively, our data suggested that TRIM25 enhanced EPI resistance via modulating PTEN/AKT pathway, and targeting TRIM25 may enhance the sensitivity of HCC cells toward chemotherapy drugs.	Epirubicin	54-57	tripartite motif containing 25	Homo sapiens	38-44
32196840-9	2020	Collectively, our data suggested that TRIM25 enhanced EPI resistance via modulating PTEN/AKT pathway, and targeting TRIM25 may enhance the sensitivity of HCC cells toward chemotherapy drugs.	Epirubicin	54-57	phosphatase and tensin homolog	Homo sapiens	84-88
32196840-9	2020	Collectively, our data suggested that TRIM25 enhanced EPI resistance via modulating PTEN/AKT pathway, and targeting TRIM25 may enhance the sensitivity of HCC cells toward chemotherapy drugs.	Epirubicin	54-57	AKT serine/threonine kinase 1	Homo sapiens	89-92
32565933-10	2020	The results indicated that LC3B protein expression was enhanced by EPI in a concentration-dependent manner, and the protein levels of cleaved caspase-3 and cleaved caspase-9 were higher in the combination group than in the EPI alone group.	Epirubicin	67-70	microtubule associated protein 1 light chain 3 beta	Homo sapiens	27-31
32565933-10	2020	The results indicated that LC3B protein expression was enhanced by EPI in a concentration-dependent manner, and the protein levels of cleaved caspase-3 and cleaved caspase-9 were higher in the combination group than in the EPI alone group.	Epirubicin	223-226	microtubule associated protein 1 light chain 3 beta	Homo sapiens	27-31
32565933-10	2020	The results indicated that LC3B protein expression was enhanced by EPI in a concentration-dependent manner, and the protein levels of cleaved caspase-3 and cleaved caspase-9 were higher in the combination group than in the EPI alone group.	Epirubicin	223-226	caspase 3	Homo sapiens	142-151
31155684-8	2020	Epirubicin, docetaxel, and vinblastine inhibited HCGB and PlGF expression while methotrexate, tamoxifen and its two metabolites increased it.	Epirubicin	0-10	chorionic gonadotropin subunit beta 5	Homo sapiens	49-53
31155684-8	2020	Epirubicin, docetaxel, and vinblastine inhibited HCGB and PlGF expression while methotrexate, tamoxifen and its two metabolites increased it.	Epirubicin	0-10	placental growth factor	Homo sapiens	58-62
32443608-9	2020	The immunohistochemistry of the EPI-treated human placentae showed enhanced proliferation and apoptosis as compared with matched chemo-naive placentae, as well as reduced neovascularization (CD34).	Epirubicin	32-35	CD34 molecule	Homo sapiens	191-195
31638266-12	2020	Overexpression of SPRY4-IT1 promoted chemo-resistance of MCF-7 and MDA-MB-231 cells to epirubicin.	Epirubicin	87-97	SPRY4 intronic transcript 1	Homo sapiens	18-27
31823667-7	2020	CONCLUSIONS: ALAS2 and the metabolic pathways which were involved may play an important role in the development of epirubicin-induced cardiomyopathy.	Epirubicin	115-125	5'-aminolevulinate synthase 2	Homo sapiens	13-18
32266101-6	2020	Further, TMP reverted epirubicin resistance by inhibiting JAK2/STAT3 signaling and decreasing FGG expression.	Epirubicin	22-32	Janus kinase 2	Homo sapiens	58-62
31823667-8	2020	ALAS2 may be useful as an early biomarker for epirubicin-induced cardiotoxicity detection.	Epirubicin	46-56	5'-aminolevulinate synthase 2	Homo sapiens	0-5
32266101-6	2020	Further, TMP reverted epirubicin resistance by inhibiting JAK2/STAT3 signaling and decreasing FGG expression.	Epirubicin	22-32	signal transducer and activator of transcription 3	Homo sapiens	63-68
32266101-6	2020	Further, TMP reverted epirubicin resistance by inhibiting JAK2/STAT3 signaling and decreasing FGG expression.	Epirubicin	22-32	fibrinogen gamma chain	Homo sapiens	94-97
32003675-9	2020	RESULTS: The results reveal that Doxorubicin, Neratinib maleate, Epirubicin and Lapatinib Ditosylate has good hydrogen bonding interaction with GPR116 receptor protein binding site.	Epirubicin	65-75	adhesion G protein-coupled receptor F5	Homo sapiens	144-150
32211111-1	2020	This study aimed to determine the correlation of human epidermal growth factor receptor 2 (HER2) codon 655 A>G polymorphism with cardiotoxicity risk in HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D-T) adjuvant chemotherapy.	Epirubicin	200-210	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-89
32211111-1	2020	This study aimed to determine the correlation of human epidermal growth factor receptor 2 (HER2) codon 655 A>G polymorphism with cardiotoxicity risk in HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D-T) adjuvant chemotherapy.	Epirubicin	200-210	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95
32357825-12	2020	CONCLUSION: Epirubicin induced apoptosis in human bladder cancer cells by up-regulating the expression of pro-apoptotic factors (caspase-3, p53 and Bax) and down-regulating the expression of anti-apoptotic factor (Bcl-2).	Epirubicin	12-22	caspase 3	Homo sapiens	129-138
32357825-12	2020	CONCLUSION: Epirubicin induced apoptosis in human bladder cancer cells by up-regulating the expression of pro-apoptotic factors (caspase-3, p53 and Bax) and down-regulating the expression of anti-apoptotic factor (Bcl-2).	Epirubicin	12-22	tumor protein p53	Homo sapiens	140-143
32357825-12	2020	CONCLUSION: Epirubicin induced apoptosis in human bladder cancer cells by up-regulating the expression of pro-apoptotic factors (caspase-3, p53 and Bax) and down-regulating the expression of anti-apoptotic factor (Bcl-2).	Epirubicin	12-22	BCL2 associated X, apoptosis regulator	Homo sapiens	148-151
32357825-12	2020	CONCLUSION: Epirubicin induced apoptosis in human bladder cancer cells by up-regulating the expression of pro-apoptotic factors (caspase-3, p53 and Bax) and down-regulating the expression of anti-apoptotic factor (Bcl-2).	Epirubicin	12-22	BCL2 apoptosis regulator	Homo sapiens	214-219
31905600-5	2019	We investigated the anti-inflammatory properties of epirubicin on the NLRP3 inflammasome and TLR4-mediated inflammation in PMA-primed THP-1 and in primary human peritoneal macrophages (PM).	Epirubicin	52-62	NLR family pyrin domain containing 3	Homo sapiens	70-75
31905600-6	2019	Low-dose epirubicin at non-cytotoxic doses downregulated NLRP3 inflammasome components and reduced the release of cleaved caspase-1, bioactive IL-1beta, and TNF-alpha following NLRP3 activation in a dose-dependent fashion.	Epirubicin	9-19	NLR family pyrin domain containing 3	Homo sapiens	57-62
31905600-6	2019	Low-dose epirubicin at non-cytotoxic doses downregulated NLRP3 inflammasome components and reduced the release of cleaved caspase-1, bioactive IL-1beta, and TNF-alpha following NLRP3 activation in a dose-dependent fashion.	Epirubicin	9-19	caspase 1	Homo sapiens	122-131
31905600-6	2019	Low-dose epirubicin at non-cytotoxic doses downregulated NLRP3 inflammasome components and reduced the release of cleaved caspase-1, bioactive IL-1beta, and TNF-alpha following NLRP3 activation in a dose-dependent fashion.	Epirubicin	9-19	interleukin 1 alpha	Homo sapiens	143-151
31905600-6	2019	Low-dose epirubicin at non-cytotoxic doses downregulated NLRP3 inflammasome components and reduced the release of cleaved caspase-1, bioactive IL-1beta, and TNF-alpha following NLRP3 activation in a dose-dependent fashion.	Epirubicin	9-19	tumor necrosis factor	Homo sapiens	157-166
31905600-6	2019	Low-dose epirubicin at non-cytotoxic doses downregulated NLRP3 inflammasome components and reduced the release of cleaved caspase-1, bioactive IL-1beta, and TNF-alpha following NLRP3 activation in a dose-dependent fashion.	Epirubicin	9-19	NLR family pyrin domain containing 3	Homo sapiens	177-182
31905600-7	2019	In addition, epirubicin attenuated inflammatory macrophage responses after TLR4 and TLR2 ligation.	Epirubicin	13-23	toll like receptor 4	Homo sapiens	75-79
31905600-7	2019	In addition, epirubicin attenuated inflammatory macrophage responses after TLR4 and TLR2 ligation.	Epirubicin	13-23	toll like receptor 2	Homo sapiens	84-88
31685331-4	2019	The epirubicin binds as monomer to G-quadruplex DNA with affinity, Kb1 = 3.8 x 106 M-1 and Kb2 = 2.7 x 106 M-1, at two independent sites externally.	Epirubicin	4-14	folate receptor 1 pseudogene 1	Homo sapiens	67-70
31819503-10	2019	Moreover, miR-193b expression enhanced epirubicin-induced autophagy and apoptosis.	Epirubicin	39-49	microRNA 193b	Homo sapiens	10-18
32357825-10	2020	The expression of caspase-3, p53 and Bax were increased and the expression of Bcl2 was decreased with epirubicin treatment on human bladder cells, which were analyzed by western blot.	Epirubicin	102-112	BCL2 apoptosis regulator	Homo sapiens	78-82
31795129-4	2019	Normalized fluorescence intensity increased linearly as the EPI concentration was raised from 0.09 muM to 189.66 muM and the fluorometric detection limit was 0.05 muM.	Epirubicin	60-63	latexin	Homo sapiens	99-102
31795129-4	2019	Normalized fluorescence intensity increased linearly as the EPI concentration was raised from 0.09 muM to 189.66 muM and the fluorometric detection limit was 0.05 muM.	Epirubicin	60-63	latexin	Homo sapiens	113-116
31795129-4	2019	Normalized fluorescence intensity increased linearly as the EPI concentration was raised from 0.09 muM to 189.66 muM and the fluorometric detection limit was 0.05 muM.	Epirubicin	60-63	latexin	Homo sapiens	113-116
31537377-0	2019	Gp130 degradation induced by epirubicin contributes to chemotherapy efficacy.	Epirubicin	29-39	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	0-5
31585112-11	2019	However, the increased secretion of inflammatory cytokines (IL-6 and IL-8) is sustained and these mediators may be involved in the pathophysiology of bladder toxicity following intravesical epirubicin treatment.	Epirubicin	190-200	interleukin 6	Homo sapiens	60-64
31585112-11	2019	However, the increased secretion of inflammatory cytokines (IL-6 and IL-8) is sustained and these mediators may be involved in the pathophysiology of bladder toxicity following intravesical epirubicin treatment.	Epirubicin	190-200	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
31537377-3	2019	Here we show that epirubicin-induced degradation of transmembrane protein gp130 contributes to antitumor effect of epirubicin.	Epirubicin	18-28	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	74-79
31537377-3	2019	Here we show that epirubicin-induced degradation of transmembrane protein gp130 contributes to antitumor effect of epirubicin.	Epirubicin	115-125	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	74-79
31537377-4	2019	gp130 is degraded by epirubicin in a proteasome- and autophagy-dependent manner.	Epirubicin	21-31	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	0-5
31537377-5	2019	Epirubicin induces activation of p38-MK2 signaling pathway to phosphorylate gp130 at Ser 782, which results in gp130 internalization and degradation by lysosome.	Epirubicin	0-10	mitogen-activated protein kinase 14	Homo sapiens	33-36
31537377-5	2019	Epirubicin induces activation of p38-MK2 signaling pathway to phosphorylate gp130 at Ser 782, which results in gp130 internalization and degradation by lysosome.	Epirubicin	0-10	MAPK activated protein kinase 2	Homo sapiens	37-40
31537377-5	2019	Epirubicin induces activation of p38-MK2 signaling pathway to phosphorylate gp130 at Ser 782, which results in gp130 internalization and degradation by lysosome.	Epirubicin	0-10	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	76-81
31537377-5	2019	Epirubicin induces activation of p38-MK2 signaling pathway to phosphorylate gp130 at Ser 782, which results in gp130 internalization and degradation by lysosome.	Epirubicin	0-10	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	111-116
31537377-6	2019	Although mutation of Ser 782 to Ala or Cys in gp130 upregulates global epirubicin-induced autophagy, reduced degradation of gp130 accompanied with enhanced Stat3 phosphorylation at tyrosine 705 is observed.	Epirubicin	71-81	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	46-51
31537377-7	2019	We also show that epirubicin-resistant tumor cells express higher level of gp130.	Epirubicin	18-28	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	75-80
31537377-8	2019	Altogether, our results indicate that degradation of gp130 and subsequent reduction of gp130-Stat3 signaling contributes to epirubicin-induced tumor cell death.	Epirubicin	124-134	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	53-58
31537377-8	2019	Altogether, our results indicate that degradation of gp130 and subsequent reduction of gp130-Stat3 signaling contributes to epirubicin-induced tumor cell death.	Epirubicin	124-134	Neutrophil migration (granulocyte glycoprotein)	Homo sapiens	87-92
31537377-8	2019	Altogether, our results indicate that degradation of gp130 and subsequent reduction of gp130-Stat3 signaling contributes to epirubicin-induced tumor cell death.	Epirubicin	124-134	signal transducer and activator of transcription 3	Homo sapiens	93-98
31502114-0	2019	Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.	Epirubicin	72-82	colony stimulating factor 3	Homo sapiens	31-68
31560141-0	2019	CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma.	Epirubicin	92-102	CD44 molecule (Indian blood group)	Homo sapiens	0-4
31560141-4	2019	CD44-specific A6 short peptide (KPSSPPEE) functionalized polymersomal epirubicin (A6-PS-EPI), which boosts targetability and anticancer efficacy toward human multiple myeloma (MM) in vivo, is described.	Epirubicin	70-80	CD44 molecule (Indian blood group)	Homo sapiens	0-4
31444414-0	2019	Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis.	Epirubicin	43-53	microRNA 1295a	Homo sapiens	135-145
31444414-0	2019	Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis.	Epirubicin	43-53	twist family bHLH transcription factor 1	Homo sapiens	146-152
31444414-11	2019	To conclude, NONHSAT101069 was upregulated in BC tissues and promoted epirubicin resistance, migration and invasion of BC cells via regulation of NONHSAT101069/miR-129-5p/Twist1 axis, highlighting its potential as an oncogene and a therapeutic biomarker for BC.	Epirubicin	70-80	microRNA 1295a	Homo sapiens	160-170
31444414-11	2019	To conclude, NONHSAT101069 was upregulated in BC tissues and promoted epirubicin resistance, migration and invasion of BC cells via regulation of NONHSAT101069/miR-129-5p/Twist1 axis, highlighting its potential as an oncogene and a therapeutic biomarker for BC.	Epirubicin	70-80	twist family bHLH transcription factor 1	Homo sapiens	171-177
31513391-6	2019	In vitro studies revealed that Tra-Ps-EPI with long-term storage stability could rapidly release drugs under a reductive condition and efficiently deliver a large amount of EPI HCl to HER2-positive SKOV-3 cells, leading to stronger cytotoxicity than the nontargeted Ps-EPI.	Epirubicin	173-180	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
31421170-0	2019	Molecular recognition of 3+1 hybrid human telomeric G-quadruplex DNA d-[AGGG(TTAGGG)3] by anticancer drugs epirubicin and adriamycin leads to thermal stabilization.	Epirubicin	107-117	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	72-76
31421170-2	2019	We have investigated interaction of epirubicin and adriamycin with G4 DNA [d-AGGG(TTAGGG)3] comprising human telomeric DNA sequence by surface plasmon resonance, absorption, fluorescence, circular dichroism and thermal denaturation.	Epirubicin	36-46	NADH:ubiquinone oxidoreductase subunit B2	Homo sapiens	77-81
31513391-0	2019	HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor.	Epirubicin	74-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
31513391-3	2019	Here, we report on trastuzumab-decorated disulfide-cross-linked polymersomes (Tra-Ps) for specific delivery of epirubicin hydrochloride (EPI HCl) to HER2-positive SKOV-3 ovarian tumor.	Epirubicin	111-135	T cell receptor alpha locus	Homo sapiens	78-81
31513391-3	2019	Here, we report on trastuzumab-decorated disulfide-cross-linked polymersomes (Tra-Ps) for specific delivery of epirubicin hydrochloride (EPI HCl) to HER2-positive SKOV-3 ovarian tumor.	Epirubicin	111-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
31513391-3	2019	Here, we report on trastuzumab-decorated disulfide-cross-linked polymersomes (Tra-Ps) for specific delivery of epirubicin hydrochloride (EPI HCl) to HER2-positive SKOV-3 ovarian tumor.	Epirubicin	137-144	T cell receptor alpha locus	Homo sapiens	78-81
31513391-3	2019	Here, we report on trastuzumab-decorated disulfide-cross-linked polymersomes (Tra-Ps) for specific delivery of epirubicin hydrochloride (EPI HCl) to HER2-positive SKOV-3 ovarian tumor.	Epirubicin	137-144	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-153
31513391-4	2019	EPI HCl-loaded Tra-Ps (Tra-Ps-EPI) with a small size of 50-60 nm and varying Tra surface densities (0.5 to 2.4 Tra per Ps) were conveniently obtained via post-conjugation of thiolated trastuzumab onto the surface of maleimide-functionalized Ps-EPI with a drug loading content of 12.7 wt %.	Epirubicin	0-3	T cell receptor alpha locus	Homo sapiens	15-18
31513391-4	2019	EPI HCl-loaded Tra-Ps (Tra-Ps-EPI) with a small size of 50-60 nm and varying Tra surface densities (0.5 to 2.4 Tra per Ps) were conveniently obtained via post-conjugation of thiolated trastuzumab onto the surface of maleimide-functionalized Ps-EPI with a drug loading content of 12.7 wt %.	Epirubicin	0-3	T cell receptor alpha locus	Homo sapiens	23-26
31513391-4	2019	EPI HCl-loaded Tra-Ps (Tra-Ps-EPI) with a small size of 50-60 nm and varying Tra surface densities (0.5 to 2.4 Tra per Ps) were conveniently obtained via post-conjugation of thiolated trastuzumab onto the surface of maleimide-functionalized Ps-EPI with a drug loading content of 12.7 wt %.	Epirubicin	0-3	T cell receptor alpha locus	Homo sapiens	23-26
31513391-4	2019	EPI HCl-loaded Tra-Ps (Tra-Ps-EPI) with a small size of 50-60 nm and varying Tra surface densities (0.5 to 2.4 Tra per Ps) were conveniently obtained via post-conjugation of thiolated trastuzumab onto the surface of maleimide-functionalized Ps-EPI with a drug loading content of 12.7 wt %.	Epirubicin	0-3	T cell receptor alpha locus	Homo sapiens	23-26
31351363-9	2019	CONCLUSIONS: Taken together, the protective effect of Magnesium Isoglycyrrhizinate on EPI-induced hepatic encephalopathy might be mediated via the Txnip/Nrf2/NF-kappaB signaling pathway.	Epirubicin	86-89	thioredoxin interacting protein	Mus musculus	147-152
31351363-9	2019	CONCLUSIONS: Taken together, the protective effect of Magnesium Isoglycyrrhizinate on EPI-induced hepatic encephalopathy might be mediated via the Txnip/Nrf2/NF-kappaB signaling pathway.	Epirubicin	86-89	nuclear factor, erythroid derived 2, like 2	Mus musculus	153-157
31351363-9	2019	CONCLUSIONS: Taken together, the protective effect of Magnesium Isoglycyrrhizinate on EPI-induced hepatic encephalopathy might be mediated via the Txnip/Nrf2/NF-kappaB signaling pathway.	Epirubicin	86-89	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	158-167
31514476-7	2019	The results showed that the plasma levels of TIMP-1 in the group of patients receiving HT were significantly lower than those levels found in the control group after the epirubicin-cyclophosphamide chemotherapy.	Epirubicin	170-180	TIMP metallopeptidase inhibitor 1	Homo sapiens	45-51
31513391-9	2019	These HER2-specific reduction-sensitive immunopolymersomes with high loading of epirubicin emerge as an attractive treatment for HER2-positive tumors.	Epirubicin	80-90	erb-b2 receptor tyrosine kinase 2	Mus musculus	6-10
31513391-9	2019	These HER2-specific reduction-sensitive immunopolymersomes with high loading of epirubicin emerge as an attractive treatment for HER2-positive tumors.	Epirubicin	80-90	erb-b2 receptor tyrosine kinase 2	Mus musculus	129-133
31433581-0	2019	miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.	Epirubicin	37-47	microRNA 1301	Homo sapiens	0-8
31433581-0	2019	miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.	Epirubicin	37-47	TP53 regulated inhibitor of apoptosis 1	Homo sapiens	9-15
31433581-3	2019	Whether miR-1301 is responsible for the chemosensitivity of osteosarcoma cells to epirubicin remains largely unknown.	Epirubicin	82-92	microRNA 1301	Homo sapiens	8-16
31433581-9	2019	RESULTS: Epirubicin inhibited proliferation in a dose-dependent manner, induced apoptosis, decreased the expression of Bcl-2, and increased the expressions of Bax, cleaved-caspase-3, and cleaved-PARP1 in osteosarcoma cells.	Epirubicin	9-19	BCL2 apoptosis regulator	Homo sapiens	119-124
31433581-9	2019	RESULTS: Epirubicin inhibited proliferation in a dose-dependent manner, induced apoptosis, decreased the expression of Bcl-2, and increased the expressions of Bax, cleaved-caspase-3, and cleaved-PARP1 in osteosarcoma cells.	Epirubicin	9-19	BCL2 associated X, apoptosis regulator	Homo sapiens	159-162
31433581-9	2019	RESULTS: Epirubicin inhibited proliferation in a dose-dependent manner, induced apoptosis, decreased the expression of Bcl-2, and increased the expressions of Bax, cleaved-caspase-3, and cleaved-PARP1 in osteosarcoma cells.	Epirubicin	9-19	poly(ADP-ribose) polymerase 1	Homo sapiens	195-200
31433581-11	2019	Importantly, epirubicin significantly increased the levels of miR-1301.	Epirubicin	13-23	microRNA 1301	Homo sapiens	62-70
31433581-14	2019	In contrast, miR-1301 depletion attenuated the epirubicin-mediated anti-osteosarcoma effect.	Epirubicin	47-57	microRNA 1301	Homo sapiens	13-21
31433581-16	2019	Furthermore, epirubicin inhibited the mRNA and protein levels of TRIAP1 by upregulating miR-1301 levels.	Epirubicin	13-23	TP53 regulated inhibitor of apoptosis 1	Homo sapiens	65-71
31433581-16	2019	Furthermore, epirubicin inhibited the mRNA and protein levels of TRIAP1 by upregulating miR-1301 levels.	Epirubicin	13-23	microRNA 1301	Homo sapiens	88-96
31433581-17	2019	Epirubicin suppressed cell proliferation by downregulating TRIAP1.	Epirubicin	0-10	TP53 regulated inhibitor of apoptosis 1	Homo sapiens	59-65
31433581-18	2019	CONCLUSION: miR-1301 was implicated in the chemosensitivity of osteosarcoma to epirubicin by modulating TRIAP1.	Epirubicin	79-89	microRNA 1301	Homo sapiens	12-20
31433581-18	2019	CONCLUSION: miR-1301 was implicated in the chemosensitivity of osteosarcoma to epirubicin by modulating TRIAP1.	Epirubicin	79-89	TP53 regulated inhibitor of apoptosis 1	Homo sapiens	104-110
31311554-7	2019	RESULTS: Epirubicin treatment resulted in a decrease in the number of primordial, primary, secondary and antral follicles, an increase in the number of atretic follicles and ovarian cell apoptosis, a decrease in estradiol and AMH levels, an increase in FSH levels, and estrous cycle arrest.	Epirubicin	9-19	anti-Mullerian hormone	Mus musculus	226-229
31311554-7	2019	RESULTS: Epirubicin treatment resulted in a decrease in the number of primordial, primary, secondary and antral follicles, an increase in the number of atretic follicles and ovarian cell apoptosis, a decrease in estradiol and AMH levels, an increase in FSH levels, and estrous cycle arrest.	Epirubicin	9-19	follicle stimulating hormone beta	Mus musculus	253-256
31311554-8	2019	However, MB-MSCs combined with BSTCR rescued epirubicin induced POF through down-regulating GADD45b and pCDC2 expressions, and up-regulating CyclinB1 and CDC2 expressions.	Epirubicin	45-55	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	92-99
31934100-5	2019	The relationship between the expression of miR-130a and drug resistance was detected by in situ hybridization in the formalin-fixed paraffin-embedded (FFPE) tissues from 50 breast cancer patients before and after Epirubicin-based neoadjuvant chemotherapy.	Epirubicin	213-223	microRNA 130a	Homo sapiens	43-51
30816492-0	2019	Isoforms S and L of MRPL33 from alternative splicing have isoform-specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway.	Epirubicin	105-115	mitochondrial ribosomal protein L33	Homo sapiens	20-26
31311554-8	2019	However, MB-MSCs combined with BSTCR rescued epirubicin induced POF through down-regulating GADD45b and pCDC2 expressions, and up-regulating CyclinB1 and CDC2 expressions.	Epirubicin	45-55	cyclin-dependent kinase 1	Mus musculus	105-109
30843093-18	2019	CONCLUSION: Epirubicin-loaded PEG microsphere b-TACE is technically feasible, safe and effective procedure for HCC treatment.	Epirubicin	12-22	ADAM metallopeptidase domain 17	Homo sapiens	48-52
31126528-24	2019	Epirubicin is an alternative drug to doxorubicin in regular R-CHOP with mild long-term cardiotoxicity.	Epirubicin	0-10	DNA damage inducible transcript 3	Homo sapiens	62-66
31137171-11	2019	With G-CSF support, epirubicin 85-90 mg/m(2) is appropriate tolerance dose for Chinese early breast cancer patients with high recurrence risk.	Epirubicin	20-30	colony stimulating factor 3	Homo sapiens	5-10
31205918-10	2019	Results: Here, we show that MARVELD1 enhances the therapeutic effects of epirubicin, while inducing the strong resistance of liver cancer cells to As2O3 treatment.	Epirubicin	73-83	MARVEL domain containing 1	Homo sapiens	28-36
30816492-0	2019	Isoforms S and L of MRPL33 from alternative splicing have isoform-specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway.	Epirubicin	105-115	AKT serine/threonine kinase 1	Homo sapiens	153-156
30816492-5	2019	MRPL33-S promoted chemosensitivity to epirubicin in gastric cancer as demonstrated by a chemoresponse assay; chemosensitivity was suppressed in response to MRPL33-L. Gene microarray analysis was performed to investigate the underlying mechanisms.	Epirubicin	38-48	mitochondrial ribosomal protein L33	Homo sapiens	0-6
30816492-9	2019	Furthermore, western blot analysis indicated that MRPL33-S promoted the chemoresponse to epirubicin by deactivating PI3K/AKT/CREB signaling and inducing apoptosis, while MRPL33-L had the opposite effects.	Epirubicin	89-99	mitochondrial ribosomal protein L33	Homo sapiens	50-56
30816492-9	2019	Furthermore, western blot analysis indicated that MRPL33-S promoted the chemoresponse to epirubicin by deactivating PI3K/AKT/CREB signaling and inducing apoptosis, while MRPL33-L had the opposite effects.	Epirubicin	89-99	cAMP responsive element binding protein 1	Homo sapiens	125-129
30816492-10	2019	In conclusion, the results of the present study revealed that isoforms S and L of MRPL33, which arise from alternative splicing, exhibited opposing roles in the chemoresponse to epirubicin in gastric cancer via the PI3K/AKT signaling pathway.	Epirubicin	178-188	mitochondrial ribosomal protein L33	Homo sapiens	82-88
30816492-10	2019	In conclusion, the results of the present study revealed that isoforms S and L of MRPL33, which arise from alternative splicing, exhibited opposing roles in the chemoresponse to epirubicin in gastric cancer via the PI3K/AKT signaling pathway.	Epirubicin	178-188	AKT serine/threonine kinase 1	Homo sapiens	220-223
30546090-7	2019	Presence of IFN-beta in the circulation of ER- breast cancer patients treated with neoadjuvant Epirubicin chemotherapy correlated with a significantly longer distant metastasis-free survival.	Epirubicin	95-105	interferon beta 1	Homo sapiens	12-20
28963609-6	2019	TIMP-1 overexpressing U87MG cells were significantly more resistant than low TIMP-1 expressing clones and parental cells when exposed to SN-38 (TOP1 inhibitor) or epirubicin (TOP2 inhibitor).	Epirubicin	163-173	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-6
30537619-5	2019	In this system, antimir-21 as an inhibitor of microRNA-21 (miR-21) which is an oncomiR overexpressed in several human cancers was condensed with PbetaAE polymer and then PLGA was electrostatically deposited on this complex and provided a reservoir for positively charged drug, epirubicin (Epi).	Epirubicin	277-287	microRNA 21	Homo sapiens	46-57
30537619-5	2019	In this system, antimir-21 as an inhibitor of microRNA-21 (miR-21) which is an oncomiR overexpressed in several human cancers was condensed with PbetaAE polymer and then PLGA was electrostatically deposited on this complex and provided a reservoir for positively charged drug, epirubicin (Epi).	Epirubicin	277-287	microRNA 21	Homo sapiens	59-65
30941173-5	2019	Among the drugs tested, only epirubicin hydrochloride and dabrafenib mesylate exhibited &gt; 50% cis-inhibitory effect, in COS-7 cells, on hOAT4-mediated uptake of estrone sulfate, a prototypical substrate for the transporter.	Epirubicin	29-53	solute carrier family 22 member 11	Homo sapiens	139-144
30941173-6	2019	The IC50 values for epirubicin hydrochloride and dabrafenib mesylate were 5.24+-0.95 muM and 8.30+-3.30 muM, respectively.	Epirubicin	20-44	latexin	Homo sapiens	85-88
30941173-6	2019	The IC50 values for epirubicin hydrochloride and dabrafenib mesylate were 5.24+-0.95 muM and 8.30+-3.30 muM, respectively.	Epirubicin	20-44	latexin	Homo sapiens	104-107
30941173-7	2019	Dixon plot analysis revealed that inhibition by epirubicin hydrochloride was noncompetitive with a Ki = 3 muM whereas inhibition by dabrafenib mesylate was competitive with a Ki = 4.26 muM.	Epirubicin	48-72	latexin	Homo sapiens	106-109
30738829-8	2019	Upregulated GPR120 signaling rendered cells resistant to epirubicin-induced cell death by upregulating ABC transporters expression and thus decreasing the intracellular accumulation of epirubicin.	Epirubicin	57-67	free fatty acid receptor 4	Homo sapiens	12-18
30738829-8	2019	Upregulated GPR120 signaling rendered cells resistant to epirubicin-induced cell death by upregulating ABC transporters expression and thus decreasing the intracellular accumulation of epirubicin.	Epirubicin	185-195	free fatty acid receptor 4	Homo sapiens	12-18
30738829-10	2019	The functional importance of GPR120 in chemoresistance was further validated using epirubicin-treated tumor xenografts, in which we showed that blockade of GPR120 signaling with AH7614 or GPR120-siRNA significantly compromised chemoresistance.	Epirubicin	83-93	free fatty acid receptor 4	Homo sapiens	29-35
30738829-10	2019	The functional importance of GPR120 in chemoresistance was further validated using epirubicin-treated tumor xenografts, in which we showed that blockade of GPR120 signaling with AH7614 or GPR120-siRNA significantly compromised chemoresistance.	Epirubicin	83-93	free fatty acid receptor 4	Homo sapiens	156-162
30738829-10	2019	The functional importance of GPR120 in chemoresistance was further validated using epirubicin-treated tumor xenografts, in which we showed that blockade of GPR120 signaling with AH7614 or GPR120-siRNA significantly compromised chemoresistance.	Epirubicin	83-93	free fatty acid receptor 4	Homo sapiens	156-162
30850026-10	2019	The percent of cells in SubG1 phase and activities of caspase-3/7 increased after DMAMCL treatment; The combination of DMAMCL with VCR or Epirubicin significantly increased cell death compared to each reagent alone.	Epirubicin	138-148	caspase 3	Homo sapiens	54-63
30941173-8	2019	Our results established that epirubicin hydrochloride and dabrafenib mesylate are inhibitors of hOAT4.	Epirubicin	29-53	solute carrier family 22 member 11	Homo sapiens	96-101
30465822-6	2019	In addition, KH-1 covalently conjugated with anthracycline anticancer agent, epirubicin, integrates the advantages of both chemosensitization function and improved intracellular drug delivery in a single system and takes effect on the same cell.	Epirubicin	77-87	potassium voltage-gated channel modifier subfamily F member 1	Homo sapiens	13-17
30719181-8	2019	GRP94-KD OS cells were more resistant to paclitaxel, gemcitabine, and epirubicin treatments than cells transfected with the scrambled control, and more cells transfected with the scrambled control underwent apoptosis after paclitaxel, gemcitabine, and epirubicin treatments than GRP94-KD cells.	Epirubicin	70-80	heat shock protein 90 beta family member 1	Homo sapiens	0-5
30719181-8	2019	GRP94-KD OS cells were more resistant to paclitaxel, gemcitabine, and epirubicin treatments than cells transfected with the scrambled control, and more cells transfected with the scrambled control underwent apoptosis after paclitaxel, gemcitabine, and epirubicin treatments than GRP94-KD cells.	Epirubicin	252-262	heat shock protein 90 beta family member 1	Homo sapiens	0-5
30719181-9	2019	Conclusions: Therefore, GRP94 silencing may increase the resistance of MG63 and 143B cells to paclitaxel, gemcitabine, and epirubicin treatments by inhibiting the induction of apoptosis.	Epirubicin	123-133	heat shock protein 90 beta family member 1	Homo sapiens	24-29
30606243-0	2019	Endometrial mesenchymal stem cells isolated from menstrual blood repaired epirubicin-induced damage to human ovarian granulosa cells by inhibiting the expression of Gadd45b in cell cycle pathway.	Epirubicin	74-84	growth arrest and DNA damage inducible beta	Homo sapiens	165-172
30606243-10	2019	Western blot showed that epirubicin upregulated Gadd45b protein expression and downregulated CyclinB1 and CDC2 protein expression, while MB-MSCs downregulated Gadd45b protein expression and upregulated CyclinB1 and CDC2 protein expression.	Epirubicin	25-35	growth arrest and DNA damage inducible beta	Homo sapiens	48-55
30606243-10	2019	Western blot showed that epirubicin upregulated Gadd45b protein expression and downregulated CyclinB1 and CDC2 protein expression, while MB-MSCs downregulated Gadd45b protein expression and upregulated CyclinB1 and CDC2 protein expression.	Epirubicin	25-35	cyclin B1	Homo sapiens	93-101
30606243-10	2019	Western blot showed that epirubicin upregulated Gadd45b protein expression and downregulated CyclinB1 and CDC2 protein expression, while MB-MSCs downregulated Gadd45b protein expression and upregulated CyclinB1 and CDC2 protein expression.	Epirubicin	25-35	cyclin dependent kinase 1	Homo sapiens	106-110
30606243-11	2019	CONCLUSIONS: MB-MSCs repaired epirubicin-induced damage to GCs, which might be related to the inhibition of Gadd45b protein expression.	Epirubicin	30-40	growth arrest and DNA damage inducible beta	Homo sapiens	108-115
30554488-0	2019	Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.	Epirubicin	92-102	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	15-21
30554488-1	2019	PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C&gt;T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy.	Epirubicin	253-263	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	69-104
30554488-1	2019	PURPOSE: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 single nucleotide polymorphism C to T (C&gt;T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoing epirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy.	Epirubicin	253-263	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	106-112
30536064-0	2018	DJ-1 Alters Epirubicin-induced Apoptosis via Modulating Epirubicinactivated Autophagy in Human Gastric Cancer Cells.	Epirubicin	12-22	Parkinsonism associated deglycase	Homo sapiens	0-4
30221675-4	2018	Consistently, knockdown of YB-1 significantly decreased the chemoresistance of cells to doxorubicin hydrochloride and epirubicin hydrochloride, as evidenced by a decrease in cell viability.	Epirubicin	118-142	Y-box binding protein 1	Homo sapiens	27-31
30476929-0	2018	Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression.	Epirubicin	111-121	nucleolar and spindle associated protein 1	Homo sapiens	0-42
30476929-0	2018	Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression.	Epirubicin	111-121	nucleolar and spindle associated protein 1	Homo sapiens	44-50
30275150-9	2018	cTnI elevations occurred only in patients treated with anthracyclines; moreover, the association of impaired relaxation or high BNP levels with cTnI elevations was significantly more frequent in doxorubicin-treated patients compared with patients treated with its analog, epirubicin.	Epirubicin	272-282	natriuretic peptide B	Homo sapiens	128-131
30275150-9	2018	cTnI elevations occurred only in patients treated with anthracyclines; moreover, the association of impaired relaxation or high BNP levels with cTnI elevations was significantly more frequent in doxorubicin-treated patients compared with patients treated with its analog, epirubicin.	Epirubicin	272-282	troponin I3, cardiac type	Homo sapiens	144-148
30353671-0	2018	Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma.	Epirubicin	53-63	AXL receptor tyrosine kinase	Mus musculus	41-44
30353671-2	2018	Herein, we investigated the role of AXL in regulating c-MYC expression and resistance to the chemotherapeutic agent epirubicin in EAC.	Epirubicin	116-126	AXL receptor tyrosine kinase	Mus musculus	36-39
30353671-3	2018	Using in vitro EAC cell models, we found that AXL overexpression enhances epirubicin resistance in sensitive cells.	Epirubicin	74-84	AXL receptor tyrosine kinase	Mus musculus	46-49
30353671-4	2018	Conversely, genetic knockdown or pharmacological inhibition of AXL sensitizes resistant cells to epirubicin.	Epirubicin	97-107	AXL receptor tyrosine kinase	Mus musculus	63-66
30353671-5	2018	Notably, we showed that inhibition or knockdown of c-MYC markedly sensitizes AXL-dependent resistant cells to epirubicin, and our data demonstrated that AXL promotes epirubicin resistance through transcriptional upregulation of c-MYC.	Epirubicin	110-120	AXL receptor tyrosine kinase	Mus musculus	77-80
30353671-9	2018	Data from a tumor xenograft mouse model indicated that inhibition of AXL with R428 in combination with epirubicin synergistically suppresses tumor growth and proliferation.	Epirubicin	103-113	AXL receptor tyrosine kinase	Mus musculus	69-72
30353671-10	2018	Our results demonstrate that AXL promotes epirubicin resistance through transcriptional upregulation of c-MYC in EAC.	Epirubicin	42-52	AXL receptor tyrosine kinase	Mus musculus	29-32
30216645-0	2018	Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to pharmorubicin by promoting autophagy via PI3K/Akt pathway.	Epirubicin	78-91	heme oxygenase 1	Homo sapiens	0-16
30216645-0	2018	Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to pharmorubicin by promoting autophagy via PI3K/Akt pathway.	Epirubicin	78-91	AKT serine/threonine kinase 1	Homo sapiens	124-127
30216645-8	2018	RESULTS: After being treated with pharmorubicin, the expression of HO-1 and autophagy related proteins was significantly enhanced, but the cell survival ratio in the two cell lines decreased.	Epirubicin	34-47	heme oxygenase 1	Homo sapiens	67-71
30216645-10	2018	When pharmorubicin-resistant cells were transfected with si-HO-1, the cell survival decreased and the protein expression of HO-1, autophagic proteins (LC3-II/LC3-I and Beclin-1) as well as autophagy were all down-regulated, while in pharmorubicin-resistant cells transfected with pcDNA3.1-HO-1, the results were reverse.	Epirubicin	5-18	heme oxygenase 1	Homo sapiens	60-64
30216645-10	2018	When pharmorubicin-resistant cells were transfected with si-HO-1, the cell survival decreased and the protein expression of HO-1, autophagic proteins (LC3-II/LC3-I and Beclin-1) as well as autophagy were all down-regulated, while in pharmorubicin-resistant cells transfected with pcDNA3.1-HO-1, the results were reverse.	Epirubicin	5-18	heme oxygenase 1	Homo sapiens	124-128
30216645-10	2018	When pharmorubicin-resistant cells were transfected with si-HO-1, the cell survival decreased and the protein expression of HO-1, autophagic proteins (LC3-II/LC3-I and Beclin-1) as well as autophagy were all down-regulated, while in pharmorubicin-resistant cells transfected with pcDNA3.1-HO-1, the results were reverse.	Epirubicin	5-18	beclin 1	Homo sapiens	168-176
30216645-10	2018	When pharmorubicin-resistant cells were transfected with si-HO-1, the cell survival decreased and the protein expression of HO-1, autophagic proteins (LC3-II/LC3-I and Beclin-1) as well as autophagy were all down-regulated, while in pharmorubicin-resistant cells transfected with pcDNA3.1-HO-1, the results were reverse.	Epirubicin	5-18	heme oxygenase 1	Homo sapiens	124-128
30216645-10	2018	When pharmorubicin-resistant cells were transfected with si-HO-1, the cell survival decreased and the protein expression of HO-1, autophagic proteins (LC3-II/LC3-I and Beclin-1) as well as autophagy were all down-regulated, while in pharmorubicin-resistant cells transfected with pcDNA3.1-HO-1, the results were reverse.	Epirubicin	233-246	heme oxygenase 1	Homo sapiens	60-64
30216645-12	2018	CONCLUSION: It was proved that HO-1 induction mediated chemoresistance of pharmorubicin in breast cancer cells by promoting autophagy via PI3K/Akt pathway.	Epirubicin	74-87	heme oxygenase 1	Homo sapiens	31-35
30216645-12	2018	CONCLUSION: It was proved that HO-1 induction mediated chemoresistance of pharmorubicin in breast cancer cells by promoting autophagy via PI3K/Akt pathway.	Epirubicin	74-87	AKT serine/threonine kinase 1	Homo sapiens	143-146
30344717-9	2018	Furthermore, it was revealed that PARP-3 overexpression was associated with shorter survival time in patients with cyclophosphamide/doxorubicin or epirubicin/5-fluorouracil (CAF/CEF) chemotherapy compared with low PARP-3 expression, but not in patients with CAF/CEF + docetaxel chemotherapy.	Epirubicin	147-157	poly(ADP-ribose) polymerase family member 3	Homo sapiens	34-40
30536064-4	2018	But the association between DJ-1 and drug resistance of epirubicin in gastric cancer is still ambiguous.	Epirubicin	56-66	Parkinsonism associated deglycase	Homo sapiens	28-32
30536064-5	2018	In the present report, we explored whether and how DJ-1 conduced to epirubicin-induced apoptosis in gastric cancer.	Epirubicin	68-78	Parkinsonism associated deglycase	Homo sapiens	51-55
30536064-6	2018	Epirubicin dose-dependently increased the expression of DJ-1 and induced autophagy.	Epirubicin	0-10	Parkinsonism associated deglycase	Homo sapiens	56-60
30536064-7	2018	Knockdown of DJ-1 notably enhanced epirubicin-induced cell apoptosis, whereas overexpression of DJ-1 attenuated epirubicin-induced cell apoptosis.	Epirubicin	35-45	Parkinsonism associated deglycase	Homo sapiens	13-17
30536064-7	2018	Knockdown of DJ-1 notably enhanced epirubicin-induced cell apoptosis, whereas overexpression of DJ-1 attenuated epirubicin-induced cell apoptosis.	Epirubicin	112-122	Parkinsonism associated deglycase	Homo sapiens	96-100
30536064-8	2018	Further studies revealed that down-regulation of DJ-1 modulated epirubicinactivated autophagy which augmented epirubicin-induced apoptosis.	Epirubicin	64-74	Parkinsonism associated deglycase	Homo sapiens	49-53
30536064-9	2018	In conclusion, our results validated that DJ-1 reduced epirubicin-induced apoptosis in gastric cancer cells via modulating epirubicin-activated autophagy.	Epirubicin	55-65	Parkinsonism associated deglycase	Homo sapiens	42-46
30536064-9	2018	In conclusion, our results validated that DJ-1 reduced epirubicin-induced apoptosis in gastric cancer cells via modulating epirubicin-activated autophagy.	Epirubicin	123-133	Parkinsonism associated deglycase	Homo sapiens	42-46
29728098-0	2018	The 21-gene Recurrence Score  assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).	Epirubicin	171-181	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
30027574-0	2018	Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12.	Epirubicin	59-69	autophagy and beclin 1 regulator 1	Homo sapiens	0-6
30027574-0	2018	Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12.	Epirubicin	59-69	autophagy related 12	Homo sapiens	98-103
30139555-7	2018	Increased nuclear levels of NFkappaB were observed in MDA-MB-231 cells treated with 0.5 muM epirubicin.	Epirubicin	92-102	nuclear factor kappa B subunit 1	Homo sapiens	28-36
29693154-10	2018	The results showed that emodin inhibited TNBC proliferation and invasion more efficiently than epirubicin when co-cultured with adipocytes by downregulating the level of CCL5 in adipocyte supernatants; inhibiting the expression level of protein kinase B (AKT); and activating glycogen synthase kinase-3i (GSK3) and beta-catenin.	Epirubicin	95-105	chemokine (C-C motif) ligand 5	Mus musculus	170-174
29845287-5	2018	Western blot analysis further demonstrated that the phosphorylation of Akt was inhibited by lapatinib, and the results of the MTT assay revealed that the combination of lapatinib with either 5-FU or gemcitabine demonstrated synergistic antitumor effects, whereas a combinatory treatment of lapatinib with epirubicin, a typical anthracycline drug, exhibited antagonistic antitumor effects in HER2-positive breast cancer cells.	Epirubicin	305-315	AKT serine/threonine kinase 1	Homo sapiens	71-74
29801407-1	2018	Epirubicin (EPI) is usedextensively in the treatment of multiple cancers despite its tendency to induce multidrug resistance though overexpressionof the ABCB1 efflux pump.	Epirubicin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	153-158
29784015-0	2018	Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles.	Epirubicin	99-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-84
29784015-4	2018	METHODS: Epirubicin (EPI)-loaded lipid microbubbles (MBs) conjugated with anti-ABCG2 monoclonal antibody (EPI-MBs + mAb) were developed and their effect on MM 138-CD34- CSCs isolated from human MM RPMI 8226 cell line plus ultrasound exposure in vitro and in vivo in a nonobese diabetic/severe combined immunodeficient mouse model were assessed.	Epirubicin	9-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-84
29784015-4	2018	METHODS: Epirubicin (EPI)-loaded lipid microbubbles (MBs) conjugated with anti-ABCG2 monoclonal antibody (EPI-MBs + mAb) were developed and their effect on MM 138-CD34- CSCs isolated from human MM RPMI 8226 cell line plus ultrasound exposure in vitro and in vivo in a nonobese diabetic/severe combined immunodeficient mouse model were assessed.	Epirubicin	9-19	CD34 molecule	Homo sapiens	163-167
30304783-5	2018	We found that the combined use of dihydroartemisinin with epirubicin could efficiently inhibit the activity of Bcl-2, facilitate release of Beclin 1, and further activate Bax.	Epirubicin	58-68	BCL2 apoptosis regulator	Homo sapiens	111-116
30304783-5	2018	We found that the combined use of dihydroartemisinin with epirubicin could efficiently inhibit the activity of Bcl-2, facilitate release of Beclin 1, and further activate Bax.	Epirubicin	58-68	beclin 1	Homo sapiens	140-148
30304783-5	2018	We found that the combined use of dihydroartemisinin with epirubicin could efficiently inhibit the activity of Bcl-2, facilitate release of Beclin 1, and further activate Bax.	Epirubicin	58-68	BCL2 associated X, apoptosis regulator	Homo sapiens	171-174
29792857-5	2018	We used epirubicin to treat MDA-MB-231 (MB-231) cells and found that TGF-beta and breast cancer stem cell markers CD44+CD24- were increased and were dose-dependent of epirubicin.	Epirubicin	8-18	transforming growth factor beta 1	Homo sapiens	69-77
29792857-5	2018	We used epirubicin to treat MDA-MB-231 (MB-231) cells and found that TGF-beta and breast cancer stem cell markers CD44+CD24- were increased and were dose-dependent of epirubicin.	Epirubicin	8-18	CD44 molecule (Indian blood group)	Homo sapiens	114-118
29792857-5	2018	We used epirubicin to treat MDA-MB-231 (MB-231) cells and found that TGF-beta and breast cancer stem cell markers CD44+CD24- were increased and were dose-dependent of epirubicin.	Epirubicin	8-18	CD24 molecule	Homo sapiens	119-123
29792857-5	2018	We used epirubicin to treat MDA-MB-231 (MB-231) cells and found that TGF-beta and breast cancer stem cell markers CD44+CD24- were increased and were dose-dependent of epirubicin.	Epirubicin	167-177	transforming growth factor beta 1	Homo sapiens	69-77
29792857-5	2018	We used epirubicin to treat MDA-MB-231 (MB-231) cells and found that TGF-beta and breast cancer stem cell markers CD44+CD24- were increased and were dose-dependent of epirubicin.	Epirubicin	167-177	CD44 molecule (Indian blood group)	Homo sapiens	114-118
29792857-5	2018	We used epirubicin to treat MDA-MB-231 (MB-231) cells and found that TGF-beta and breast cancer stem cell markers CD44+CD24- were increased and were dose-dependent of epirubicin.	Epirubicin	167-177	CD24 molecule	Homo sapiens	119-123
29792857-13	2018	Taken together, our findings suggest that TGF-beta plays a vital role in TNBC epirubicin-resistance through regulating stemness, EMT and apoptosis.	Epirubicin	78-88	transforming growth factor beta 1	Homo sapiens	42-50
29792857-13	2018	Taken together, our findings suggest that TGF-beta plays a vital role in TNBC epirubicin-resistance through regulating stemness, EMT and apoptosis.	Epirubicin	78-88	IL2 inducible T cell kinase	Homo sapiens	129-132
30001772-0	2018	Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway.	Epirubicin	90-100	microRNA 4443	Homo sapiens	18-26
30001772-0	2018	Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway.	Epirubicin	90-100	inositol polyphosphate-4-phosphatase type I A	Homo sapiens	114-120
30001772-1	2018	We aimed to elucidate the roles and regulatory mechanism of miR-4443 in regulating the resistance of non-small cell lung cancer (NSCLC) cells to epirubicin (EPI).	Epirubicin	145-155	microRNA 4443	Homo sapiens	60-68
29728098-0	2018	The 21-gene Recurrence Score  assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).	Epirubicin	206-216	nuclear receptor subfamily 4 group A member 1	Homo sapiens	88-104
29565454-7	2018	Oncomine analysis revealed that the expression levels of SIRT5 were higher in epirubicin/cyclophosphamide-docetaxel responders compared with non-responders.	Epirubicin	78-88	sirtuin 5	Homo sapiens	57-62
29505745-0	2018	Cardioprotective effect of paeonol against epirubicin-induced heart injury via regulating miR-1 and PI3K/AKT pathway.	Epirubicin	43-53	fibronectin type III and SPRY domain containing 1	Homo sapiens	90-95
29505745-0	2018	Cardioprotective effect of paeonol against epirubicin-induced heart injury via regulating miR-1 and PI3K/AKT pathway.	Epirubicin	43-53	AKT serine/threonine kinase 1	Homo sapiens	105-108
29505745-6	2018	Further studies suggest that paeonol upregulates the decreased expression of miR-1 caused by epirubicin and thus inhibits the activation of PI3K/AKT/mTOR and NF-kappaB pathways.	Epirubicin	93-103	fibronectin type III and SPRY domain containing 1	Homo sapiens	77-82
29438316-3	2018	Here we assessed the PD-L1 expression on different breast cancer cell lines under standard in vitro culture conditions and as a function of Epirubicin or Paclitaxel treatment.	Epirubicin	140-150	CD274 molecule	Homo sapiens	21-26
28940965-0	2018	Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-beta-induced expression in urothelial carcinoma.	Epirubicin	0-10	transforming growth factor beta induced	Homo sapiens	79-118
28940965-7	2018	We evaluated the effect of Epirubicin (EPI) on the regulation of TGFBI expression and found that TGFBI acts as a downstream target of EPI and is suppressed by EPI in UC cells.	Epirubicin	27-37	transforming growth factor beta induced	Homo sapiens	65-70
28940965-7	2018	We evaluated the effect of Epirubicin (EPI) on the regulation of TGFBI expression and found that TGFBI acts as a downstream target of EPI and is suppressed by EPI in UC cells.	Epirubicin	27-37	transforming growth factor beta induced	Homo sapiens	97-102
29893327-12	2018	Conclusion: We determined that uPAR and CAIX levels were higher in the fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy group than in the control group, but there was no difference between the FEC and epirubicin/adriamycin chemotherapy groups in terms of basal and postchemotherapy uPAR, CAIX levels.	Epirubicin	85-95	plasminogen activator, urokinase receptor	Homo sapiens	31-35
29893327-12	2018	Conclusion: We determined that uPAR and CAIX levels were higher in the fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy group than in the control group, but there was no difference between the FEC and epirubicin/adriamycin chemotherapy groups in terms of basal and postchemotherapy uPAR, CAIX levels.	Epirubicin	85-95	carbonic anhydrase 9	Homo sapiens	40-44
29893327-12	2018	Conclusion: We determined that uPAR and CAIX levels were higher in the fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy group than in the control group, but there was no difference between the FEC and epirubicin/adriamycin chemotherapy groups in terms of basal and postchemotherapy uPAR, CAIX levels.	Epirubicin	218-228	plasminogen activator, urokinase receptor	Homo sapiens	31-35
29541177-0	2018	RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells.	Epirubicin	70-80	transient receptor potential cation channel subfamily M member 8	Homo sapiens	39-44
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	86-96	transient receptor potential cation channel subfamily M member 8	Homo sapiens	43-48
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	151-161	transient receptor potential cation channel subfamily M member 8	Homo sapiens	43-48
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	151-161	mitogen-activated protein kinase 14	Homo sapiens	217-220
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	151-161	mitogen-activated protein kinase 14	Homo sapiens	265-268
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	151-161	mitogen-activated protein kinase 8	Homo sapiens	274-297
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	151-161	mitogen-activated protein kinase 8	Homo sapiens	299-302
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	151-161	mitogen-activated protein kinase 14	Homo sapiens	265-268
29541177-4	2018	The RNA interference-mediated depletion of TRPM8 inhibited proliferation and enhanced epirubicin chemosensitivity of LNCaP and PC3 cells, and promoted epirubicin-induced apoptosis by increasing the phosphorylation of p38 mitogen-activated protein kinase (hereafter p38) and c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase signaling pathways, which was demonstrated via the use of specific inhibitors of phosphorylation of p38 and JNK.	Epirubicin	151-161	mitogen-activated protein kinase 8	Homo sapiens	445-448
29499932-7	2018	The aptamer RA16 adducted with epirubicin (RA16-epirubicin) showed significantly higher toxicity against targeted NCI-H460 cells and low toxicity against non-targeted tumor cells.	Epirubicin	31-41	RA16	Homo sapiens	12-16
29499932-7	2018	The aptamer RA16 adducted with epirubicin (RA16-epirubicin) showed significantly higher toxicity against targeted NCI-H460 cells and low toxicity against non-targeted tumor cells.	Epirubicin	31-41	RA16	Homo sapiens	43-47
29415318-10	2018	ALKBH3 may also play some role on chemosensitivity to certain genotoxic reagents, such as cisplatin (CDDP) and epirubicin.	Epirubicin	111-121	alkB homolog 3, alpha-ketoglutarate dependent dioxygenase	Homo sapiens	0-6
29571250-0	2018	Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity.	Epirubicin	64-74	ATP binding cassette subfamily B member 1	Homo sapiens	116-130
29281902-19	2018	Local application of rAd-p53 combined with local injection of bleomycin and intravenous infusion of cisplatin, epirubicin and isocyclophosphamide was effective for treatment of uterine sarcoma, especially for patients with liver metastases.	Epirubicin	111-121	tumor protein p53	Homo sapiens	25-28
29296238-0	2017	The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer.	Epirubicin	75-85	zinc fingers and homeoboxes 2	Homo sapiens	25-28
30449179-0	2018	Development and characterization of folic acid-functionalized apoferritin as a delivery vehicle for epirubicin against MCF-7 breast cancer cells.	Epirubicin	100-110	ferritin heavy chain 1	Homo sapiens	62-73
29758926-0	2018	Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer.	Epirubicin	35-45	C-C motif chemokine ligand 5	Homo sapiens	7-11
29758926-14	2018	Epirubicin susceptibility decreased in the breast cancer cells treated by recombinant CCL5.	Epirubicin	0-10	C-C motif chemokine ligand 5	Homo sapiens	86-90
29737107-7	2018	R-CHOP (rituximab,cyclophosphamide,epirubicin,vindesine,prednisone) or CHOP regimen chemotherapy significantly improved the survival of the patients (P=0.000 2).	Epirubicin	35-45	DNA damage inducible transcript 3	Homo sapiens	2-6
29296238-8	2017	Conclusion: ERK signaling pathway was more activated in epirubicin treated TNBC, possibly contributing to the epirubicin resistance in TNBC, it implicated that ERK pathway could be used as an novel candidate for targeting therapy in refractory and relapse TNBC.	Epirubicin	110-120	mitogen-activated protein kinase 1	Homo sapiens	12-15
29352223-4	2018	At the molecular level, ectopic expression of ZEB1 impaired the responsiveness of breast cancer cells to genotoxic drug treatment, such as epirubicin (EPI).	Epirubicin	139-149	zinc finger E-box binding homeobox 1	Homo sapiens	46-50
30001529-4	2018	More specifically, the extent and precise mechanism of the involvement of miR-34as in chemoresistance to epirubicin (EPI) in the treatment of bladder cancer remains unclear.	Epirubicin	105-115	microRNA 34a	Homo sapiens	74-80
28889000-0	2017	HSF1 upregulates ATG4B expression and enhances epirubicin-induced protective autophagy in hepatocellular carcinoma cells.	Epirubicin	47-57	heat shock factor 1	Mus musculus	0-4
28889000-3	2017	In this study, we for the first time demonstrated that HSF1 markedly attenuated the killing effect of epirubicin (EPI) to HCC cells via enhancing the EPI-induced protective autophagy.	Epirubicin	102-112	heat shock factor 1	Mus musculus	55-59
29296238-8	2017	Conclusion: ERK signaling pathway was more activated in epirubicin treated TNBC, possibly contributing to the epirubicin resistance in TNBC, it implicated that ERK pathway could be used as an novel candidate for targeting therapy in refractory and relapse TNBC.	Epirubicin	110-120	mitogen-activated protein kinase 1	Homo sapiens	160-163
29296238-0	2017	The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer.	Epirubicin	75-85	mitogen-activated protein kinase 1	Homo sapiens	29-32
29296238-5	2017	Results: In epirubicin treated TNBC samples and cells, we found ERK pathway components (eg.	Epirubicin	12-22	mitogen-activated protein kinase 1	Homo sapiens	64-67
29296238-6	2017	MAPK13, MAP3K1, MAPK12, MAPK11 and MAPKAPK3) were obviously enriched, also, expression of ERK pathway positive regulation genes significantly increased (P&lt;0.05) and negative regulation genes decreased (P&lt;0.05) in epirubicin resistant cells.	Epirubicin	219-229	mitogen-activated protein kinase 13	Homo sapiens	0-6
29296238-6	2017	MAPK13, MAP3K1, MAPK12, MAPK11 and MAPKAPK3) were obviously enriched, also, expression of ERK pathway positive regulation genes significantly increased (P&lt;0.05) and negative regulation genes decreased (P&lt;0.05) in epirubicin resistant cells.	Epirubicin	219-229	MAPK activated protein kinase 3	Homo sapiens	35-43
29296238-6	2017	MAPK13, MAP3K1, MAPK12, MAPK11 and MAPKAPK3) were obviously enriched, also, expression of ERK pathway positive regulation genes significantly increased (P&lt;0.05) and negative regulation genes decreased (P&lt;0.05) in epirubicin resistant cells.	Epirubicin	219-229	mitogen-activated protein kinase 1	Homo sapiens	90-93
29296238-7	2017	Moreover, phosphorylated ERK levels were significantly elevated in MDA-MB-231 cells after epirubicin treatment.	Epirubicin	90-100	mitogen-activated protein kinase 1	Homo sapiens	25-28
29296238-8	2017	Conclusion: ERK signaling pathway was more activated in epirubicin treated TNBC, possibly contributing to the epirubicin resistance in TNBC, it implicated that ERK pathway could be used as an novel candidate for targeting therapy in refractory and relapse TNBC.	Epirubicin	56-66	mitogen-activated protein kinase 1	Homo sapiens	12-15
29296238-8	2017	Conclusion: ERK signaling pathway was more activated in epirubicin treated TNBC, possibly contributing to the epirubicin resistance in TNBC, it implicated that ERK pathway could be used as an novel candidate for targeting therapy in refractory and relapse TNBC.	Epirubicin	56-66	mitogen-activated protein kinase 1	Homo sapiens	160-163
29066893-5	2017	Action mechanism studies showed that multifunctional targeting epirubicin liposomes could downregulate PI3K, MMP-2, MMP-9, VE-Cadherin, and FAK and activate apoptotic enzyme caspase 3.	Epirubicin	63-73	matrix metallopeptidase 2	Mus musculus	109-114
28919026-2	2017	In this study, we demonstrated the anti-tumor activity of a novel targeting drug formed by conjugating epirubicin (EPI) with an FAPalpha-specific dipeptide (Z-Gly-Pro) and named it Z-GP-EPI.	Epirubicin	103-113	fibroblast activation protein	Mus musculus	128-136
29066893-5	2017	Action mechanism studies showed that multifunctional targeting epirubicin liposomes could downregulate PI3K, MMP-2, MMP-9, VE-Cadherin, and FAK and activate apoptotic enzyme caspase 3.	Epirubicin	63-73	matrix metallopeptidase 9	Mus musculus	116-121
29066893-5	2017	Action mechanism studies showed that multifunctional targeting epirubicin liposomes could downregulate PI3K, MMP-2, MMP-9, VE-Cadherin, and FAK and activate apoptotic enzyme caspase 3.	Epirubicin	63-73	cadherin 5	Mus musculus	123-134
29066893-5	2017	Action mechanism studies showed that multifunctional targeting epirubicin liposomes could downregulate PI3K, MMP-2, MMP-9, VE-Cadherin, and FAK and activate apoptotic enzyme caspase 3.	Epirubicin	63-73	PTK2 protein tyrosine kinase 2	Mus musculus	140-143
29066893-5	2017	Action mechanism studies showed that multifunctional targeting epirubicin liposomes could downregulate PI3K, MMP-2, MMP-9, VE-Cadherin, and FAK and activate apoptotic enzyme caspase 3.	Epirubicin	63-73	caspase 3	Mus musculus	174-183
28968471-0	2017	Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.	Epirubicin	76-86	ELAV like RNA binding protein 1	Homo sapiens	39-42
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	cyclin D1	Homo sapiens	97-106
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	BCL2 apoptosis regulator	Homo sapiens	108-113
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	ATP binding cassette subfamily B member 1	Homo sapiens	115-119
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	ATP binding cassette subfamily C member 1	Homo sapiens	121-125
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	ATP binding cassette subfamily C member 2	Homo sapiens	131-135
28968471-6	2017	Consistently, the co-treatment of epirubicin and siHuR diminished the expressions of galectin-3, ss-catenin, c-Myc, P-gp and MRP1.	Epirubicin	34-44	galectin 3	Homo sapiens	85-95
28968471-6	2017	Consistently, the co-treatment of epirubicin and siHuR diminished the expressions of galectin-3, ss-catenin, c-Myc, P-gp and MRP1.	Epirubicin	34-44	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	109-114
28968471-6	2017	Consistently, the co-treatment of epirubicin and siHuR diminished the expressions of galectin-3, ss-catenin, c-Myc, P-gp and MRP1.	Epirubicin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
28968471-6	2017	Consistently, the co-treatment of epirubicin and siHuR diminished the expressions of galectin-3, ss-catenin, c-Myc, P-gp and MRP1.	Epirubicin	34-44	ATP binding cassette subfamily C member 1	Homo sapiens	125-129
28968471-7	2017	HuR silencing enhanced the intracellular accumulation of epirubicin in colon cancer cells.	Epirubicin	57-67	ELAV like RNA binding protein 1	Homo sapiens	0-3
28968471-10	2017	The combined treatments of siHuR and epirubicin significantly reduced the expression of Bcl-2, but increased the expression of Bax, as well as activity and expression levels of caspase-3 and -9.	Epirubicin	37-47	BCL2 apoptosis regulator	Homo sapiens	88-93
28968471-10	2017	The combined treatments of siHuR and epirubicin significantly reduced the expression of Bcl-2, but increased the expression of Bax, as well as activity and expression levels of caspase-3 and -9.	Epirubicin	37-47	BCL2 associated X, apoptosis regulator	Homo sapiens	127-130
28968471-10	2017	The combined treatments of siHuR and epirubicin significantly reduced the expression of Bcl-2, but increased the expression of Bax, as well as activity and expression levels of caspase-3 and -9.	Epirubicin	37-47	caspase 3	Homo sapiens	177-193
28968471-12	2017	Our findings provide insight into the mechanisms by which siHuR potentiated epirubicin-induced cytotoxicity via inhibiting galectin-3/beta-catenin signaling, suppressing MDR transporters and provoking apoptosis.	Epirubicin	76-86	galectin 3	Homo sapiens	123-133
28968471-12	2017	Our findings provide insight into the mechanisms by which siHuR potentiated epirubicin-induced cytotoxicity via inhibiting galectin-3/beta-catenin signaling, suppressing MDR transporters and provoking apoptosis.	Epirubicin	76-86	catenin beta 1	Homo sapiens	134-146
29075112-3	2017	In this study, we reduced the phagocytosis of epirubicin (EPI)-loaded folic acid-conjugated pullulan acetate (FPA/EPI) nanoparticles by Kupffer cells (KCs) through internalization and nuclear factor kappa B (NF-kB) signal pathway inhibitors, thus allowing development of FPA/EPI nanoparticles as a nanodrug delivery system (NDDS) based on our previous study.	Epirubicin	46-56	nuclear factor kappa B subunit 1	Rattus norvegicus	208-213
29075112-3	2017	In this study, we reduced the phagocytosis of epirubicin (EPI)-loaded folic acid-conjugated pullulan acetate (FPA/EPI) nanoparticles by Kupffer cells (KCs) through internalization and nuclear factor kappa B (NF-kB) signal pathway inhibitors, thus allowing development of FPA/EPI nanoparticles as a nanodrug delivery system (NDDS) based on our previous study.	Epirubicin	58-61	nuclear factor kappa B subunit 1	Rattus norvegicus	208-213
28979810-5	2017	It was found that chemotherapy drugs, such as epirubicin (EPB) and mitomycin C (MMC), effectively blocked expression of PcG in p53-wild-type HepG2 cells but not in PLC/PRF5 and Hep3B cells with p53 mutation or deletion.	Epirubicin	46-56	tumor protein p53	Homo sapiens	127-130
28979810-5	2017	It was found that chemotherapy drugs, such as epirubicin (EPB) and mitomycin C (MMC), effectively blocked expression of PcG in p53-wild-type HepG2 cells but not in PLC/PRF5 and Hep3B cells with p53 mutation or deletion.	Epirubicin	46-56	tumor protein p53	Homo sapiens	194-197
28968471-3	2017	In this study, we aim to elucidate the HuR-regulating pathways related to epirubicin-mediated resistance in human colorectal carcinoma cells.	Epirubicin	74-84	ELAV like RNA binding protein 1	Homo sapiens	39-42
28968471-4	2017	The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR).	Epirubicin	30-40	catenin beta 1	Homo sapiens	106-118
28968471-4	2017	The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR).	Epirubicin	30-40	ATP binding cassette subfamily B member 1	Homo sapiens	159-163
28968471-4	2017	The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR).	Epirubicin	30-40	BCL2 apoptosis regulator	Homo sapiens	200-205
28968471-4	2017	The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR).	Epirubicin	30-40	ELAV like RNA binding protein 1	Homo sapiens	237-240
28968471-4	2017	The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR).	Epirubicin	30-40	ELAV like RNA binding protein 1	Homo sapiens	254-257
28968471-4	2017	The effects and mechanisms of epirubicin treatment on the expressions of upstream survival signals (e.g., beta-catenin) and downstream MDR transporters (e.g., P-gp) and anti-apoptotic pathways (e.g., Bcl-2) were assessed with or without HuR knockdown (siHuR) or overexpression (overHuR; ectopic HuR or pcDNA3/HA-HuR).	Epirubicin	30-40	ELAV like RNA binding protein 1	Homo sapiens	254-257
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	galectin 3	Homo sapiens	71-81
28968471-5	2017	Our results showed that siHuR decreased transcriptional expressions of galectin-3, beta-catenin, cyclin D1, Bcl-2, P-gp, MRP1, and MRP2 in epirubicin-treated colon cancer cells.	Epirubicin	139-149	catenin beta 1	Homo sapiens	83-95
27864890-5	2017	In contrast, mAbs combined with DNA-damaging agents (cisplatin or epirubicin) had a synergistic effect in the BRCA1-mutant cell line SUM-1315 (wild-type KRAS and PTEN).	Epirubicin	66-76	BRCA1 DNA repair associated	Homo sapiens	110-115
28423359-4	2017	Mechanically, the chemotherapeutic drug epidoxorubicin induces GRO-alpha expression in primary bladder cancer cells at G1/S phase via p38-dependent activation of NF-kappaB.	Epirubicin	40-54	C-X-C motif chemokine ligand 1	Homo sapiens	63-72
28423359-4	2017	Mechanically, the chemotherapeutic drug epidoxorubicin induces GRO-alpha expression in primary bladder cancer cells at G1/S phase via p38-dependent activation of NF-kappaB.	Epirubicin	40-54	mitogen-activated protein kinase 14	Homo sapiens	134-137
28476032-6	2017	Among 24 patients, AKT1 gene expression increased 24 hrs after the initial epirubicin exposure in ER positive tumors responding to therapy (n=6), as compared to ER positive non-responders (n=7) or ER negative tumors (n=11).	Epirubicin	75-85	AKT serine/threonine kinase 1	Homo sapiens	19-23
28476032-6	2017	Among 24 patients, AKT1 gene expression increased 24 hrs after the initial epirubicin exposure in ER positive tumors responding to therapy (n=6), as compared to ER positive non-responders (n=7) or ER negative tumors (n=11).	Epirubicin	75-85	estrogen receptor 1	Homo sapiens	98-100
28615943-6	2017	This study demonstrated that functional epirubicin liposomes could significantly induce programmed death of refractory breast cancer by activating caspases and ROS-related apoptotic signaling pathways, in addition to the direct killing effect of the anticancer drug itself.	Epirubicin	40-50	caspase 8	Mus musculus	147-155
28232025-0	2017	Enhancing the anti-multiple myeloma efficiency in a cancer stem cell xenograft model by conjugating the ABCG2 antibody with microbubbles for a targeted delivery of ultrasound mediated epirubicin.	Epirubicin	184-194	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
28232025-3	2017	In this study, we used the targeting microbubbles (MBs) conjugated with anti-ABCG2 monoclonal antibody (mAb) for ultrasound mediated epirubicin (EPI) delivery to evaluate the therapeutic effectiveness of the novel agent in MM CSC xenograft model.	Epirubicin	133-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
27530622-0	2017	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.	Epirubicin	88-98	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-18
27530622-8	2017	CONCLUSIONS: HER2 status is an independent prognostic biomarker in gastroesophageal adenocarcinomas receiving epirubicin-based chemotherapy.	Epirubicin	110-120	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
27864890-5	2017	In contrast, mAbs combined with DNA-damaging agents (cisplatin or epirubicin) had a synergistic effect in the BRCA1-mutant cell line SUM-1315 (wild-type KRAS and PTEN).	Epirubicin	66-76	KRAS proto-oncogene, GTPase	Homo sapiens	153-157
27864890-5	2017	In contrast, mAbs combined with DNA-damaging agents (cisplatin or epirubicin) had a synergistic effect in the BRCA1-mutant cell line SUM-1315 (wild-type KRAS and PTEN).	Epirubicin	66-76	phosphatase and tensin homolog	Homo sapiens	162-166
28211872-5	2017	Noteworthy, rictor-deficient keratinocytes displayed increased lifespan, protection from senescence, and enhanced tolerance to cellular stressors such as growth factors deprivation, epirubicin and X-ray in vitro and radioresistance in vivo.	Epirubicin	182-192	RPTOR independent companion of MTOR, complex 2	Mus musculus	12-18
28685553-12	2017	Thus, it can be concluded that oxaliplatin in combination with epirubicin can improve survival quality, extend survival time, and decrease the serum AFP and CEA levels in the treatment of primary liver carcinoma, with definite effects but without aggravating toxic and side effects.	Epirubicin	63-73	alpha fetoprotein	Homo sapiens	149-152
28685553-12	2017	Thus, it can be concluded that oxaliplatin in combination with epirubicin can improve survival quality, extend survival time, and decrease the serum AFP and CEA levels in the treatment of primary liver carcinoma, with definite effects but without aggravating toxic and side effects.	Epirubicin	63-73	CEA cell adhesion molecule 3	Homo sapiens	157-160
28182993-7	2017	RESULTS: 5-FU or epirubicin treatment resulted in the generation of CD90+ and CD105+ cells in vitro in HuH1 and HuH7 cells, which originally contain no CD90+ or CD105+ cells.	Epirubicin	17-27	chloride intracellular channel 4	Homo sapiens	103-107
27721408-5	2017	The glycolytic CAFs feed the extra pyruvate and lactate to tumor cells for augmentation of mitochondrial activity, and this energy metabolically coupled in a "host-parasite relationship" between catabolic CAFs and anabolic cancer cells confers the tumor cells with multiple drug resistance to several conventional clinical treatments including endocrine therapy (tamoxifen), Her-2-targeted therapy (herceptin) and chemotherapy (epirubicin).	Epirubicin	428-438	erb-b2 receptor tyrosine kinase 2	Homo sapiens	375-380
28182993-7	2017	RESULTS: 5-FU or epirubicin treatment resulted in the generation of CD90+ and CD105+ cells in vitro in HuH1 and HuH7 cells, which originally contain no CD90+ or CD105+ cells.	Epirubicin	17-27	MIR7-3 host gene	Homo sapiens	112-116
28182993-7	2017	RESULTS: 5-FU or epirubicin treatment resulted in the generation of CD90+ and CD105+ cells in vitro in HuH1 and HuH7 cells, which originally contain no CD90+ or CD105+ cells.	Epirubicin	17-27	Thy-1 cell surface antigen	Homo sapiens	152-156
28300219-4	2017	We found that doxorubicin and related anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated the expression of death receptors (DRs) (TNFR1, Fas, DR4 and DR5) in iPS-derived cardiomyocytes at both protein and mRNA levels.	Epirubicin	96-106	TNF receptor superfamily member 1A	Homo sapiens	175-180
28300219-4	2017	We found that doxorubicin and related anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated the expression of death receptors (DRs) (TNFR1, Fas, DR4 and DR5) in iPS-derived cardiomyocytes at both protein and mRNA levels.	Epirubicin	96-106	TNF receptor superfamily member 10a	Homo sapiens	187-190
28300219-4	2017	We found that doxorubicin and related anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated the expression of death receptors (DRs) (TNFR1, Fas, DR4 and DR5) in iPS-derived cardiomyocytes at both protein and mRNA levels.	Epirubicin	96-106	TNF receptor superfamily member 10b	Homo sapiens	195-198
29108296-1	2017	Aims: To compare the safety and efficacy of TACE using raltitrexed, oxaliplatin and epirubicin with 5-fluorouracil, oxaliplatin and epirubicin for patients with unresectable hepatocelluar carcinoma.	Epirubicin	84-94	ADAM metallopeptidase domain 17	Homo sapiens	44-48
28196064-9	2017	In a pre-clinical model, the growth of MT4-MMP overexpressing xenografts, but not of control ones, was reduced by epirubicin or erlotinib.	Epirubicin	114-124	matrix metallopeptidase 17	Homo sapiens	39-46
28278080-6	2017	Our data revealed that SKA1 overexpression reduced the expression of some multidrug resistance genes, and enhanced the sensitivity of two common chemotherapeutic drugs used in osteosarcoma patients, epirubicin (EPI) and ifosfamide (IFO).	Epirubicin	199-209	spindle and kinetochore associated complex subunit 1	Homo sapiens	23-27
28182993-3	2017	METHODS: The EpCAM+ cell lines HuH1 and HuH7 were treated with 5-fluorouracil (5-FU) or epirubicin in vitro.	Epirubicin	88-98	epithelial cell adhesion molecule	Homo sapiens	13-18
28182993-3	2017	METHODS: The EpCAM+ cell lines HuH1 and HuH7 were treated with 5-fluorouracil (5-FU) or epirubicin in vitro.	Epirubicin	88-98	chloride intracellular channel 4	Homo sapiens	31-35
28182993-3	2017	METHODS: The EpCAM+ cell lines HuH1 and HuH7 were treated with 5-fluorouracil (5-FU) or epirubicin in vitro.	Epirubicin	88-98	MIR7-3 host gene	Homo sapiens	40-44
28182993-7	2017	RESULTS: 5-FU or epirubicin treatment resulted in the generation of CD90+ and CD105+ cells in vitro in HuH1 and HuH7 cells, which originally contain no CD90+ or CD105+ cells.	Epirubicin	17-27	Thy-1 cell surface antigen	Homo sapiens	68-72
28278080-6	2017	Our data revealed that SKA1 overexpression reduced the expression of some multidrug resistance genes, and enhanced the sensitivity of two common chemotherapeutic drugs used in osteosarcoma patients, epirubicin (EPI) and ifosfamide (IFO).	Epirubicin	211-214	spindle and kinetochore associated complex subunit 1	Homo sapiens	23-27
27193868-0	2017	Synthesis and application of thiol-functionalized magnetic nanoparticles for studying interactions of epirubicin hydrochloride with bovine serum albumin by fluorescence spectrometry.	Epirubicin	102-126	albumin	Homo sapiens	139-152
27193868-1	2017	A novel method was developed for studying the interaction between epirubicin hydrochloride (EPI) and bovine serum albumin (BSA) by fluorescence spectrometry.	Epirubicin	66-90	albumin	Homo sapiens	108-121
28196134-2	2017	We have observed that MCF-7 breast tumor cells selected for resistance to doxorubicin or epirubicin (MCF-7DOX2 and MCF-7EPI cells, respectively) exhibited increased expression of several members of the aldo-keto reductase (AKR) gene family (in particular AKR1C3 and AKR1B10) relative to control MCF-7CC cells selected by propagation in the absence of drug.	Epirubicin	89-99	aldo-keto reductase family 1 member C3	Homo sapiens	255-261
28196134-2	2017	We have observed that MCF-7 breast tumor cells selected for resistance to doxorubicin or epirubicin (MCF-7DOX2 and MCF-7EPI cells, respectively) exhibited increased expression of several members of the aldo-keto reductase (AKR) gene family (in particular AKR1C3 and AKR1B10) relative to control MCF-7CC cells selected by propagation in the absence of drug.	Epirubicin	89-99	aldo-keto reductase family 1 member B10	Homo sapiens	266-273
27693116-0	2017	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.	Epirubicin	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	187-191
27940053-0	2017	Paeonol alleviates epirubicin-induced renal injury in mice by regulating Nrf2 and NF-kappaB pathways.	Epirubicin	19-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	73-77
28075465-0	2017	Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.	Epirubicin	118-128	macrophage stimulating 1 receptor	Homo sapiens	36-39
27940053-6	2017	Moreover, paeonol inhibited epirubicin-induced apoptosis by suppressing the activation of caspase-9 and caspase-3, the Bax/Bcl-2 imbalance and cytochrome c release.	Epirubicin	28-38	caspase 9	Mus musculus	90-99
27940053-6	2017	Moreover, paeonol inhibited epirubicin-induced apoptosis by suppressing the activation of caspase-9 and caspase-3, the Bax/Bcl-2 imbalance and cytochrome c release.	Epirubicin	28-38	caspase 3	Mus musculus	104-113
27940053-6	2017	Moreover, paeonol inhibited epirubicin-induced apoptosis by suppressing the activation of caspase-9 and caspase-3, the Bax/Bcl-2 imbalance and cytochrome c release.	Epirubicin	28-38	BCL2-associated X protein	Mus musculus	119-122
27940053-6	2017	Moreover, paeonol inhibited epirubicin-induced apoptosis by suppressing the activation of caspase-9 and caspase-3, the Bax/Bcl-2 imbalance and cytochrome c release.	Epirubicin	28-38	B cell leukemia/lymphoma 2	Mus musculus	123-128
27940053-8	2017	In conclusion, paeonol alleviates epirubicin-induced renal injury in mice by regulating the Nrf2 and NF-kappaB signaling pathways.	Epirubicin	34-44	nuclear factor, erythroid derived 2, like 2	Mus musculus	92-96
27627783-8	2016	Moreover, CITED2 caused chemoresistance to epirubicin and 5-fluorouracil, but not paclitaxel, in these cells, and it inhibited p53 accumulation after 5-fluorouracil treatment in MCF-7 cells.	Epirubicin	43-53	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2	Homo sapiens	10-16
27586823-15	2016	CONCLUSIONS: Our data suggest that XML may be effective for mitigating epirubicin-induced cardiomyopathy and inhibits autophagy via activating the PI3K/Akt signaling pathway and inhibiting the Erk1/2 and P38 MAPK signaling pathways.	Epirubicin	71-81	AKT serine/threonine kinase 1	Rattus norvegicus	152-155
27586823-15	2016	CONCLUSIONS: Our data suggest that XML may be effective for mitigating epirubicin-induced cardiomyopathy and inhibits autophagy via activating the PI3K/Akt signaling pathway and inhibiting the Erk1/2 and P38 MAPK signaling pathways.	Epirubicin	71-81	mitogen activated protein kinase 3	Rattus norvegicus	193-199
27586823-15	2016	CONCLUSIONS: Our data suggest that XML may be effective for mitigating epirubicin-induced cardiomyopathy and inhibits autophagy via activating the PI3K/Akt signaling pathway and inhibiting the Erk1/2 and P38 MAPK signaling pathways.	Epirubicin	71-81	mitogen activated protein kinase 14	Rattus norvegicus	204-207
27586823-15	2016	CONCLUSIONS: Our data suggest that XML may be effective for mitigating epirubicin-induced cardiomyopathy and inhibits autophagy via activating the PI3K/Akt signaling pathway and inhibiting the Erk1/2 and P38 MAPK signaling pathways.	Epirubicin	71-81	mitogen activated protein kinase 3	Rattus norvegicus	208-212
27560771-5	2016	This inhibition increased mitochondrial cytochrome C release which augmented epirubicin-induced caspase-dependent apoptosis and cytotoxicity.	Epirubicin	77-87	cytochrome c, somatic	Homo sapiens	40-52
27560771-6	2016	In addition, the lysosomal neutralizing agent ammonia chloride (AC), and Atg7 knockdown by siRNA, could inhibit epirubicin-triggered autophagy, enhance cytotoxicity, and increase caspase-9- and caspase-3-dependent apoptosis.	Epirubicin	112-122	autophagy related 7	Homo sapiens	73-77
27665942-3	2016	We examined the effects of anti-human CYR61 monoclonal antibody on proliferation and evaluated the changes in CYR61 expression and cell proliferation in response to treatment with either epirubicin or interferon (IFN)-alpha.	Epirubicin	187-197	cellular communication network factor 1	Homo sapiens	110-115
27665942-5	2016	Following the treatment of B16 cells with epirubicin and IFN-alpha, CYR61 levels increased, cell growth was inhibited, and proliferating cell nuclear antigen expression decreased.	Epirubicin	42-52	cellular communication network factor 1	Homo sapiens	68-73
27899782-7	2016	Consequently, it was decided to treat the patient with trans-arterial chemoembolization(TACE)by selectingintra -arterial infusion of 5-FU, epirubicin(EPI), and mitomycin C prior to EPI-loaded HepaSphere(super-absorbent polymer microsphere)embolization, combined with concurrent systemic gemcitabine chemotherapy.	Epirubicin	139-149	ADAM metallopeptidase domain 17	Homo sapiens	88-92
27474751-6	2016	UGT2B7 protein levels were repressed in both HuH-7 and Hep3B cells in the presence of increasing miR-216b-5p concentrations, corresponding with significant (P &lt; 0.001 and P = 0.011, respectively) decreases in glucuronidation activity against the UGT2B7-specific substrate epirubicin.	Epirubicin	275-285	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	0-6
27457217-3	2016	We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high-mobility group box 1 protein (HMGB1) in the circulation.	Epirubicin	27-37	high mobility group box 1	Homo sapiens	112-137
27457217-3	2016	We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high-mobility group box 1 protein (HMGB1) in the circulation.	Epirubicin	27-37	high mobility group box 1	Homo sapiens	147-152
25268149-9	2016	The level of the tumor suppressor protein p53 in HeLa cells increased significantly upon treatment with free epirubicin, but remained relatively unchanged when cells were treated with equivalent dose of nanoparticle-loaded drug, suggesting a possible shift from p53-dependent DNA/RNA intercalation-based induction of cytotoxicity by free epirubicin to a caspase 3-induced cell death by the epirubicin-loaded PBCA formulation.	Epirubicin	109-119	tumor protein p53	Homo sapiens	42-45
25268149-9	2016	The level of the tumor suppressor protein p53 in HeLa cells increased significantly upon treatment with free epirubicin, but remained relatively unchanged when cells were treated with equivalent dose of nanoparticle-loaded drug, suggesting a possible shift from p53-dependent DNA/RNA intercalation-based induction of cytotoxicity by free epirubicin to a caspase 3-induced cell death by the epirubicin-loaded PBCA formulation.	Epirubicin	109-119	caspase 3	Homo sapiens	354-363
25268149-9	2016	The level of the tumor suppressor protein p53 in HeLa cells increased significantly upon treatment with free epirubicin, but remained relatively unchanged when cells were treated with equivalent dose of nanoparticle-loaded drug, suggesting a possible shift from p53-dependent DNA/RNA intercalation-based induction of cytotoxicity by free epirubicin to a caspase 3-induced cell death by the epirubicin-loaded PBCA formulation.	Epirubicin	338-348	tumor protein p53	Homo sapiens	42-45
25268149-9	2016	The level of the tumor suppressor protein p53 in HeLa cells increased significantly upon treatment with free epirubicin, but remained relatively unchanged when cells were treated with equivalent dose of nanoparticle-loaded drug, suggesting a possible shift from p53-dependent DNA/RNA intercalation-based induction of cytotoxicity by free epirubicin to a caspase 3-induced cell death by the epirubicin-loaded PBCA formulation.	Epirubicin	338-348	tumor protein p53	Homo sapiens	42-45
27272157-9	2016	In conclusion, Paeonol (a) enhanced the antitumor activity of Epirubicin in a synergistic manner against breast cancer cells via inhibiting p38/JNK/ERK MAPKs and (b) alleviated Epirubicin-induced cardiotoxicity by suppressing NF-kB pathway.	Epirubicin	62-72	mitogen-activated protein kinase 14	Homo sapiens	140-143
27272157-9	2016	In conclusion, Paeonol (a) enhanced the antitumor activity of Epirubicin in a synergistic manner against breast cancer cells via inhibiting p38/JNK/ERK MAPKs and (b) alleviated Epirubicin-induced cardiotoxicity by suppressing NF-kB pathway.	Epirubicin	62-72	mitogen-activated protein kinase 8	Homo sapiens	144-147
27272157-9	2016	In conclusion, Paeonol (a) enhanced the antitumor activity of Epirubicin in a synergistic manner against breast cancer cells via inhibiting p38/JNK/ERK MAPKs and (b) alleviated Epirubicin-induced cardiotoxicity by suppressing NF-kB pathway.	Epirubicin	62-72	mitogen-activated protein kinase 1	Homo sapiens	148-151
27609577-0	2016	[Knockdown of Drosha promotes chemosensitivity of epirubicin for gastric cancer MGC-803 cells].	Epirubicin	50-60	drosha ribonuclease III	Homo sapiens	14-20
27609577-1	2016	Objective To establish a gastric cancer cell line with stable Drosha silenced and explore the effect of Drosha on the chemosensitivity of gastric cancer cells to epirubicin.	Epirubicin	162-172	drosha ribonuclease III	Homo sapiens	104-110
27609577-6	2016	After the cells were treated with 0.5 mg/L(IC50) epirubicin, the apoptosis rate of MGC-803 cells was raised, the protein expressions of caspase-3 , caspase-9 and Bax were significantly upregulated and Bcl-2 was downregulated.	Epirubicin	49-59	caspase 3	Homo sapiens	136-145
27609577-6	2016	After the cells were treated with 0.5 mg/L(IC50) epirubicin, the apoptosis rate of MGC-803 cells was raised, the protein expressions of caspase-3 , caspase-9 and Bax were significantly upregulated and Bcl-2 was downregulated.	Epirubicin	49-59	caspase 9	Homo sapiens	148-157
27609577-6	2016	After the cells were treated with 0.5 mg/L(IC50) epirubicin, the apoptosis rate of MGC-803 cells was raised, the protein expressions of caspase-3 , caspase-9 and Bax were significantly upregulated and Bcl-2 was downregulated.	Epirubicin	49-59	BCL2 associated X, apoptosis regulator	Homo sapiens	162-165
27609577-6	2016	After the cells were treated with 0.5 mg/L(IC50) epirubicin, the apoptosis rate of MGC-803 cells was raised, the protein expressions of caspase-3 , caspase-9 and Bax were significantly upregulated and Bcl-2 was downregulated.	Epirubicin	49-59	BCL2 apoptosis regulator	Homo sapiens	201-206
27609577-7	2016	Conclusion The silence of Drosha expression can promote the sensitivity of gastric cancer to epirubicin.	Epirubicin	93-103	drosha ribonuclease III	Homo sapiens	26-32
27526106-0	2016	RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment.	Epirubicin	93-103	ring finger protein 168	Homo sapiens	0-6
27526106-0	2016	RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment.	Epirubicin	93-103	ring finger protein 8	Homo sapiens	23-27
27526106-0	2016	RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment.	Epirubicin	93-103	forkhead box M1	Homo sapiens	39-44
27526106-5	2016	Co-immunoprecipitation studies in MCF-7 cells revealed that RNF168 interacted with FOXM1 and that upon epirubicin treatment FOXM1 downregulation was associated with an increase in RNF168 binding and conjugation to the protein degradation-associated K48-linked polyubiquitin chains.	Epirubicin	103-113	forkhead box M1	Homo sapiens	124-129
27526106-5	2016	Co-immunoprecipitation studies in MCF-7 cells revealed that RNF168 interacted with FOXM1 and that upon epirubicin treatment FOXM1 downregulation was associated with an increase in RNF168 binding and conjugation to the protein degradation-associated K48-linked polyubiquitin chains.	Epirubicin	103-113	ring finger protein 168	Homo sapiens	180-186
27526106-7	2016	Conversely, RNF168, knockdown significantly enhanced the half-life of FOXM1 in both absence and presence of epirubicin.	Epirubicin	108-118	ring finger protein 168	Homo sapiens	12-18
27526106-7	2016	Conversely, RNF168, knockdown significantly enhanced the half-life of FOXM1 in both absence and presence of epirubicin.	Epirubicin	108-118	forkhead box M1	Homo sapiens	70-75
27526106-9	2016	In addition, clonogenic assays also showed that RNF168 mediates epirubicin action through targeting FOXM1, as RNF168 could synergise with epirubicin to repress clonal formation in wild-type but not in FOXM1-deficient mouse embryo fibroblasts (MEFs).	Epirubicin	64-74	ring finger protein 168	Mus musculus	48-54
27526106-9	2016	In addition, clonogenic assays also showed that RNF168 mediates epirubicin action through targeting FOXM1, as RNF168 could synergise with epirubicin to repress clonal formation in wild-type but not in FOXM1-deficient mouse embryo fibroblasts (MEFs).	Epirubicin	64-74	forkhead box M1	Mus musculus	100-105
27526106-9	2016	In addition, clonogenic assays also showed that RNF168 mediates epirubicin action through targeting FOXM1, as RNF168 could synergise with epirubicin to repress clonal formation in wild-type but not in FOXM1-deficient mouse embryo fibroblasts (MEFs).	Epirubicin	138-148	ring finger protein 168	Mus musculus	48-54
27526106-9	2016	In addition, clonogenic assays also showed that RNF168 mediates epirubicin action through targeting FOXM1, as RNF168 could synergise with epirubicin to repress clonal formation in wild-type but not in FOXM1-deficient mouse embryo fibroblasts (MEFs).	Epirubicin	138-148	forkhead box M1	Mus musculus	100-105
27526106-11	2016	Moreover, we also obtained evidence that RNF8 recruits RNF168 to FOXM1 upon epirubicin treatment and cooperates with RNF168 to catalyse FOXM1 ubiquitination and degradation.	Epirubicin	76-86	ring finger protein 8	Homo sapiens	41-45
27526106-11	2016	Moreover, we also obtained evidence that RNF8 recruits RNF168 to FOXM1 upon epirubicin treatment and cooperates with RNF168 to catalyse FOXM1 ubiquitination and degradation.	Epirubicin	76-86	ring finger protein 168	Homo sapiens	55-61
27526106-11	2016	Moreover, we also obtained evidence that RNF8 recruits RNF168 to FOXM1 upon epirubicin treatment and cooperates with RNF168 to catalyse FOXM1 ubiquitination and degradation.	Epirubicin	76-86	forkhead box M1	Homo sapiens	65-70
27367026-4	2016	In this study, we found that chemotherapeutic agents (doxorubicin, cisplatin and epirubicin) and sorafenib treatment downregulated SIRT3 mRNA and protein levels in three HCC cell lines.	Epirubicin	81-91	sirtuin 3	Homo sapiens	131-136
26767845-0	2016	Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells.	Epirubicin	58-68	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
27284967-0	2016	Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity.	Epirubicin	0-10	forkhead box P3	Mus musculus	67-72
27284967-4	2016	Using this system, we screened our chemical library consisting of approximately 2,100 compounds and discovered that a cancer chemotherapeutic drug epirubicin restored the Foxp3-inhibited NF-kappaB activity in a concentration-dependent manner without influencing cell viability.	Epirubicin	147-157	forkhead box P3	Mus musculus	171-176
27284967-5	2016	Using immunoprecipitation assay in a Treg-like cell line Karpas-299, we found that epirubicin inhibited the interaction between Foxp3 and p65.	Epirubicin	83-93	forkhead box P3	Mus musculus	128-133
27284967-5	2016	Using immunoprecipitation assay in a Treg-like cell line Karpas-299, we found that epirubicin inhibited the interaction between Foxp3 and p65.	Epirubicin	83-93	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	138-141
27284967-7	2016	Administration of low dose epirubicin into tumor-bearing mice modulated the function of immune cells at the tumor site and promoted their IFN-gamma production without direct cytotoxicity.	Epirubicin	27-37	interferon gamma	Mus musculus	138-147
27284967-8	2016	In summary, we identified the novel action of epirubicin as a Foxp3 inhibitor using a newly established luciferase-based cellular screen.	Epirubicin	46-56	forkhead box P3	Mus musculus	62-67
26883473-4	2016	The sensitivity of stable Mda-7/IL-24 overexpressing Raji and Daudi cells to cis-diamminedichloroplatinum (CDDP), epirubicin and vinblastine (VCR) were assessed by the MTS method, and the IC50 value calculated.	Epirubicin	114-124	interleukin 24	Homo sapiens	26-31
26883473-4	2016	The sensitivity of stable Mda-7/IL-24 overexpressing Raji and Daudi cells to cis-diamminedichloroplatinum (CDDP), epirubicin and vinblastine (VCR) were assessed by the MTS method, and the IC50 value calculated.	Epirubicin	114-124	interleukin 24	Homo sapiens	32-37
26883473-8	2016	Growth inhibition and apoptosis rates of Mda-7/IL-24 overexpressing Raji and Daudi cells were higher than those of non-transfected cells and cells transfected with vector alone when treated with CDDP, epirubicin and VCR.	Epirubicin	201-211	interleukin 24	Homo sapiens	41-46
26883473-8	2016	Growth inhibition and apoptosis rates of Mda-7/IL-24 overexpressing Raji and Daudi cells were higher than those of non-transfected cells and cells transfected with vector alone when treated with CDDP, epirubicin and VCR.	Epirubicin	201-211	interleukin 24	Homo sapiens	47-52
26883473-9	2016	The IC50 values of CDDP, epirubicin and VCR were lower for Mda-7/IL-24-overexpressing Raji and Daudi cells than for non-transfected cells and cells transfected with empty vector.	Epirubicin	25-35	interleukin 24	Homo sapiens	59-64
26883473-9	2016	The IC50 values of CDDP, epirubicin and VCR were lower for Mda-7/IL-24-overexpressing Raji and Daudi cells than for non-transfected cells and cells transfected with empty vector.	Epirubicin	25-35	interleukin 24	Homo sapiens	65-70
27235542-3	2016	In the present study, we demonstrate that integrin beta3 signaling inhibits apoptosis induced by a DNA-damaging chemotherapeutic agent, epirubicin, in MDA-MB-231 breast cancer cells.	Epirubicin	136-146	integrin subunit beta 3	Homo sapiens	42-56
27235542-6	2016	Further, our results indicate that integrin beta3 helps inhibit epirubicin induced cytotoxicity by repression of the pro-apoptotic protein BAD, thus promoting an anti-apoptotic response.	Epirubicin	64-74	integrin subunit beta 3	Homo sapiens	35-49
27127018-23	2016	In the DBCG 89D, a significant heterogeneity was observed between a beneficial effect on DFS and OS of epirubicin and the presence of TOP2A, but not the presence of HER2 aberrations.	Epirubicin	103-113	DNA topoisomerase II alpha	Homo sapiens	134-139
26615421-7	2016	Our results showed that upregulation of CMTM8 in the T24 cell line could suppress T24 cells proliferation, migration and invasion and enhance the sensitivity to Epirubicin.	Epirubicin	161-171	CKLF like MARVEL transmembrane domain containing 8	Homo sapiens	40-45
26812610-1	2016	Epirubicin (EPI) is a P-gp substrate antracycline analogue which elicits poor oral bioavailability.	Epirubicin	0-10	phosphoglycolate phosphatase	Homo sapiens	22-26
26452313-0	2016	A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.	Epirubicin	60-70	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	2-37
26452313-1	2016	BACKGROUND: Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7), an enzyme rich in single nucleotide polymorphisms (SNPs).	Epirubicin	12-22	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	41-76
26452313-1	2016	BACKGROUND: Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7), an enzyme rich in single nucleotide polymorphisms (SNPs).	Epirubicin	12-22	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	78-84
26452313-2	2016	We studied whether the -161 C &gt; T germline SNP in UGT2B7 was related to epirubicin metabolism and whether differences exist in the toxicity and efficacy of epirubicin-based chemotherapy among patients who were TT homozygotes, CT heterozygotes, and CC homozygotes.	Epirubicin	75-85	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	53-59
26452313-9	2016	CONCLUSION: The results of the present prospective pharmacogenetic study suggest that the UGT2B7 -161 C &gt; T SNP correlate with drug metabolism, toxicity, and efficacy in patients receiving epirubicin chemotherapy.	Epirubicin	192-202	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	90-96
26452313-10	2016	Further studies of this UGT2B7 SNP as a predictor of epirubicin toxicity and efficacy are warranted.	Epirubicin	53-63	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	24-30
26948952-0	2016	Human cytosolic sulfotransferase SULT1C4 mediates the sulfation of doxorubicin and epirubicin.	Epirubicin	83-93	sulfotransferase family 1C member 4	Homo sapiens	33-40
26948952-3	2016	A systematic analysis of thirteen known human SULTs, previously cloned, expressed, and purified, revealed SULT1C4 as the only human SULT capable of sulfating doxorubicin and epirubicin.	Epirubicin	174-184	sulfotransferase family 1C member 4	Homo sapiens	106-113
26148240-0	2016	OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.	Epirubicin	80-90	OTU deubiquitinase, ubiquitin aldehyde binding 1	Homo sapiens	0-5
27045718-0	2016	[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].	Epirubicin	78-88	DNA topoisomerase II alpha	Homo sapiens	19-24
27045718-1	2016	OBJECTIVE: To retrospectively analyze the relevance between DNA topoisomerase II alpha (TOP2A), epidermal growth factor receptor (EGFR) gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer (TNBC) patients.	Epirubicin	183-193	epidermal growth factor receptor	Homo sapiens	96-128
27045718-1	2016	OBJECTIVE: To retrospectively analyze the relevance between DNA topoisomerase II alpha (TOP2A), epidermal growth factor receptor (EGFR) gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer (TNBC) patients.	Epirubicin	183-193	epidermal growth factor receptor	Homo sapiens	130-134
27045718-10	2016	CONCLUSIONS: Efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in TNBC patients can be predicted by detecting TOP2A, EGFR gene expression.	Epirubicin	40-50	DNA topoisomerase II alpha	Homo sapiens	126-131
27045718-10	2016	CONCLUSIONS: Efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in TNBC patients can be predicted by detecting TOP2A, EGFR gene expression.	Epirubicin	40-50	epidermal growth factor receptor	Homo sapiens	133-137
26748365-0	2016	Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers.	Epirubicin	31-41	C-X-C motif chemokine receptor 4	Homo sapiens	49-54
26748365-2	2016	The surface of nanoparticle was conjugated with LFC131 peptide to increase the specific interaction of carrier with CXCR4 overexpressing liver cancers to enhance the Epirubicin (EPI) delivery to tumors.	Epirubicin	166-176	C-X-C motif chemokine receptor 4	Homo sapiens	116-121
26148240-9	2016	In addition, proliferative and clonogenic assays also show that OTUB1 can enhance the proliferative rate and epirubicin resistance through targeting FOXM1, as OTUB1 has little effect on FOXM1-deficient cells.	Epirubicin	109-119	OTU deubiquitinase, ubiquitin aldehyde binding 1	Homo sapiens	64-69
26867764-0	2016	A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.	Epirubicin	20-30	DNA topoisomerase II alpha	Homo sapiens	103-108
25008867-6	2016	CONCLUSION: Among Japanese women who received epirubicin and cyclophosphamide as perioperative chemotherapy for early breast cancer, those with the A/A genotype of the GSTP1 polymorphism (rs1695) were more likely to have FN.	Epirubicin	46-56	glutathione S-transferase pi 1	Homo sapiens	168-173
26676840-0	2016	Utility of epirubicin-incorporating micelles tagged with anti-tissue factor antibody clone with no anticoagulant effect.	Epirubicin	11-21	coagulation factor III, tissue factor	Homo sapiens	62-75
26676840-3	2016	We recently developed anti-TF antibody (clone1849)-conjugated epirubicin-incorporating micelles (NC-6300), and reported that this anti-TF1849-NC-6300 showed enhanced antitumor activity against TF-high expressed human pancreatic cancer cells, when compared with NC-6300 alone.	Epirubicin	62-72	coagulation factor III, tissue factor	Homo sapiens	27-29
26676840-3	2016	We recently developed anti-TF antibody (clone1849)-conjugated epirubicin-incorporating micelles (NC-6300), and reported that this anti-TF1849-NC-6300 showed enhanced antitumor activity against TF-high expressed human pancreatic cancer cells, when compared with NC-6300 alone.	Epirubicin	62-72	coagulation factor III, tissue factor	Homo sapiens	135-137
26867764-4	2016	TOP2A gene amplifications predict improved efficacy of epirubicin in patients with breast cancer and thus could be an alternative option for patients with CRC and amplified TOP2A gene.	Epirubicin	55-65	DNA topoisomerase II alpha	Homo sapiens	0-5
26867764-8	2016	METHODS/DESIGN: The study is an open label, single arm, phase II study, investigating the efficacy of epirubicin in patients with oxaliplatin refractory mCRC and with a cancer cell TOP2A/CEN-17 ratio &gt;= 1.5.	Epirubicin	102-112	DNA topoisomerase II alpha	Homo sapiens	181-186
26646421-6	2016	It is concluded that paeonol alleviates epirubicin-induced hepatotoxicity in 4T1-tumor bearing mice by inhibiting the PI3K/Akt/NF-kB pathway.	Epirubicin	40-50	thymoma viral proto-oncogene 1	Mus musculus	123-126
26625313-5	2016	What"s more, MLL mutated bladder cancer cells obtained with CRISPR/Cas9 showed increased ability of drug-resistance to epirubicin (a chemotherapy drug for bladder cancer) than wild type cells.	Epirubicin	119-129	lysine methyltransferase 2A	Homo sapiens	13-16
26588055-8	2016	Moreover, miR-671-5p sensitized breast cancer cells to cisplatin, 5-fluorouracil (5-FU) and epirubicin exposure.	Epirubicin	92-102	microRNA 671	Homo sapiens	10-17
26793992-4	2016	Our aim was to analyze miR-20b, miR-27a and miR-181a expression with respect to (epirubicin/oxaliplatin/capecitabine (EOX)) chemotherapy regimen in a set of GC patients, in order to investigate whether miRNAs deregulation may influence GC MDR also via hypoxia signaling modulation.	Epirubicin	81-91	microRNA 20b	Homo sapiens	23-30
25915842-4	2016	Ectopic expression of SIRT3 inhibited cell growth and induced apoptosis in HCC cells, whereas depletion of SIRT3 in immortalized hepatocyte promoted cell growth and decreased epirubicin-induced apoptosis.	Epirubicin	175-185	sirtuin 3	Homo sapiens	107-112
26714930-4	2016	Mus81 expression in HepG2 and Bel-7402 HCC cell lines was depleted by lentivirus-mediated short hairpin RNA and the elevated sensitivity of these Mus81-inhibited HCC cells to therapeutic agents, especially to epirubicin (EPI), was evidenced by MTT assay and an HCC chemotherapy mouse model.	Epirubicin	209-219	MUS81 structure-specific endonuclease subunit	Homo sapiens	0-5
26714930-4	2016	Mus81 expression in HepG2 and Bel-7402 HCC cell lines was depleted by lentivirus-mediated short hairpin RNA and the elevated sensitivity of these Mus81-inhibited HCC cells to therapeutic agents, especially to epirubicin (EPI), was evidenced by MTT assay and an HCC chemotherapy mouse model.	Epirubicin	209-219	MUS81 structure-specific endonuclease subunit	Homo sapiens	146-151
26772202-8	2016	J82 cells transfected with RON showed a survival advantage in the presence of epirubicin and hypoxia.	Epirubicin	78-88	macrophage stimulating 1 receptor	Homo sapiens	27-30
26867764-2	2016	BACKGROUND: Epirubicin is an anthracycline that targets DNA topoisomerase 2-alpha enzyme encoded by the TOP2A gene.	Epirubicin	12-22	DNA topoisomerase II alpha	Homo sapiens	56-81
26867764-2	2016	BACKGROUND: Epirubicin is an anthracycline that targets DNA topoisomerase 2-alpha enzyme encoded by the TOP2A gene.	Epirubicin	12-22	DNA topoisomerase II alpha	Homo sapiens	104-109
26204324-0	2016	Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells.	Epirubicin	21-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-84
26443186-5	2016	Vinorelbine and epirubicin stimulate neurite outgrowth of cerebellar neurons via the neural cell adhesion molecule, via myristoylated alanine-rich C kinase substrate, and via fibroblast growth factor receptor, signaling through Erk pathways.	Epirubicin	16-26	myristoylated alanine rich protein kinase C substrate	Homo sapiens	120-165
26443186-5	2016	Vinorelbine and epirubicin stimulate neurite outgrowth of cerebellar neurons via the neural cell adhesion molecule, via myristoylated alanine-rich C kinase substrate, and via fibroblast growth factor receptor, signaling through Erk pathways.	Epirubicin	16-26	mitogen-activated protein kinase 1	Homo sapiens	228-231
26443186-9	2016	Ablating NCAM, inhibiting fibroblast growth factor (FGFR) receptor, or adding the effector domain of myristoylated alanine-rich C kinase substrate (MARCKS) minimize the vinorelbine and epirubicin effects, indicating that they are true PSA mimetics triggering PSA-mediated functions.	Epirubicin	185-195	myristoylated alanine rich protein kinase C substrate	Homo sapiens	101-146
26443186-9	2016	Ablating NCAM, inhibiting fibroblast growth factor (FGFR) receptor, or adding the effector domain of myristoylated alanine-rich C kinase substrate (MARCKS) minimize the vinorelbine and epirubicin effects, indicating that they are true PSA mimetics triggering PSA-mediated functions.	Epirubicin	185-195	myristoylated alanine rich protein kinase C substrate	Homo sapiens	148-154
26809377-2	2016	Epirubicin-induced decrease in cell viability and increase in caspase-3/7 activity were reversed by a cAMP analog dibutyryl cAMP (DBcAMP) or an activator of adenylate cyclase forskolin concomitant with a phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine.	Epirubicin	0-10	caspase 3	Homo sapiens	62-71
26499190-9	2015	Overexpression of ABCC4 by lentivirus transfection induced chemotherapy resistance to epirubicin (EPI) and cisplatin (DDP) in YTS cells.	Epirubicin	86-96	ATP binding cassette subfamily C member 4	Homo sapiens	18-23
26335193-12	2015	Collectively, our findings provide the first evidence that cotreatment with free or liposomal chrysophsin-1 and epirubicin leads to cell death in human cervical cancer cells through the ROS-mediated inhibition of P-gp and MRPs and concerted activation of mitochondrial apoptosis pathway.	Epirubicin	112-122	phosphoglycolate phosphatase	Homo sapiens	213-217
26637880-11	2015	Drug screening revealed a marked sensitivity of FH(-/-) cells to mitoxantrone, epirubicin, topotecan and a high sensitivity to bortezomib.	Epirubicin	79-89	fumarate hydratase	Homo sapiens	48-50
26340918-6	2015	Expression of the TGFbeta receptor TGFbetaR1 and its effector molecule SMAD4 was required for enrichment of CD44(hi) cells exposed to the chemotherapeutic drug epirubicin, which suggests a feed-forward loop to enrich for and enhance the function of surviving CSCs.	Epirubicin	160-170	SMAD family member 4	Homo sapiens	71-76
26340918-6	2015	Expression of the TGFbeta receptor TGFbetaR1 and its effector molecule SMAD4 was required for enrichment of CD44(hi) cells exposed to the chemotherapeutic drug epirubicin, which suggests a feed-forward loop to enrich for and enhance the function of surviving CSCs.	Epirubicin	160-170	CD44 molecule (Indian blood group)	Homo sapiens	108-112
26162378-0	2015	Identification of four new degradation products of epirubicin through forced degradation, LC-UV, MSn and LC-MS-TOF studies.	Epirubicin	51-61	moesin	Homo sapiens	97-100
26095183-7	2015	In cell lines, CHD4 knockdown increased chemosensitivity and CHD4 overexpression induced epirubicin chemoresistance.	Epirubicin	89-99	chromodomain helicase DNA binding protein 4	Homo sapiens	61-65
26887513-1	2015	OBJECTIVE: To detect the expression of IGF1R and estrogen receptor, and to explore the relationship between their expression and the pathological complete response (pCR) rate of neoadjuvant chemotherapy (docetaxel plus epirubicin) in breast cancer patients.	Epirubicin	219-229	insulin like growth factor 1 receptor	Homo sapiens	39-66
26887513-10	2015	CONCLUSIONS: Breast cancer patients with negative expression of ER and high expression of IGF1R are more sensitive to neoadjuvant chemotherapy of docetaxel plus epirubicin, and their pCR rate is significantly higher than that of other patients.	Epirubicin	161-171	insulin like growth factor 1 receptor	Homo sapiens	90-95
26393585-1	2015	This study aims to explore the effects and mechanisms of hepcidin, a potential antimicrobial peptide from Tilapia, and epirubicin (Epi), an antineoplastic agent, on the generation of reactive oxygen species (ROS) and link the ROS levels to the reversal mechanisms of multidrug resistance (MDR) by epirubicin and hepcidin in human squamous cell carcinoma SCC15 and human embryonal carcinoma NT2D1 cells.	Epirubicin	119-129	hepcidin antimicrobial peptide	Homo sapiens	312-320
26300546-4	2015	Epirubicin also reduced the secretion of matrix metalloproteinase-9 by 48 and 56% at concentrations of 2.5 and 5 microM, respectively.	Epirubicin	0-10	matrix metallopeptidase 9	Rattus norvegicus	41-67
26393585-3	2015	We found that hepcidin significantly enhanced the cytotoxicity of epirubicin in liposomes.	Epirubicin	66-76	hepcidin antimicrobial peptide	Homo sapiens	14-22
26393585-4	2015	The co-incubation of epirubicin with hepcidin in liposomes intensified the ROS production, including hydrogen peroxide and superoxide free radicals.	Epirubicin	21-31	hepcidin antimicrobial peptide	Homo sapiens	37-45
26393585-5	2015	Hepcidin significantly increased epirubicin intracellular uptake into NT2D1 and SCC15 cells, as supported by the diminished mRNA expressions of MDR1, MDR-associated protein (MRP) 1, and MRP2.	Epirubicin	33-43	hepcidin antimicrobial peptide	Homo sapiens	0-8
26393585-5	2015	Hepcidin significantly increased epirubicin intracellular uptake into NT2D1 and SCC15 cells, as supported by the diminished mRNA expressions of MDR1, MDR-associated protein (MRP) 1, and MRP2.	Epirubicin	33-43	MDM4 regulator of p53	Homo sapiens	150-180
26393585-5	2015	Hepcidin significantly increased epirubicin intracellular uptake into NT2D1 and SCC15 cells, as supported by the diminished mRNA expressions of MDR1, MDR-associated protein (MRP) 1, and MRP2.	Epirubicin	33-43	ATP binding cassette subfamily C member 2	Homo sapiens	186-190
26393585-7	2015	As far as we know, this is the first example showing that PEGylated liposomal TH1-5 and epirubicin gives rise to cell death in human squamous carcinoma and testicular embryonic carcinoma cells through the reduced epirubicin efflux via ROS-mediated suppression of P-gp and MRPs and concomitant initiation of mitochondrial apoptosis pathway.	Epirubicin	88-98	phosphoglycolate phosphatase	Homo sapiens	263-267
26393585-7	2015	As far as we know, this is the first example showing that PEGylated liposomal TH1-5 and epirubicin gives rise to cell death in human squamous carcinoma and testicular embryonic carcinoma cells through the reduced epirubicin efflux via ROS-mediated suppression of P-gp and MRPs and concomitant initiation of mitochondrial apoptosis pathway.	Epirubicin	213-223	negative elongation factor complex member C/D	Homo sapiens	78-83
26344694-11	2015	In summary, our results suggest that paclitaxel and epirubicin target the FOXK2 to modulate their cytotoxicity and deregulated FOXK2 confers drug resistance.	Epirubicin	52-62	forkhead box K2	Homo sapiens	74-79
26354850-5	2015	GSTP1 rs1695 and GSTO1 rs4925 were also associated with RFS in the epirubicin group.	Epirubicin	67-77	glutathione S-transferase pi 1	Homo sapiens	0-5
26354850-5	2015	GSTP1 rs1695 and GSTO1 rs4925 were also associated with RFS in the epirubicin group.	Epirubicin	67-77	glutathione S-transferase omega 1	Homo sapiens	17-22
26354850-7	2015	Patients with the GSTP1 AA and GSTO1 CC genotypes had a reduced risk of recurrence after the instillation of epirubicin.	Epirubicin	109-119	glutathione S-transferase pi 1	Homo sapiens	18-23
26354850-7	2015	Patients with the GSTP1 AA and GSTO1 CC genotypes had a reduced risk of recurrence after the instillation of epirubicin.	Epirubicin	109-119	glutathione S-transferase omega 1	Homo sapiens	31-36
26354850-9	2015	Our results suggest that GSTP1 and GSTO1 polymorphisms are associated with epirubicin treatment outcomes as well as with epirubicin-related toxicity.	Epirubicin	75-85	glutathione S-transferase pi 1	Homo sapiens	25-30
26354850-9	2015	Our results suggest that GSTP1 and GSTO1 polymorphisms are associated with epirubicin treatment outcomes as well as with epirubicin-related toxicity.	Epirubicin	75-85	glutathione S-transferase omega 1	Homo sapiens	35-40
26354850-9	2015	Our results suggest that GSTP1 and GSTO1 polymorphisms are associated with epirubicin treatment outcomes as well as with epirubicin-related toxicity.	Epirubicin	121-131	glutathione S-transferase pi 1	Homo sapiens	25-30
26354850-9	2015	Our results suggest that GSTP1 and GSTO1 polymorphisms are associated with epirubicin treatment outcomes as well as with epirubicin-related toxicity.	Epirubicin	121-131	glutathione S-transferase omega 1	Homo sapiens	35-40
26344694-11	2015	In summary, our results suggest that paclitaxel and epirubicin target the FOXK2 to modulate their cytotoxicity and deregulated FOXK2 confers drug resistance.	Epirubicin	52-62	forkhead box K2	Homo sapiens	127-132
26305791-0	2015	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.	Epirubicin	161-171	microRNA 19a	Homo sapiens	24-31
26344694-0	2015	Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.	Epirubicin	26-36	forkhead box K2	Homo sapiens	0-15
26344694-0	2015	Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.	Epirubicin	26-36	forkhead box O3	Homo sapiens	72-78
26344694-3	2015	Clonogenic and cell viability assays showed that enhanced FOXK2 expression sensitizes MCF-7 breast cancer cells to paclitaxel or epirubicin treatment, whereas FOXK2 depletion by small interfering RNAs (siRNAs) confers drug resistance.	Epirubicin	129-139	forkhead box K2	Homo sapiens	58-63
26344694-4	2015	Our data also showed that the activation of the tumour suppressor FOXO3a by paclitaxel and epirubicin is mediated through the induction of FOXK2, as depletion of FOXK2 by siRNA limits the induction of FOXO3a by these drugs in MCF-7 cells.	Epirubicin	91-101	forkhead box O3	Homo sapiens	66-72
26344694-4	2015	Our data also showed that the activation of the tumour suppressor FOXO3a by paclitaxel and epirubicin is mediated through the induction of FOXK2, as depletion of FOXK2 by siRNA limits the induction of FOXO3a by these drugs in MCF-7 cells.	Epirubicin	91-101	forkhead box K2	Homo sapiens	139-144
26344694-6	2015	Furthermore, we also uncovered that FOXK2 is deregulated and, therefore, can express at high levels in the nucleus of both the paclitaxel and epirubicin drug-resistant MCF-7 cells.	Epirubicin	142-152	forkhead box K2	Homo sapiens	36-41
26344694-8	2015	Crucially, we found that FOXO3a is required for the anti-proliferative and epirubicin-induced cytotoxic function of FOXK2 in MCF-7 cells by sulphorhodamine and clonogenic assays.	Epirubicin	75-85	forkhead box O3	Homo sapiens	25-31
26344694-8	2015	Crucially, we found that FOXO3a is required for the anti-proliferative and epirubicin-induced cytotoxic function of FOXK2 in MCF-7 cells by sulphorhodamine and clonogenic assays.	Epirubicin	75-85	forkhead box K2	Homo sapiens	116-121
26295137-6	2015	The results showed that the targeting epirubicin plus quinacrine liposomes could enhance the accumulation and uptake of the drugs in cancer tissues, kill cancer cells directly, activate apoptotic enzymes, destroy the VM channels and downregulate the VM channel-forming marker molecules (EphA2, FAK, PI3K, MMP 9, MMP 14, VE-Cad and HIF-alpha), thereby exhibiting a strong overall anticancer efficacy.	Epirubicin	38-48	EPH receptor A2	Homo sapiens	287-292
26295137-6	2015	The results showed that the targeting epirubicin plus quinacrine liposomes could enhance the accumulation and uptake of the drugs in cancer tissues, kill cancer cells directly, activate apoptotic enzymes, destroy the VM channels and downregulate the VM channel-forming marker molecules (EphA2, FAK, PI3K, MMP 9, MMP 14, VE-Cad and HIF-alpha), thereby exhibiting a strong overall anticancer efficacy.	Epirubicin	38-48	protein tyrosine kinase 2	Homo sapiens	294-297
26295137-6	2015	The results showed that the targeting epirubicin plus quinacrine liposomes could enhance the accumulation and uptake of the drugs in cancer tissues, kill cancer cells directly, activate apoptotic enzymes, destroy the VM channels and downregulate the VM channel-forming marker molecules (EphA2, FAK, PI3K, MMP 9, MMP 14, VE-Cad and HIF-alpha), thereby exhibiting a strong overall anticancer efficacy.	Epirubicin	38-48	matrix metallopeptidase 9	Homo sapiens	305-310
26295137-6	2015	The results showed that the targeting epirubicin plus quinacrine liposomes could enhance the accumulation and uptake of the drugs in cancer tissues, kill cancer cells directly, activate apoptotic enzymes, destroy the VM channels and downregulate the VM channel-forming marker molecules (EphA2, FAK, PI3K, MMP 9, MMP 14, VE-Cad and HIF-alpha), thereby exhibiting a strong overall anticancer efficacy.	Epirubicin	38-48	matrix metallopeptidase 14	Homo sapiens	312-318
26464661-11	2015	The expressions of HIF-1alpha were more increased in the DM3 and DM6 groups.	Epirubicin	65-68	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	19-29
26464661-12	2015	However, the expressions of survivin only were upregulated in DM6 group .These data suggest that HIF-1alpha induced the upregulation of survivin in the early stage of DR. Survivin contributed to the development and progression of DR through the HIF-1alpha pathway and become an important progression marker of DR.	Epirubicin	62-65	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	97-107
26464661-12	2015	However, the expressions of survivin only were upregulated in DM6 group .These data suggest that HIF-1alpha induced the upregulation of survivin in the early stage of DR. Survivin contributed to the development and progression of DR through the HIF-1alpha pathway and become an important progression marker of DR.	Epirubicin	62-65	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	245-255
26305791-0	2015	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.	Epirubicin	161-171	microRNA 205	Homo sapiens	36-43
26125773-3	2015	Epirubicin (0.01-100 muM) was applied to MCF-7, MCF-7/PUMA, and MCF-7/pCDNA3 cells for 72 h. The MTT assay was used to calculate the cell survival rate in each group, and the 50% inhibitory concentration (IC50) was calculated.	Epirubicin	0-10	latexin	Homo sapiens	21-24
25677905-1	2015	The most important cytotoxic drug namely, cyclophosphamide used in breast cancer along with epirubicin and 5-fluorouracil, is transported by ABCC transporters and detoxified by glutathione S-transferases (GSTs).	Epirubicin	92-102	ATP binding cassette subfamily C member 1	Homo sapiens	141-145
25677905-1	2015	The most important cytotoxic drug namely, cyclophosphamide used in breast cancer along with epirubicin and 5-fluorouracil, is transported by ABCC transporters and detoxified by glutathione S-transferases (GSTs).	Epirubicin	92-102	glutathione S-transferase pi 1	Homo sapiens	205-209
25616696-0	2015	XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C.	Epirubicin	93-103	X-ray repair cross complementing 1	Homo sapiens	0-5
26379919-0	2015	Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin.	Epirubicin	144-154	X-ray repair cross complementing 1	Homo sapiens	36-41
26379919-2	2015	We investigated the relationship between the distribution of XRCC1 polymorphisms (rs915927 and rs2854501) and clinical outcomes following intravesical instillation with epirubicin (EPI) or mitomycin C (MMC).	Epirubicin	169-179	X-ray repair cross complementing 1	Homo sapiens	61-66
26185453-0	2015	High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer.	Epirubicin	39-49	ubiquitin D	Homo sapiens	19-22
26185453-4	2015	Since the role of UBD in epirubicin resistance and its prognostic value in TNBC have not been reported, the study reported here was designed to identify the epirubicin-resistance molecule and clarify the related biomarker for TNBC prognosis.	Epirubicin	25-35	ubiquitin D	Homo sapiens	18-21
26185453-4	2015	Since the role of UBD in epirubicin resistance and its prognostic value in TNBC have not been reported, the study reported here was designed to identify the epirubicin-resistance molecule and clarify the related biomarker for TNBC prognosis.	Epirubicin	157-167	ubiquitin D	Homo sapiens	18-21
26185453-5	2015	METHODS: UBD plasmid was transfected into MDA-MB-231 cells, and the cells were exposed to epirubicin to observe the ability of UBD in epirubicin resistance.	Epirubicin	134-144	ubiquitin D	Homo sapiens	127-130
26185453-7	2015	Statistical methods were used to study the relationship between UBD expression and epirubicin resistance in TNBC treatment.	Epirubicin	83-93	ubiquitin D	Homo sapiens	64-67
26185453-11	2015	High expression of UBD was found in TNBC, compared with in non-TNBC, and this played a positive role in epirubicin resistance and indicated the poor prognosis of TNBC treatment.	Epirubicin	104-114	ubiquitin D	Homo sapiens	19-22
26185453-12	2015	CONCLUSION: UBD may play an important role in epirubicin resistance in TNBC.	Epirubicin	46-56	ubiquitin D	Homo sapiens	12-15
26125773-4	2015	The IC50 values of epirubicin in MCF-7, MCF-7/PUMA, and MCF-7/pCDNA3 cells were 13 +- 1.4, 1.8 +- 0.2, and 10.7 +- 1.3 muM, respectively.	Epirubicin	19-29	latexin	Homo sapiens	119-122
26125773-7	2015	Low concentrations of epirubicin (0.1 muM) caused low levels of apoptosis of MCF-7/pCDNA3 (1.15 +- 0.26%) and MCF-7 cells (0.9 +- 0.24%), but significantly induced apoptosis of MCF-7/PUMA cells (6.44 +- 1.46%).	Epirubicin	22-32	latexin	Homo sapiens	38-41
26125773-8	2015	High epirubicin concentration (1 muM) induced apoptosis in each group, but the epirubicin MCF-7/PUMA apoptosis rate (35.47 +- 9.36%) was significantly higher than that of MCF-7 (12.6 +- 3.73%) and MCF-7/ pCDNA3 (15.2 +- 5.17%) cells (P &lt; 0 01).	Epirubicin	5-15	latexin	Homo sapiens	33-36
25711681-0	2015	Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models.	Epirubicin	68-78	coagulation factor III, tissue factor	Homo sapiens	34-47
25711681-6	2015	The intracellular uptake of epirubicin was faster and greater in BxPC3 cells treated with anti-TF-NC-6300, compared with NC-6300.	Epirubicin	28-38	coagulation factor III, tissue factor	Homo sapiens	95-97
25713207-1	2015	We recently reported induction of UGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells.	Epirubicin	58-68	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	34-40
25713207-1	2015	We recently reported induction of UGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells.	Epirubicin	58-68	tumor protein p53	Homo sapiens	131-134
25713207-1	2015	We recently reported induction of UGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells.	Epirubicin	58-68	tumor protein p53	Homo sapiens	165-168
25713207-1	2015	We recently reported induction of UGT2B7 by its substrate epirubicin, a cytotoxic anthracycline anticancer drug, via activation of p53 and subsequent recruitment of p53 to the UGT2B7 promoter in hepatocellular carcinoma HepG2 cells.	Epirubicin	58-68	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	176-182
25713207-3	2015	We first demonstrated by reverse transcriptase quantitative real-time polymerase chain reaction that, as observed with epirubicin, nine cytotoxic drugs including three anthracyclines (doxorubicin, daunorubicin, and idarubicin) and six nonanthracyclines (mitomycin C, 5-fluorouracil, camptothecin, 7-ethyl-10-hydroxycamptothecin, topotecan, and etoposide) significantly increased UGT2B7 mRNA levels.	Epirubicin	119-129	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	379-385
25742747-9	2015	Knockdown of DDX27, TH1L or IDH3G sensitized cells to epirubicin or cisplatin, and knockdown of RAI14 reduced cell proliferation.	Epirubicin	54-64	DEAD-box helicase 27	Homo sapiens	13-18
25713207-10	2015	The cytotoxic drug-induced UGT2B7 activity in target liver cancer cells or possibly in normal liver cells may affect the therapeutic efficacy of co-administered cytotoxic drugs (e.g., epirubicin) and noncytotoxic drugs (e.g., morphine), which are UGT2B7 substrates.	Epirubicin	184-194	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	27-33
25928429-4	2015	Results showed that TIGAR was increased and relocated to the nucleus after epirubicin or hypoxia treatment in cancer cells.	Epirubicin	75-85	TP53 induced glycolysis regulatory phosphatase	Homo sapiens	20-25
25742747-9	2015	Knockdown of DDX27, TH1L or IDH3G sensitized cells to epirubicin or cisplatin, and knockdown of RAI14 reduced cell proliferation.	Epirubicin	54-64	negative elongation factor complex member C/D	Homo sapiens	20-24
25742747-9	2015	Knockdown of DDX27, TH1L or IDH3G sensitized cells to epirubicin or cisplatin, and knockdown of RAI14 reduced cell proliferation.	Epirubicin	54-64	isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma	Homo sapiens	28-33
25742747-10	2015	Further studies showed that overexpression of DDX27 reduced epirubicin-induced DNA damage and apoptosis.	Epirubicin	60-70	DEAD-box helicase 27	Homo sapiens	46-51
25815885-0	2015	Ulinastatin reduces the resistance of liver cancer cells to epirubicin by inhibiting autophagy.	Epirubicin	60-70	alpha 1 microglobulin/bikunin precursor	Mus musculus	0-11
25780421-0	2015	Knockdown of autophagy-related gene LC3 enhances the sensitivity of HepG2 cells to epirubicin.	Epirubicin	83-93	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	36-39
25780421-4	2015	In this study, tetracycline-inducible lentivirus-mediated RNA interference (RNAi) was employed to knock down microtubule-associated protein 1 light chain 3 (LC3) gene, which encodes a key protein in the induction of autophagy, to study the protective function of autophagy in liver cancer tolerant to epirubicin.	Epirubicin	301-311	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	157-160
25815885-2	2015	The purpose of this study is to show that ulinastatin (UTI), a trypsin inhibitor, could reduce the resistance of liver cancer cells to chemotherapeutic agent epirubicin (EPI).	Epirubicin	158-168	alpha 1 microglobulin/bikunin precursor	Mus musculus	42-53
25739083-0	2015	Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.	Epirubicin	96-106	ubiquitin conjugating enzyme E2 C	Homo sapiens	13-19
25739083-6	2015	Furthermore, UbcH10 knockdown increased the sensitivity of MCF-7/EPB/TXT cells to epirubicin and docetaxel and promoted the apoptosis induced by these two drugs.	Epirubicin	82-92	ubiquitin conjugating enzyme E2 C	Homo sapiens	13-19
25739083-8	2015	Our research in the current study demonstrated that up-regulation of UbcH10 was involved in breast cancer and its knockdown can inhibit the growth of cancer cells and increase the chemosensitivity of the dual drug resistant breast cancer cells to epirubicin and docetaxel, suggesting that UbcH10 may be a promising target for the therapy of breast cancer.	Epirubicin	247-257	ubiquitin conjugating enzyme E2 C	Homo sapiens	69-75
26359224-4	2015	For human epidermal growth factor receptors 2 (HER2) negative cancer, standard treatments are combinations of fluoropyrimidine and platinum with or without epirubicin or docetaxel in first-line therapy.	Epirubicin	156-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	47-51
25887473-3	2015	Proliferation inhibition and apoptosis in NGDN over-expressing myeloid multidrug-resistant leukemia cells (K562/A02-NGDN) was significantly higher than in control K562/A02 cells following treatment with vincristine, etoposide, and epirubicin, indicating that NGDN over-expression can increase the sensitivity of multidrug-resistant leukemia cells to chemotherapeutic drugs.	Epirubicin	231-241	neuroguidin	Homo sapiens	42-46
25480692-7	2015	We found that higher nuclear PARP1 (nPARP1) expression correlated with increased in vitro chemosensitivity against docetaxel (p=0.001) and epirubicin (p=0.022) based on CD-DST results.	Epirubicin	139-149	poly(ADP-ribose) polymerase 1	Homo sapiens	29-34
26126066-0	2015	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.	Epirubicin	108-118	SLC9A3 regulator 1	Homo sapiens	41-47
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Epirubicin	170-180	SLC9A3 regulator 1	Homo sapiens	62-68
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Epirubicin	170-180	sorcin	Homo sapiens	90-96
26126066-3	2015	Herein, we aimed to analyze the potential association between NHERF1 expression and P-gp, sorcin and HIF-1alpha MDR-related proteins in advanced GC patients treated with epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy regimen, and its relation to response.	Epirubicin	170-180	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-111
25759054-10	2015	Moreover, exposure to epirubicin increased intracellular lipid peroxide levels and enhanced the phosphorylation of p38 mitogen-activated protein kinase.	Epirubicin	22-32	mitogen-activated protein kinase 14	Homo sapiens	115-118
25561897-13	2015	Furthermore, cell lines with T889C mutation in POLB gene were more resistant to the treatment of 5-fluorouracil, cisplatin and epirubicin than those with wild type POLB.	Epirubicin	127-137	DNA polymerase beta	Homo sapiens	47-51
25535473-4	2015	Results of the mechanism study highlighted the cooperation between SG and epirubicin or paclitaxel in activating caspase-3 and -9 but not caspase-8.	Epirubicin	74-84	caspase 3	Homo sapiens	113-129
25535473-5	2015	Moreover, SG significantly increased the mitochondrial accumulation of both Bax and Bak triggered by epirubicin or paclitaxel as well as the subsequent release of cytochrome c in the targeted cells.	Epirubicin	101-111	BCL2 associated X, apoptosis regulator	Homo sapiens	76-79
25535473-5	2015	Moreover, SG significantly increased the mitochondrial accumulation of both Bax and Bak triggered by epirubicin or paclitaxel as well as the subsequent release of cytochrome c in the targeted cells.	Epirubicin	101-111	BCL2 antagonist/killer 1	Homo sapiens	84-87
25085248-6	2014	In parallel, TIGAR silencing also enhanced the epirubicin-induced activation of autophagy, in a manner that was also blocked by ectopic addition of NADPH.	Epirubicin	47-57	Trp53 induced glycolysis regulatory phosphatase	Mus musculus	13-18
25460146-0	2014	Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.	Epirubicin	19-29	prominin 1	Mus musculus	123-128
25460146-4	2014	Furthermore, a procedure for the coencapsulation of epirubicin (EPI) and metformin (MET) was developed with the primary goal of eradicating the bulk population of CD133- cells and the rare population of CD133+ cancer stem-like cells, thus ultimately preventing tumor relapse.	Epirubicin	52-62	prominin 1	Mus musculus	163-168
25460146-4	2014	Furthermore, a procedure for the coencapsulation of epirubicin (EPI) and metformin (MET) was developed with the primary goal of eradicating the bulk population of CD133- cells and the rare population of CD133+ cancer stem-like cells, thus ultimately preventing tumor relapse.	Epirubicin	52-62	prominin 1	Mus musculus	203-208
25329677-3	2014	In the present study, we investigated the expression pattern of ATG-5 and multidrug resistance-associated protein-1 (MRP-1) in 135 gastric cancers (GC) patients who were treated with epirubicin, cisplatin and 5-FU adjuvant chemotherapy (ECF) following surgical resection and explored their potential clinical significance.	Epirubicin	183-193	autophagy related 5	Homo sapiens	64-69
25055937-9	2014	An NQO2 exonic SNP was associated with a higher exposure to epirubicinol relative to epirubicin (p = 0.011).	Epirubicin	60-70	N-ribosyldihydronicotinamide:quinone reductase 2	Homo sapiens	3-7
25372840-9	2014	The intracellular level of ATP decreased 44%, 46% in the presence of 12.5.25 microM 3-Bromopyruvate, whereas the accumulation of rhodamine 123 and epirubicin (two typical P-glycoprotein substrates) in cells was significantly increased.	Epirubicin	147-157	ATP binding cassette subfamily B member 1	Homo sapiens	171-185
25085248-3	2014	In liver or lung cancer cells treated with the anticancer drug epirubicin, TIGAR levels increased in a dose- and time-dependent manner.	Epirubicin	63-73	Trp53 induced glycolysis regulatory phosphatase	Mus musculus	75-80
25085248-4	2014	TIGAR silencing enhanced epirubicin-induced elevations in ROS levels and apoptosis rates, in a manner that was blocked by ectopic addition of NADPH or N-acetyl cysteine.	Epirubicin	25-35	Trp53 induced glycolysis regulatory phosphatase	Mus musculus	0-5
25085248-7	2014	Notably, TIGAR silencing also licensed epirubicin-mediated inactivation of the mTOR pathway, suggesting TIGAR also exerted a negative impact on autophagy.	Epirubicin	39-49	Trp53 induced glycolysis regulatory phosphatase	Mus musculus	9-14
25085248-7	2014	Notably, TIGAR silencing also licensed epirubicin-mediated inactivation of the mTOR pathway, suggesting TIGAR also exerted a negative impact on autophagy.	Epirubicin	39-49	mechanistic target of rapamycin kinase	Mus musculus	79-83
25085248-7	2014	Notably, TIGAR silencing also licensed epirubicin-mediated inactivation of the mTOR pathway, suggesting TIGAR also exerted a negative impact on autophagy.	Epirubicin	39-49	Trp53 induced glycolysis regulatory phosphatase	Mus musculus	104-109
25085248-8	2014	However, genetic or pharmacologic inhibition of autophagy increased epirubicin-induced apoptosis in TIGAR-silenced cells.	Epirubicin	68-78	Trp53 induced glycolysis regulatory phosphatase	Mus musculus	100-105
24362530-4	2014	We show that FOXM1 SUMOylation is enhanced in MCF-7 breast cancer cells in response to treatment with epirubicin and mitotic inhibitors.	Epirubicin	102-112	forkhead box M1	Homo sapiens	13-18
24381054-8	2014	In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype.	Epirubicin	60-70	progesterone receptor	Homo sapiens	46-49
25137071-0	2014	Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.	Epirubicin	149-159	microRNA 19a	Homo sapiens	12-19
25137071-0	2014	Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.	Epirubicin	149-159	microRNA 205	Homo sapiens	24-31
25137071-14	2014	CONCLUSIONS: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.	Epirubicin	139-149	microRNA 19a	Homo sapiens	32-39
25137071-14	2014	CONCLUSIONS: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.	Epirubicin	139-149	microRNA 205	Homo sapiens	44-51
24141789-0	2014	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.	Epirubicin	65-75	forkhead box M1	Homo sapiens	0-5
24141789-0	2014	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.	Epirubicin	65-75	nibrin	Homo sapiens	14-18
24141789-2	2014	We show here that FOXM1-depletion can sensitize breast cancer cells and mouse embryonic fibroblasts (MEFs) into entering epirubicin-induced senescence, with the loss of long-term cell proliferation ability, the accumulation of gammaH2AX foci, and the induction of senescence-associated beta-galactosidase activity and cell morphology.	Epirubicin	121-131	forkhead box M1	Mus musculus	18-23
24141789-2	2014	We show here that FOXM1-depletion can sensitize breast cancer cells and mouse embryonic fibroblasts (MEFs) into entering epirubicin-induced senescence, with the loss of long-term cell proliferation ability, the accumulation of gammaH2AX foci, and the induction of senescence-associated beta-galactosidase activity and cell morphology.	Epirubicin	121-131	galactosidase, beta 1	Mus musculus	286-304
24141789-5	2014	Like FOXM1, NBS1 is overexpressed in the epirubicin-resistant MCF-7Epi(R) cells and its expression level is low but inducible by epirubicin in MCF-7 cells.	Epirubicin	41-51	forkhead box M1	Homo sapiens	5-10
24141789-5	2014	Like FOXM1, NBS1 is overexpressed in the epirubicin-resistant MCF-7Epi(R) cells and its expression level is low but inducible by epirubicin in MCF-7 cells.	Epirubicin	41-51	nibrin	Homo sapiens	12-16
24141789-5	2014	Like FOXM1, NBS1 is overexpressed in the epirubicin-resistant MCF-7Epi(R) cells and its expression level is low but inducible by epirubicin in MCF-7 cells.	Epirubicin	129-139	nibrin	Homo sapiens	12-16
24141789-6	2014	Consistently, overexpression of FOXM1 augmented and FOXM1 depletion reduced NBS1 expression and epirubicin-induced ataxia-telangiectasia mutated (ATM)phosphorylation in breast cancer cells.	Epirubicin	96-106	forkhead box M1	Homo sapiens	32-37
24141789-6	2014	Consistently, overexpression of FOXM1 augmented and FOXM1 depletion reduced NBS1 expression and epirubicin-induced ataxia-telangiectasia mutated (ATM)phosphorylation in breast cancer cells.	Epirubicin	96-106	forkhead box M1	Homo sapiens	52-57
24141789-6	2014	Consistently, overexpression of FOXM1 augmented and FOXM1 depletion reduced NBS1 expression and epirubicin-induced ataxia-telangiectasia mutated (ATM)phosphorylation in breast cancer cells.	Epirubicin	96-106	ATM serine/threonine kinase	Homo sapiens	146-149
24141789-8	2014	Consistent with this idea, the loss of P-ATM induction by epirubicin in the NBS1-deficient NBS1-LBI fibroblasts can be rescued by NBS1 reconstitution.	Epirubicin	58-68	ATM serine/threonine kinase	Homo sapiens	41-44
24141789-8	2014	Consistent with this idea, the loss of P-ATM induction by epirubicin in the NBS1-deficient NBS1-LBI fibroblasts can be rescued by NBS1 reconstitution.	Epirubicin	58-68	nibrin	Homo sapiens	76-80
24141789-9	2014	Resembling FOXM1, NBS1 depletion also rendered MCF-7 and MCF-7Epi(R) cells more sensitive to epirubicin-induced cellular senescence.	Epirubicin	93-103	nibrin	Homo sapiens	18-22
24915873-9	2014	In ER-negative disease, there was evidence for greater benefit from anthracyclines in the National Epirubicin Adjuvant Trial in patients with CD8+ tumours [hazard ratio (HR) = 0.54; 95% CI 0.37-0.79] versus CD8-negative tumours (HR = 0.87; 95% CI 0.55-1.38).	Epirubicin	99-109	CD8a molecule	Homo sapiens	142-145
24811259-3	2014	The positively charged surface of Gd-NGO was capable of simultaneous adsorption of the anti-cancer drug epirubicin (EPI) and interaction with negatively charged Let-7g miRNA.	Epirubicin	104-114	tissue factor pathway inhibitor	Homo sapiens	116-119
24899685-6	2014	Interestingly, we found that breast cancer cells that were resistant to epirubicin expressed a high level of activated AurA and also have a high CD24(Low)/CD44(High) TIC population.	Epirubicin	72-82	aurora kinase A	Homo sapiens	119-123
24899685-6	2014	Interestingly, we found that breast cancer cells that were resistant to epirubicin expressed a high level of activated AurA and also have a high CD24(Low)/CD44(High) TIC population.	Epirubicin	72-82	CD24 molecule	Homo sapiens	145-149
24899685-6	2014	Interestingly, we found that breast cancer cells that were resistant to epirubicin expressed a high level of activated AurA and also have a high CD24(Low)/CD44(High) TIC population.	Epirubicin	72-82	CD44 molecule (Indian blood group)	Homo sapiens	155-159
24899685-7	2014	The inhibition of AurA kinase by AKI603 abolished the epirubicin-induced enrichment of TICs.	Epirubicin	54-64	aurora kinase A	Homo sapiens	18-22
24794111-6	2014	Results demonstrate that both EPI and EPI-Dx induced the phosphorylation/activation of PI3K, PDK-1, AKT and eNOS.	Epirubicin	38-44	pyruvate dehydrogenase kinase 1	Homo sapiens	93-98
24794111-6	2014	Results demonstrate that both EPI and EPI-Dx induced the phosphorylation/activation of PI3K, PDK-1, AKT and eNOS.	Epirubicin	38-44	AKT serine/threonine kinase 1	Homo sapiens	100-103
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Epirubicin	200-210	colony stimulating factor 3	Homo sapiens	34-71
24595405-2	2014	PURPOSE: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is used in many institutions across the UK due to unacceptable febrile neutropenia (FN) rates with FEC-D (fluorouracil, epirubicin, cyclophosphamide-docetaxel).	Epirubicin	200-210	colony stimulating factor 3	Homo sapiens	73-78
24682467-0	2014	Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway.	Epirubicin	0-10	transformation related protein 53, pseudogene	Mus musculus	96-99
24594218-0	2014	Progesterone augments epirubicin-induced apoptosis in HA22T/VGH cells by increasing oxidative stress and upregulating Fas/FasL.	Epirubicin	22-32	Fas ligand	Homo sapiens	122-126
24594218-5	2014	RESULTS: HA22T/VGH cells treated with epirubicin increased the production of reactive oxygen species and nitric oxide, the expression of Fas, FasL, and Fas-associated death domain, and the activities of caspase-8 and caspase-3.	Epirubicin	38-48	Fas ligand	Homo sapiens	142-146
24594218-5	2014	RESULTS: HA22T/VGH cells treated with epirubicin increased the production of reactive oxygen species and nitric oxide, the expression of Fas, FasL, and Fas-associated death domain, and the activities of caspase-8 and caspase-3.	Epirubicin	38-48	caspase 8	Homo sapiens	203-212
24594218-5	2014	RESULTS: HA22T/VGH cells treated with epirubicin increased the production of reactive oxygen species and nitric oxide, the expression of Fas, FasL, and Fas-associated death domain, and the activities of caspase-8 and caspase-3.	Epirubicin	38-48	caspase 3	Homo sapiens	217-226
25844392-2	2014	METHODOLOGY: Gemcitabine and epirubicin were covalently bond to anti-EGFR and anti-HER2/neu utilizing a rapid multi-phase synthetic organic chemistry reaction scheme.	Epirubicin	29-39	epidermal growth factor receptor	Homo sapiens	69-73
25844392-2	2014	METHODOLOGY: Gemcitabine and epirubicin were covalently bond to anti-EGFR and anti-HER2/neu utilizing a rapid multi-phase synthetic organic chemistry reaction scheme.	Epirubicin	29-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87
25844392-9	2014	RESULTS: Dual-combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] produced greater levels of anti-neoplastic cytotoxicity than either of the covalent immunochemotherapeutics alone.	Epirubicin	69-80	epidermal growth factor receptor	Homo sapiens	58-62
25844392-9	2014	RESULTS: Dual-combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] produced greater levels of anti-neoplastic cytotoxicity than either of the covalent immunochemotherapeutics alone.	Epirubicin	69-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-105
24381054-8	2014	In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype.	Epirubicin	60-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-56
24381054-8	2014	In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype.	Epirubicin	60-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	274-278
24381054-8	2014	In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype.	Epirubicin	60-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	274-278
24381054-8	2014	In patients with triple negative tumors (ER-, PgR-, HER2-), epirubicin-containing regimens yielded better DFS (HR 0.33, 95 % CI 0.17-0.62, P = 0.0007) and OS (HR 0.24, 95 % CI 0.10-0.57, P = 0.001) compared with CMF alone, whereas no differences were found in patients with HER2-positive (HER2+, ER-, PgR-) subtype.	Epirubicin	60-70	progesterone receptor	Homo sapiens	301-304
24381054-10	2014	In triple unfavorable (ER-, PgR-, Ki67 &gt; 20 %) tumors, the use of epirubicin yielded better DFS (HR 0.45,95 % CI 0.26-0.78, P = 0.005) and OS (HR 0.30, 95 % CI 0.15-0.63, P = 0.001).	Epirubicin	69-79	progesterone receptor	Homo sapiens	28-31
24310817-2	2014	The consistent association of anthracylines (e.g., epirubicin and idarubicin) in inducing therapy-related acute leukemias (t-AL) with mixed lineage leukemia (MLL) gene rearrangement suggests that MLL translocations are causative events for t-AL.	Epirubicin	51-61	lysine methyltransferase 2A	Homo sapiens	158-161
24637737-8	2014	Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2.	Epirubicin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	96-100
24637737-8	2014	Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2.	Epirubicin	0-10	MDM4 regulator of p53	Homo sapiens	102-106
24637737-8	2014	Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2.	Epirubicin	0-10	ATP binding cassette subfamily C member 2	Homo sapiens	108-112
24637737-8	2014	Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2.	Epirubicin	0-10	BCL2 apoptosis regulator	Homo sapiens	118-123
24637737-10	2014	The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study.	Epirubicin	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
24637737-10	2014	The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study.	Epirubicin	19-29	MDM4 regulator of p53	Homo sapiens	79-83
24637737-10	2014	The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study.	Epirubicin	19-29	ATP binding cassette subfamily C member 2	Homo sapiens	89-93
24637737-10	2014	The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study.	Epirubicin	19-29	BCL2 apoptosis regulator	Homo sapiens	120-125
24637737-10	2014	The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study.	Epirubicin	19-29	BCL2 like 1	Homo sapiens	126-132
24637737-11	2014	Our results provide a novel insight into the mechanisms by which PEGylated liposomal ASOs against both resistance types act as activators to epirubicin-induced apoptosis through suppressing MDR1, MRP1, and MRP2, as well as triggering intrinsic mitochondrial and extrinsic death receptor pathways.	Epirubicin	141-151	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
24637737-11	2014	Our results provide a novel insight into the mechanisms by which PEGylated liposomal ASOs against both resistance types act as activators to epirubicin-induced apoptosis through suppressing MDR1, MRP1, and MRP2, as well as triggering intrinsic mitochondrial and extrinsic death receptor pathways.	Epirubicin	141-151	MDM4 regulator of p53	Homo sapiens	196-200
24637737-11	2014	Our results provide a novel insight into the mechanisms by which PEGylated liposomal ASOs against both resistance types act as activators to epirubicin-induced apoptosis through suppressing MDR1, MRP1, and MRP2, as well as triggering intrinsic mitochondrial and extrinsic death receptor pathways.	Epirubicin	141-151	ATP binding cassette subfamily C member 2	Homo sapiens	206-210
24464946-0	2014	Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.	Epirubicin	157-168	troponin T2, cardiac type	Homo sapiens	79-97
24464946-1	2014	AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure.	Epirubicin	166-176	troponin T2, cardiac type	Homo sapiens	101-105
24310817-2	2014	The consistent association of anthracylines (e.g., epirubicin and idarubicin) in inducing therapy-related acute leukemias (t-AL) with mixed lineage leukemia (MLL) gene rearrangement suggests that MLL translocations are causative events for t-AL.	Epirubicin	51-61	lysine methyltransferase 2A	Homo sapiens	196-199
24971383-8	2014	Cotreatment with progesterone enhanced epirubicin-induced apoptosis, as evidenced by greater increase in caspase-3 activity and in the ratio of the apoptosis-regulating protein, Bax/Bcl-X(L).	Epirubicin	39-49	caspase 3	Homo sapiens	105-114
25027743-6	2014	Our data for the first time suggested that PIK3CA mutation status may be a predictor for better understanding clinical response to the combination of epirubicin and docetaxel NCT in patients with BC.	Epirubicin	150-160	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	43-49
24971383-8	2014	Cotreatment with progesterone enhanced epirubicin-induced apoptosis, as evidenced by greater increase in caspase-3 activity and in the ratio of the apoptosis-regulating protein, Bax/Bcl-X(L).	Epirubicin	39-49	BCL2 associated X, apoptosis regulator	Homo sapiens	178-181
24971383-8	2014	Cotreatment with progesterone enhanced epirubicin-induced apoptosis, as evidenced by greater increase in caspase-3 activity and in the ratio of the apoptosis-regulating protein, Bax/Bcl-X(L).	Epirubicin	39-49	BCL2 like 1	Homo sapiens	182-190
24303084-0	2013	Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via beta-catenin/GSK-3beta modulation in colorectal carcinoma.	Epirubicin	30-40	galectin 3	Homo sapiens	0-10
24391455-0	2013	Knockdown of TRPM8 suppresses cancer malignancy and enhances epirubicin-induced apoptosis in human osteosarcoma cells.	Epirubicin	61-71	transient receptor potential cation channel subfamily M member 8	Homo sapiens	13-18
24391455-4	2013	Knockdown of TRPM8 not only negatively influences the cell proliferation and metastasis but also enhances epirubicin-induced cell apoptosis.	Epirubicin	106-116	transient receptor potential cation channel subfamily M member 8	Homo sapiens	13-18
24303084-3	2013	Thus, the inhibition of galectin-3 has the potential to enhance the efficacy of the anticancer drug epirubicin.	Epirubicin	100-110	galectin 3	Homo sapiens	24-34
24303084-5	2013	Galectin-3 knockdown increased the intracellular accumulation of epirubicin in Caco-2 cells; suppressed the mRNA expression of galectin-3, beta-catenin, cyclin D1, c-myc, P-glycoprotein (P-gp), MDR-associated protein (MRP) 1, and MRP2; and downregulated the protein expression of P-gp, cyclin D1, galectin-3, beta-catenin, c-Myc, and Bcl-2.	Epirubicin	65-75	galectin 3	Homo sapiens	0-10
24303084-8	2013	Epirubicin-mediated resistance was effectively inhibited via galectin-3 RNAi treatment.	Epirubicin	0-10	galectin 3	Homo sapiens	61-71
24303084-10	2013	We show for the first time that the silencing of galectin-3 sensitizes MDR cells to epirubicin by inhibiting ABC transporters and activating the mitochondrial pathway of apoptosis through modulation of the beta-catenin/GSK-3beta pathway in human colon cancer cells.	Epirubicin	84-94	galectin 3	Homo sapiens	49-59
24303084-10	2013	We show for the first time that the silencing of galectin-3 sensitizes MDR cells to epirubicin by inhibiting ABC transporters and activating the mitochondrial pathway of apoptosis through modulation of the beta-catenin/GSK-3beta pathway in human colon cancer cells.	Epirubicin	84-94	catenin beta 1	Homo sapiens	206-218
23867903-6	2013	Epirubicin alone markedly increased the mRNA expression of MDR1, MDR-associated protein (MRP) 1, and MRP2.	Epirubicin	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
24200057-8	2013	RESULTS: The killing rates of docetaxel, epirubicin and fluorouracil on CD55(high) subgroup MCF-7 cells were much lower than on total MCF-7 cells.	Epirubicin	41-51	CD55 molecule (Cromer blood group)	Homo sapiens	72-76
24490494-6	2013	The sensitivity to epirubicin was reduced after downregulating the expression of RABEX-5, the 50% inhibition concentration (IC50) of MCF-7/RNAi [(3.590 0 +/- 0.228 69) microg/mL] was higher than that of MCF-7/Vvector [(1.193 3 +/- 0.187 71) microg/mL, P &lt; 0.05]; while the same effect was not found in docetaxel group, the IC50 were (11.162 7 +/- 0.210 26) microg/mL and (10.536 7 +/- 0.430 97) microg/mL, respectively (P &gt; 0.05).	Epirubicin	19-29	RAB guanine nucleotide exchange factor 1	Homo sapiens	81-88
24490494-7	2013	CONCLUSION: Downregulation of RABEX-5 can induce chemoresistance to epirubicin in human breast cancer cell MCF-7; while its effect on sensitivity to docetaxel is not significant.	Epirubicin	68-78	RAB guanine nucleotide exchange factor 1	Homo sapiens	30-37
23867903-6	2013	Epirubicin alone markedly increased the mRNA expression of MDR1, MDR-associated protein (MRP) 1, and MRP2.	Epirubicin	0-10	ATP binding cassette subfamily C member 1	Homo sapiens	65-95
23867903-6	2013	Epirubicin alone markedly increased the mRNA expression of MDR1, MDR-associated protein (MRP) 1, and MRP2.	Epirubicin	0-10	ATP binding cassette subfamily C member 2	Homo sapiens	101-105
23867903-14	2013	This study pioneered in demonstrating that formononetin may potentiate the cytotoxicity of epirubicin in HeLa cells through the ROS-mediated MRP inhibition and concurrent activation of the mitochondrial and death receptor pathways of apoptosis.	Epirubicin	91-101	ATP binding cassette subfamily C member 1	Homo sapiens	141-144
24106899-0	2013	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.	Epirubicin	79-89	DNA topoisomerase II alpha	Homo sapiens	0-5
23800742-3	2013	Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment.	Epirubicin	129-139	epidermal growth factor receptor	Mus musculus	21-53
23108394-0	2013	The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.	Epirubicin	80-90	forkhead box M1	Homo sapiens	4-19
23108394-0	2013	The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.	Epirubicin	80-90	BRCA1 interacting helicase 1	Homo sapiens	38-43
23108394-3	2013	We find that FOXM1 expression is associated with epirubicin sensitivity and DSB repair.	Epirubicin	49-59	forkhead box M1	Homo sapiens	13-18
23108394-4	2013	Ectopic expression of FOXM1 can increase cell viability and abrogate DSBs sustained by MCF-7 cells following epirubicin, owing to an enhancement in repair efficiency.	Epirubicin	109-119	forkhead box M1	Homo sapiens	22-27
23108394-5	2013	Conversely, alkaline comet and gammaH2AX foci formation assays show that Foxm1-null cells are hypersensitive to DNA damage, epirubicin and gamma-irradiation.	Epirubicin	124-134	forkhead box M1	Homo sapiens	73-78
23108394-8	2013	In agreement, depletion of FOXM1 expression by small interfering RNA downregulates BRIP1 expression at the protein and mRNA levels in MCF-7 and the epirubicin-resistant MCF-7 Epi(R) cells.	Epirubicin	148-158	forkhead box M1	Homo sapiens	27-32
23108394-8	2013	In agreement, depletion of FOXM1 expression by small interfering RNA downregulates BRIP1 expression at the protein and mRNA levels in MCF-7 and the epirubicin-resistant MCF-7 Epi(R) cells.	Epirubicin	148-158	BRCA1 interacting helicase 1	Homo sapiens	83-88
23845851-0	2013	Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation.	Epirubicin	0-10	microRNA 302b	Homo sapiens	34-42
23845851-5	2013	Notably, miR-302b, which is stably low-expressed in osteosarcoma, could be induced by the epirubicin.	Epirubicin	90-100	microRNA 302b	Homo sapiens	9-17
23800742-3	2013	Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment.	Epirubicin	129-139	epidermal growth factor receptor	Mus musculus	55-59
23514751-0	2013	SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.	Epirubicin	31-41	sirtuin 6	Homo sapiens	0-5
23108394-11	2013	These data suggest that FOXM1 regulates BRIP1 expression to modulate epirubicin-induced DNA damage repair and drug resistance.	Epirubicin	69-79	forkhead box M1	Homo sapiens	24-29
23108394-11	2013	These data suggest that FOXM1 regulates BRIP1 expression to modulate epirubicin-induced DNA damage repair and drug resistance.	Epirubicin	69-79	BRCA1 interacting helicase 1	Homo sapiens	40-45
23584895-2	2013	Epidermal growth factor receptor-targeted NDLPs are highly biocompatible particles that provide cell-specific imaging, promote tumor retention of ND-complexes, prevent epirubicin toxicities and mediate regression of triple negative breast cancers.	Epirubicin	168-178	epidermal growth factor receptor	Homo sapiens	0-32
23514751-10	2013	Collectively, our data suggest that SIRT6 has a role in paclitaxel and epirubicin sensitivity via targeting FOXO proteins and that SIRT6 could be a useful biomarker and therapeutic target for paclitaxel- and epirubicin-resistant cancer.	Epirubicin	208-218	sirtuin 6	Homo sapiens	36-41
23514751-10	2013	Collectively, our data suggest that SIRT6 has a role in paclitaxel and epirubicin sensitivity via targeting FOXO proteins and that SIRT6 could be a useful biomarker and therapeutic target for paclitaxel- and epirubicin-resistant cancer.	Epirubicin	208-218	sirtuin 6	Homo sapiens	131-136
23514751-1	2013	In this study, we report the identification of a novel role of SIRT6 in both epirubicin and paclitaxel resistance in breast cancer.	Epirubicin	77-87	sirtuin 6	Homo sapiens	63-68
23514751-2	2013	We found that SIRT6 protein levels are elevated in paclitaxel- and epirubicin-resistant MCF-7 cells compared with the parental sensitive cells.	Epirubicin	67-77	sirtuin 6	Homo sapiens	14-19
23514751-3	2013	SIRT6 knockout and depletion sensitized cells to both paclitaxel and epirubicin treatment, whereas SIRT6 ectopic overexpression led to increased resistance to paclitaxel and epirubicin.	Epirubicin	69-79	sirtuin 6	Homo sapiens	0-5
23514751-3	2013	SIRT6 knockout and depletion sensitized cells to both paclitaxel and epirubicin treatment, whereas SIRT6 ectopic overexpression led to increased resistance to paclitaxel and epirubicin.	Epirubicin	174-184	sirtuin 6	Homo sapiens	99-104
23514751-4	2013	Moreover, our data suggest that SIRT6 could be mediating epirubicin resistance through enhancing the DNA repair response to epirubicin-induced DNA damage.	Epirubicin	57-67	sirtuin 6	Homo sapiens	32-37
23514751-4	2013	Moreover, our data suggest that SIRT6 could be mediating epirubicin resistance through enhancing the DNA repair response to epirubicin-induced DNA damage.	Epirubicin	124-134	sirtuin 6	Homo sapiens	32-37
23514751-5	2013	Clonogenic assays also revealed that mouse embryonic fibroblasts (MEFs) lacking SIRT6 have decreased long-term viability in response to epirubicin.	Epirubicin	136-146	sirtuin 6	Mus musculus	80-85
23514751-6	2013	The tumour suppressor FOXO3a increases its levels of acetylation in MEFs depleted of SIRT6, whereas its induction by epirubicin is attenuated in breast cancer cells overexpressing SIRT6.	Epirubicin	117-127	forkhead box O3	Homo sapiens	22-28
23514751-6	2013	The tumour suppressor FOXO3a increases its levels of acetylation in MEFs depleted of SIRT6, whereas its induction by epirubicin is attenuated in breast cancer cells overexpressing SIRT6.	Epirubicin	117-127	sirtuin 6	Homo sapiens	180-185
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Epirubicin	124-134	forkhead box O1	Homo sapiens	60-65
23396606-0	2013	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).	Epirubicin	199-209	ATP binding cassette subfamily C member 1	Homo sapiens	27-68
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Epirubicin	124-134	sirtuin 6	Homo sapiens	152-157
23396606-0	2013	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).	Epirubicin	199-209	ATP binding cassette subfamily C member 1	Homo sapiens	70-75
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Epirubicin	181-191	forkhead box O1	Homo sapiens	60-65
23396606-0	2013	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).	Epirubicin	199-209	ATP binding cassette subfamily C member 1	Homo sapiens	76-80
23514751-7	2013	Further cell viability studies demonstrate that deletion of FOXO1/3/4 in MEFs can confer sensitivity to both paclitaxel and epirubicin, suggesting that SIRT6 reduces paclitaxel and epirubicin sensitivity, at least in part, through modulating FOXO acetylation and expression.	Epirubicin	181-191	sirtuin 6	Homo sapiens	152-157
23514751-10	2013	Collectively, our data suggest that SIRT6 has a role in paclitaxel and epirubicin sensitivity via targeting FOXO proteins and that SIRT6 could be a useful biomarker and therapeutic target for paclitaxel- and epirubicin-resistant cancer.	Epirubicin	71-81	sirtuin 6	Homo sapiens	36-41
23410002-0	2013	Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.	Epirubicin	40-50	high mobility group box 1	Homo sapiens	7-13
23570501-2	2013	The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil (CMF) treatment.	Epirubicin	215-225	TIMP metallopeptidase inhibitor 1	Homo sapiens	68-107
23570501-2	2013	The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil (CMF) treatment.	Epirubicin	215-225	TIMP metallopeptidase inhibitor 1	Homo sapiens	109-115
23570501-2	2013	The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil (CMF) treatment.	Epirubicin	215-225	erb-b2 receptor tyrosine kinase 2	Homo sapiens	153-157
23570501-2	2013	The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil (CMF) treatment.	Epirubicin	215-225	DNA topoisomerase II alpha	Homo sapiens	161-166
23410002-6	2013	RESULTS: Treatment of HCC1143 cells with epirubicin/docetaxel resulted in a significant HMGB-1 release in vitro.	Epirubicin	41-51	high mobility group box 1	Homo sapiens	88-94
23450278-0	2013	Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.	Epirubicin	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
23450278-0	2013	Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.	Epirubicin	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	80-85
23450278-1	2013	BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer.	Epirubicin	60-70	nuclear receptor subfamily 4 group A member 1	Homo sapiens	222-238
23450278-1	2013	BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer.	Epirubicin	60-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	249-254
23466962-6	2013	RESULTS: LINE-1 ORF-1p contributed to the resistance to several chemotherapeutic drugs (cisplatin and epirubicin) in HepG2 cells.	Epirubicin	102-112	ORF1	Homo sapiens	16-22
23466962-8	2013	Repression of LINE-1 ORF-1p expression by the siRNA could markedly enhance the response of HepG2 cells to the epirubicin and cisplatin.	Epirubicin	110-120	ORF1	Homo sapiens	21-27
23410002-3	2013	We hypothesized that the initial dose of NCT with epirubicin/docetaxel induces changes in plasma HMGB-1 which could allow for an early prediction of response to therapy.	Epirubicin	50-60	high mobility group box 1	Homo sapiens	97-103
23410002-4	2013	MATERIALS AND METHODS: First, we analysed whether epirubicin/docetaxel releases HMGB-1 from HCC1143 breast cancer cells in vitro.	Epirubicin	50-60	high mobility group box 1	Homo sapiens	80-86
23086576-0	2013	Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.	Epirubicin	181-191	kallikrein related peptidase 4	Homo sapiens	88-92
23086576-0	2013	Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.	Epirubicin	181-191	kallikrein related peptidase 5	Homo sapiens	94-98
23086576-0	2013	Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.	Epirubicin	181-191	kallikrein related peptidase 14	Homo sapiens	103-108
23086576-7	2013	The most significant alterations were a 12-fold and tenfold increase of KLK5 in docetaxel and methotrexate-treated cells, respectively, while the KLK4 levels decreased by ten-fold in epirubicin, five-fold in docetaxel and twenty-fold in methotrexate treated-cells, compared to the untreated ones.	Epirubicin	183-193	kallikrein related peptidase 4	Homo sapiens	146-150
23086576-8	2013	In the case of KLK14 levels, a twofold increase in epirubicin and threefold decrease in methotrexate-treated cells were observed.	Epirubicin	51-61	kallikrein related peptidase 14	Homo sapiens	15-20
22370641-0	2013	WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells.	Epirubicin	71-81	Wnt family member 6	Homo sapiens	0-4
22370641-0	2013	WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells.	Epirubicin	71-81	caveolin 1	Homo sapiens	31-41
22370641-6	2013	WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox).	Epirubicin	166-176	Wnt family member 6	Homo sapiens	65-69
23679263-0	2013	Epirubicin inhibits soluble CD25 secretion by Treg cells isolated from diffuse large B-cell lymphoma patients.	Epirubicin	0-10	interleukin 2 receptor subunit alpha	Homo sapiens	28-32
23679263-1	2013	OBJECTIVE: To investigate the effect of epirubicin on soluble CD25 (sCD25) secretion by CD4+CD25+ regulatory T (Treg) cells isolated from diffuse large B-cell lymphoma (DLBCL) patients.	Epirubicin	40-50	interleukin 2 receptor subunit alpha	Homo sapiens	62-66
23679263-1	2013	OBJECTIVE: To investigate the effect of epirubicin on soluble CD25 (sCD25) secretion by CD4+CD25+ regulatory T (Treg) cells isolated from diffuse large B-cell lymphoma (DLBCL) patients.	Epirubicin	40-50	CD4 molecule	Homo sapiens	88-91
23679263-1	2013	OBJECTIVE: To investigate the effect of epirubicin on soluble CD25 (sCD25) secretion by CD4+CD25+ regulatory T (Treg) cells isolated from diffuse large B-cell lymphoma (DLBCL) patients.	Epirubicin	40-50	interleukin 2 receptor subunit alpha	Homo sapiens	69-73
23679263-7	2013	When equal numbers of CD4+CD25+ Treg cells of the epirubicin group and the control group were cultured for another 24 h without epirubicin the CD25 fluorescence intensity on the surface of Treg cells was obviously higher in the epirubicin group than that in the control group (P&lt;0.01), while the sCD25 concentration in the supernatant in the epirubicin group was significantly lower than that in the control group (P&lt;0.05).	Epirubicin	50-60	CD4 molecule	Homo sapiens	22-25
23679263-7	2013	When equal numbers of CD4+CD25+ Treg cells of the epirubicin group and the control group were cultured for another 24 h without epirubicin the CD25 fluorescence intensity on the surface of Treg cells was obviously higher in the epirubicin group than that in the control group (P&lt;0.01), while the sCD25 concentration in the supernatant in the epirubicin group was significantly lower than that in the control group (P&lt;0.05).	Epirubicin	50-60	interleukin 2 receptor subunit alpha	Homo sapiens	26-30
23679263-7	2013	When equal numbers of CD4+CD25+ Treg cells of the epirubicin group and the control group were cultured for another 24 h without epirubicin the CD25 fluorescence intensity on the surface of Treg cells was obviously higher in the epirubicin group than that in the control group (P&lt;0.01), while the sCD25 concentration in the supernatant in the epirubicin group was significantly lower than that in the control group (P&lt;0.05).	Epirubicin	50-60	interleukin 2 receptor subunit alpha	Homo sapiens	143-147
23679263-7	2013	When equal numbers of CD4+CD25+ Treg cells of the epirubicin group and the control group were cultured for another 24 h without epirubicin the CD25 fluorescence intensity on the surface of Treg cells was obviously higher in the epirubicin group than that in the control group (P&lt;0.01), while the sCD25 concentration in the supernatant in the epirubicin group was significantly lower than that in the control group (P&lt;0.05).	Epirubicin	128-138	CD4 molecule	Homo sapiens	22-25
23679263-7	2013	When equal numbers of CD4+CD25+ Treg cells of the epirubicin group and the control group were cultured for another 24 h without epirubicin the CD25 fluorescence intensity on the surface of Treg cells was obviously higher in the epirubicin group than that in the control group (P&lt;0.01), while the sCD25 concentration in the supernatant in the epirubicin group was significantly lower than that in the control group (P&lt;0.05).	Epirubicin	128-138	interleukin 2 receptor subunit alpha	Homo sapiens	143-147
22914566-2	2012	This study aims to explore the effects and mechanisms of 7,3",4"-trihydroxyisoflavone (7,3",4"-THIF), one of the major metabolites of daidzein, on potentiating cytotoxicity of epirubicin (Epi), an anticancer drug in human cervical cancer HeLa cells.	Epirubicin	176-186	thioredoxin interacting protein	Homo sapiens	95-99
23249627-8	2013	Both univariable and multivariable COX regressions analyses showed that KEAP1 methylation was associated with a better progression free survival in patients treated with epirubicin/cyclophosfamide and docetaxel as sequential chemotherapy (HR = 0.082; 95%CI: 0.007-0.934).	Epirubicin	170-180	kelch like ECH associated protein 1	Homo sapiens	72-77
22948777-4	2012	By aiming to explore how the molecular profile of KLK13 is modified in stomach cancer cells treated with antineoplastic drugs, we examined, for the first time, the mRNA alterations of this gene following gastric cancer cells" exposure to the prominent chemotherapeutic substances epirubicin, oxaliplatin, or methotrexate.	Epirubicin	280-290	kallikrein related peptidase 13	Homo sapiens	50-55
22101791-6	2012	Up-regulation of miR-200c with transfection of miR-200c mimics in breast cancer cells could enhance the chemosensitivity to epirubicin and reduce expression of multidrug resistance 1 mRNA and P-glycoprotein.	Epirubicin	124-134	microRNA 200c	Homo sapiens	17-25
22101791-6	2012	Up-regulation of miR-200c with transfection of miR-200c mimics in breast cancer cells could enhance the chemosensitivity to epirubicin and reduce expression of multidrug resistance 1 mRNA and P-glycoprotein.	Epirubicin	124-134	microRNA 200c	Homo sapiens	47-55
22948777-9	2012	Distinct KLK13 profiles resulted from AGS cells" incubation with epirubicin or methotrexate for 24, 36, and 48 h. KLK13 expression increased in a time-dependent manner up to 5.70 times (for epirubicin) or 5.76 times (for methotrexate) at 48 h compared with the corresponding untreated cells.	Epirubicin	65-75	kallikrein related peptidase 13	Homo sapiens	9-14
22948777-9	2012	Distinct KLK13 profiles resulted from AGS cells" incubation with epirubicin or methotrexate for 24, 36, and 48 h. KLK13 expression increased in a time-dependent manner up to 5.70 times (for epirubicin) or 5.76 times (for methotrexate) at 48 h compared with the corresponding untreated cells.	Epirubicin	65-75	kallikrein related peptidase 13	Homo sapiens	114-119
22948777-9	2012	Distinct KLK13 profiles resulted from AGS cells" incubation with epirubicin or methotrexate for 24, 36, and 48 h. KLK13 expression increased in a time-dependent manner up to 5.70 times (for epirubicin) or 5.76 times (for methotrexate) at 48 h compared with the corresponding untreated cells.	Epirubicin	190-200	kallikrein related peptidase 13	Homo sapiens	9-14
22948777-9	2012	Distinct KLK13 profiles resulted from AGS cells" incubation with epirubicin or methotrexate for 24, 36, and 48 h. KLK13 expression increased in a time-dependent manner up to 5.70 times (for epirubicin) or 5.76 times (for methotrexate) at 48 h compared with the corresponding untreated cells.	Epirubicin	190-200	kallikrein related peptidase 13	Homo sapiens	114-119
26225190-0	2012	Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.	Epirubicin	64-74	erb-b2 receptor tyrosine kinase 2	Homo sapiens	352-356
26225190-3	2012	Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes.	Epirubicin	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
26225190-3	2012	Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes.	Epirubicin	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-17
26225190-3	2012	Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes.	Epirubicin	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-13
26225190-3	2012	Retained HER2/neu binding characteristics of epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-SS-[anti-HER2/neu] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/neu receptor complexes.	Epirubicin	87-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	9-17
22895628-0	2012	Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity             of EJ bladder cancer cells to epirubicin in vitro.	Epirubicin	122-132	clusterin	Homo sapiens	40-49
22895628-3	2012	In the present study, we aimed to elucidate the role of CLU in the chemoresistance             of bladder cancer cells to epirubicin.	Epirubicin	122-132	clusterin	Homo sapiens	56-59
22895628-9	2012	CLU knockdown             increased the cytotoxicity of epirubicin to EJ bladder cancer cells.	Epirubicin	56-66	clusterin	Homo sapiens	0-3
22895628-11	2012	Furthermore, cell cycle analysis indicated that CLU knockdown             reinforced the efficacy of epirubicin on G0/G1 cell cycle arrest.	Epirubicin	101-111	clusterin	Homo sapiens	48-51
22895628-12	2012	Taken together,             our results suggest that CLU silencing enhances chemosensitivity of EJ bladder             cancer cells to epirubicin.	Epirubicin	135-145	clusterin	Homo sapiens	53-56
21920731-7	2012	RESULTS: Mib-1 expression was associated with sensitivity against Paclitaxel/Epirubicin (p = 0.014) and Docetaxel/Epirubicin (p = 0.014).	Epirubicin	77-87	MIB E3 ubiquitin protein ligase 1	Homo sapiens	9-14
21920731-7	2012	RESULTS: Mib-1 expression was associated with sensitivity against Paclitaxel/Epirubicin (p = 0.014) and Docetaxel/Epirubicin (p = 0.014).	Epirubicin	114-124	MIB E3 ubiquitin protein ligase 1	Homo sapiens	9-14
21920731-10	2012	In vitro response for Paclitaxel/Epirubicin was most frequently observed for cases in the basal category (40.3%) compared to HER2-like (25.8%) and luminal cases (28.6%).	Epirubicin	33-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
22815059-5	2012	The anthracycline anticancer drug epirubicin (EPB) synergizes the cytotoxicity of HMCAZ5 in cancer cells by upregulating DR5 expression on the cell surfaces, enhancing p53 expression, Bid cleavage, and JNK phosphorylation and downregulating c-FLIP expression and Akt phosphorylation.	Epirubicin	34-44	TNF receptor superfamily member 10b	Homo sapiens	121-124
22543673-3	2012	PATIENTS AND METHODS: This study aimed to evaluate the associations between ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype with progression-free survival (PFS) and overall survival (OS) in 177 SCLC patients treated with cisplatin-etoposide or cyclophosphamide-epirubicin-vincristine chemotherapy.	Epirubicin	271-281	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
22815059-5	2012	The anthracycline anticancer drug epirubicin (EPB) synergizes the cytotoxicity of HMCAZ5 in cancer cells by upregulating DR5 expression on the cell surfaces, enhancing p53 expression, Bid cleavage, and JNK phosphorylation and downregulating c-FLIP expression and Akt phosphorylation.	Epirubicin	34-44	tumor protein p53	Homo sapiens	168-171
22815059-5	2012	The anthracycline anticancer drug epirubicin (EPB) synergizes the cytotoxicity of HMCAZ5 in cancer cells by upregulating DR5 expression on the cell surfaces, enhancing p53 expression, Bid cleavage, and JNK phosphorylation and downregulating c-FLIP expression and Akt phosphorylation.	Epirubicin	34-44	BH3 interacting domain death agonist	Homo sapiens	184-187
22815059-5	2012	The anthracycline anticancer drug epirubicin (EPB) synergizes the cytotoxicity of HMCAZ5 in cancer cells by upregulating DR5 expression on the cell surfaces, enhancing p53 expression, Bid cleavage, and JNK phosphorylation and downregulating c-FLIP expression and Akt phosphorylation.	Epirubicin	34-44	mitogen-activated protein kinase 8	Homo sapiens	202-205
22815059-5	2012	The anthracycline anticancer drug epirubicin (EPB) synergizes the cytotoxicity of HMCAZ5 in cancer cells by upregulating DR5 expression on the cell surfaces, enhancing p53 expression, Bid cleavage, and JNK phosphorylation and downregulating c-FLIP expression and Akt phosphorylation.	Epirubicin	34-44	CASP8 and FADD like apoptosis regulator	Homo sapiens	241-247
22802261-0	2012	The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.	Epirubicin	64-74	mitogen-activated protein kinase 14	Homo sapiens	4-7
22802261-0	2012	The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.	Epirubicin	64-74	MAPK activated protein kinase 2	Homo sapiens	13-16
22802261-0	2012	The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.	Epirubicin	64-74	forkhead box M1	Homo sapiens	41-46
22802261-0	2012	The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.	Epirubicin	64-74	E2F transcription factor 1	Homo sapiens	32-36
22802261-1	2012	E2F1 is responsible for the regulation of FOXM1 expression, which plays a key role in epirubicin resistance.	Epirubicin	86-96	E2F transcription factor 1	Homo sapiens	0-4
22465428-12	2012	Levels of CITED2 were increased in gastric tumor samples from patients who had complete responses to epirubicin.	Epirubicin	101-111	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2	Homo sapiens	10-16
22802261-1	2012	E2F1 is responsible for the regulation of FOXM1 expression, which plays a key role in epirubicin resistance.	Epirubicin	86-96	forkhead box M1	Homo sapiens	42-47
22802261-2	2012	Here, we examined the role and regulation of E2F1 in response to epirubicin in cancer cells.	Epirubicin	65-75	E2F transcription factor 1	Homo sapiens	45-49
22802261-3	2012	We first showed that E2F1 plays a key role in promoting FOXM1 expression, cell survival, and epirubicin resistance as its depletion by siRNA attenuated FOXM1 induction and cell viability in response to epirubicin.	Epirubicin	93-103	E2F transcription factor 1	Homo sapiens	21-25
22802261-3	2012	We first showed that E2F1 plays a key role in promoting FOXM1 expression, cell survival, and epirubicin resistance as its depletion by siRNA attenuated FOXM1 induction and cell viability in response to epirubicin.	Epirubicin	202-212	E2F transcription factor 1	Homo sapiens	21-25
22802261-3	2012	We first showed that E2F1 plays a key role in promoting FOXM1 expression, cell survival, and epirubicin resistance as its depletion by siRNA attenuated FOXM1 induction and cell viability in response to epirubicin.	Epirubicin	202-212	forkhead box M1	Homo sapiens	56-61
22802261-3	2012	We first showed that E2F1 plays a key role in promoting FOXM1 expression, cell survival, and epirubicin resistance as its depletion by siRNA attenuated FOXM1 induction and cell viability in response to epirubicin.	Epirubicin	202-212	forkhead box M1	Homo sapiens	152-157
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	99-109	mitogen-activated protein kinase 14	Homo sapiens	23-26
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	99-109	E2F transcription factor 1	Homo sapiens	76-80
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	99-109	forkhead box M1	Homo sapiens	85-90
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	99-109	mitogen-activated protein kinase 14	Homo sapiens	178-181
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	99-109	E2F transcription factor 1	Homo sapiens	207-211
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	227-237	mitogen-activated protein kinase 14	Homo sapiens	23-26
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	227-237	E2F transcription factor 1	Homo sapiens	76-80
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	227-237	forkhead box M1	Homo sapiens	85-90
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	227-237	mitogen-activated protein kinase 14	Homo sapiens	178-181
22802261-4	2012	We also found that the p38-MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance.	Epirubicin	227-237	E2F transcription factor 1	Homo sapiens	207-211
22802261-5	2012	Consistently, studies using pharmacologic inhibitors, siRNA knockdown, and knockout mouse embryonic fibroblasts (MEF) revealed that p38 mediates the E2F1 induction by epirubicin and that the induction of E2F1 by p38 is, in turn, mediated through its downstream kinase MK2 [mitogen-activated protein kinase (MAPK)-activated protein kinase 2; MAPKAPK2].	Epirubicin	167-177	mitogen-activated protein kinase 14	Mus musculus	132-135
22802261-5	2012	Consistently, studies using pharmacologic inhibitors, siRNA knockdown, and knockout mouse embryonic fibroblasts (MEF) revealed that p38 mediates the E2F1 induction by epirubicin and that the induction of E2F1 by p38 is, in turn, mediated through its downstream kinase MK2 [mitogen-activated protein kinase (MAPK)-activated protein kinase 2; MAPKAPK2].	Epirubicin	167-177	E2F transcription factor 1	Mus musculus	149-153
22802261-7	2012	Transfection assays also showed that E2F1 phosphorylation at Ser-364 participates in its induction by epirubicin but also suggests that other phosphorylation events are also involved.	Epirubicin	102-112	E2F transcription factor 1	Homo sapiens	37-41
22802261-8	2012	In addition, the p38-MK2 axis can also limit c-jun-NH(2)-kinase (JNK) induction by epirubicin and, notably, JNK represses FOXM1 expression.	Epirubicin	83-93	mitogen-activated protein kinase 14	Homo sapiens	17-20
22802261-8	2012	In addition, the p38-MK2 axis can also limit c-jun-NH(2)-kinase (JNK) induction by epirubicin and, notably, JNK represses FOXM1 expression.	Epirubicin	83-93	MAPK activated protein kinase 2	Homo sapiens	21-24
22802261-8	2012	In addition, the p38-MK2 axis can also limit c-jun-NH(2)-kinase (JNK) induction by epirubicin and, notably, JNK represses FOXM1 expression.	Epirubicin	83-93	mitogen-activated protein kinase 8	Homo sapiens	45-63
22802261-8	2012	In addition, the p38-MK2 axis can also limit c-jun-NH(2)-kinase (JNK) induction by epirubicin and, notably, JNK represses FOXM1 expression.	Epirubicin	83-93	mitogen-activated protein kinase 8	Homo sapiens	65-68
22802261-9	2012	Collectively, these findings underscore the importance of p38-MK2 signaling in the control of E2F1 and FOXM1 expression as well as epirubicin sensitivity.	Epirubicin	131-141	MAPK activated protein kinase 2	Homo sapiens	62-65
22315133-2	2012	The aim of this study was to investigate whether 14-3-3sigma expression is also associated with resistance to neoadjuvant chemotherapy consisting of paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC) in human breast cancer patients.	Epirubicin	177-187	stratifin	Homo sapiens	49-60
22465428-14	2012	Levels of CITED2 in gastric tumors correlate with patients" response to epirubicin.	Epirubicin	72-82	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2	Homo sapiens	10-16
22736131-13	2012	CONCLUSIONS: Triplets regimens (epirubicin, platins and fluorouracil) show benefit on disease-free survival for the stage III( gastric cancer patients staged by TNM staging 2010 edition.	Epirubicin	32-42	teneurin transmembrane protein 1	Homo sapiens	161-164
22160255-1	2012	The purpose of the study is to evaluate the 10 years follow-up of the efficacy in Chinese patients receiving cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) regimen as the initial treatment for diffuse large B cell lymphoma (DLBCL).	Epirubicin	139-149	DNA damage inducible transcript 3	Homo sapiens	180-184
22712078-7	2012	The statin also mitigated subacute anthracycline-provoked hepatotoxicity as shown on the level of doxorubicin- and epirubicin-stimulated CTGF mRNA expression as well as histopathologically detectable fibrosis and serum concentration of marker enzymes of hepatotoxicity (GPT/GLDH).	Epirubicin	115-125	cellular communication network factor 2	Mus musculus	137-141
22712078-7	2012	The statin also mitigated subacute anthracycline-provoked hepatotoxicity as shown on the level of doxorubicin- and epirubicin-stimulated CTGF mRNA expression as well as histopathologically detectable fibrosis and serum concentration of marker enzymes of hepatotoxicity (GPT/GLDH).	Epirubicin	115-125	glutamic pyruvic transaminase, soluble	Mus musculus	270-273
22330067-0	2012	Activation of p38 MAPK by oxidative stress underlying epirubicin-induced vascular endothelial cell injury.	Epirubicin	54-64	mitogen-activated protein kinase 14	Homo sapiens	14-17
22131069-0	2012	Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL.	Epirubicin	0-10	TNF superfamily member 10	Homo sapiens	76-81
22131069-0	2012	Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL.	Epirubicin	0-10	TNF superfamily member 10	Homo sapiens	175-180
22131069-7	2012	RESULTS: Subtoxic doses of epirubicin potentiated rAAV2/5-mediated TRAIL expression in FLS and simultaneously enhanced the sensitivity of FLS to TRAIL.	Epirubicin	27-37	TNF superfamily member 10	Homo sapiens	67-72
22131069-7	2012	RESULTS: Subtoxic doses of epirubicin potentiated rAAV2/5-mediated TRAIL expression in FLS and simultaneously enhanced the sensitivity of FLS to TRAIL.	Epirubicin	27-37	TNF superfamily member 10	Homo sapiens	145-150
22131069-8	2012	Epirubicin treatment up-regulated death receptor 4 (DR-4) and DR-5 expression and down-regulated FLIP expression, thereby enhancing the activation of procaspase 3, procaspase 8, and procaspase 9.	Epirubicin	0-10	TNF receptor superfamily member 10a	Homo sapiens	34-50
22131069-8	2012	Epirubicin treatment up-regulated death receptor 4 (DR-4) and DR-5 expression and down-regulated FLIP expression, thereby enhancing the activation of procaspase 3, procaspase 8, and procaspase 9.	Epirubicin	0-10	TNF receptor superfamily member 10a	Homo sapiens	52-56
22131069-8	2012	Epirubicin treatment up-regulated death receptor 4 (DR-4) and DR-5 expression and down-regulated FLIP expression, thereby enhancing the activation of procaspase 3, procaspase 8, and procaspase 9.	Epirubicin	0-10	TNF receptor superfamily member 10b	Homo sapiens	62-66
22131069-8	2012	Epirubicin treatment up-regulated death receptor 4 (DR-4) and DR-5 expression and down-regulated FLIP expression, thereby enhancing the activation of procaspase 3, procaspase 8, and procaspase 9.	Epirubicin	0-10	caspase 3	Homo sapiens	150-162
22131069-12	2012	Results of a viral genome copy number assay indicated that epirubicin dramatically augmented the expression of rAAV2/5-TRAIL without altering its tissue distribution.	Epirubicin	59-69	TNF superfamily member 10	Homo sapiens	119-124
22131069-13	2012	CONCLUSION: These results suggest that epirubicin enhances the antiarthritic effect of rAAV2/5-TRAIL and that combination treatment might be an important therapeutic alternative, with practical significance for rheumatoid arthritis.	Epirubicin	39-49	TNF superfamily member 10	Homo sapiens	95-100
22320227-1	2012	The purpose of the present study was to investigate the association of glutathione S-transferase P1 (GSTP1) expression with resistance to neoadjuvant paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (P-FEC) in human breast cancers.	Epirubicin	188-198	glutathione S-transferase pi 1	Homo sapiens	71-99
22326270-8	2012	Additionally, Cdk10 overexpression enhanced the chemosensitivity of HCC cells to cisplatin and epidoxorubicin, two chemotherapeutic agents commonly used in HCC.	Epirubicin	95-109	cyclin dependent kinase 10	Homo sapiens	14-19
22330067-6	2012	Epirubicin increased the activity of caspase-3/7, apoptotic cells, and intracellular lipid peroxide levels, and also induced depolarization of mitochondrial membranes.	Epirubicin	0-10	caspase 3	Homo sapiens	37-46
22330067-8	2012	The epirubicin-induced cell injury and increase of caspase-3/7 activity were also attenuated by p38 mitogen-activated protein kinase (MAPK) inhibitors, SB203580 and PD169316.	Epirubicin	4-14	caspase 3	Homo sapiens	51-60
22330067-8	2012	The epirubicin-induced cell injury and increase of caspase-3/7 activity were also attenuated by p38 mitogen-activated protein kinase (MAPK) inhibitors, SB203580 and PD169316.	Epirubicin	4-14	mitogen-activated protein kinase 14	Homo sapiens	96-99
22330067-9	2012	Moreover, epirubicin significantly enhanced the phosphorylation of p38 MAPK, and these effects were attenuated by GSH and NAC.	Epirubicin	10-20	mitogen-activated protein kinase 14	Homo sapiens	67-70
22330067-11	2012	These results indicate that an activation of p38 MAPK by oxidative stress is involved in the epirubicin-induced endothelial cell injury.	Epirubicin	93-103	mitogen-activated protein kinase 14	Homo sapiens	45-48
21821547-0	2012	Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.	Epirubicin	142-152	cyclin dependent kinase 1	Homo sapiens	56-60
21821547-0	2012	Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.	Epirubicin	142-152	cyclin dependent kinase 2	Homo sapiens	65-69
22205156-6	2012	Epirubicin and pirarubicin significantly increased the TRAIL-R2 expression at both the mRNA and the protein levels.	Epirubicin	0-10	TNF receptor superfamily member 10b	Homo sapiens	55-63
22320884-6	2012	MARVELD1 overexpression could enhance chemosensitivity of HCC cells to epirubicin and 10-hydroxycamptothecin.	Epirubicin	71-81	MARVEL domain containing 1	Homo sapiens	0-8
21706156-0	2012	MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.	Epirubicin	117-127	MDM2 proto-oncogene	Homo sapiens	0-4
21706156-1	2012	The aim of this study was to investigate the association of two genetic polymorphisms, MDM2 SNP309 and TP53 R72P, with incidence of neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide (FEC).	Epirubicin	188-198	MDM2 proto-oncogene	Homo sapiens	87-91
21831476-2	2012	Since 1992 we used a combination of epirubicin and ifosfamide (EI) as a non-cross-resistant regimen in relapsed or refractory SCLC.	Epirubicin	36-46	SCLC1	Homo sapiens	126-130
22244504-6	2012	Furthermore, epirubicin therapy significantly improved recurrence-free rate for the patients with DR4-high (P = .006) or DR5-high (P = .042) tumor.	Epirubicin	13-23	TNF receptor superfamily member 10a	Homo sapiens	98-101
22244504-6	2012	Furthermore, epirubicin therapy significantly improved recurrence-free rate for the patients with DR4-high (P = .006) or DR5-high (P = .042) tumor.	Epirubicin	13-23	TNF receptor superfamily member 10b	Homo sapiens	121-124
22244504-8	2012	In addition, patients with high expression of both DR4 and DR5 might benefit from epirubicin therapy.	Epirubicin	82-92	TNF receptor superfamily member 10a	Homo sapiens	51-54
22244504-8	2012	In addition, patients with high expression of both DR4 and DR5 might benefit from epirubicin therapy.	Epirubicin	82-92	TNF receptor superfamily member 10b	Homo sapiens	59-62
22184372-7	2012	Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone).	Epirubicin	201-211	POF1B actin binding protein	Homo sapiens	19-22
22240029-0	2012	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.	Epirubicin	79-89	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
22240029-0	2012	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.	Epirubicin	79-89	DNA topoisomerase II alpha	Homo sapiens	9-14
22928012-7	2012	Statistical analysis of data demonstrated that ALDH1(high) cells of SW-982 and SW-1353 showed higher resistance to commonly used chemotherapeutic agents like doxorubicin, epirubicin, and cisplatin than ALDH1(low) cells.	Epirubicin	171-181	aldehyde dehydrogenase 1 family member A1	Homo sapiens	47-52
22191802-2	2012	A synthetic covalent bond between the UV-photoactivated epirubicin-(C(3)-amide) intermediate and the e-amine of lysine residues within the amino acid sequence of anti-HER2/neu monoclonal immunoglobulin was subsequently created by exposure to UV light (354 nm) for 15 minutes.	Epirubicin	56-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	167-171
22191802-5	2012	Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin.	Epirubicin	8-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
22191802-5	2012	Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin.	Epirubicin	8-18	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-119
22191802-5	2012	Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin.	Epirubicin	81-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
22191802-5	2012	Between epirubicin-equivalent concentrations of 10(-10) to 10(-6) M the covalent epirubicin-(C(3)-amide)-[anti-HER2/neu] immunochemotherapeutic consistently evoked levels of cytotoxic anti-neoplastic potency that were highly analogous to chemotherapeutic-equivalent concentrations of epirubicin.	Epirubicin	81-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	116-119
22191802-6	2012	Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival).	Epirubicin	37-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-75
22191802-6	2012	Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival).	Epirubicin	37-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
22191802-6	2012	Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival).	Epirubicin	37-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-75
22191802-6	2012	Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival).	Epirubicin	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-75
22191802-6	2012	Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival).	Epirubicin	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71
22191802-6	2012	Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival).	Epirubicin	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-75
22191802-6	2012	Cytotoxic anti-neoplastic potency of epirubicin-(C(3)-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3 challenged with epirubicin-(C(3)-amide)-[anti-HER2/neu] at an epirubicin-equivalent concentration of 10(-6) M was 88.5% (e.g., 11.5% residual survival).	Epirubicin	158-168	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-75
22191802-7	2012	Between final epirubicin-equivalent concentrations of 10(-8) and 10(-7) M there was a marked threshold increase in the mean cytotoxic anti-neoplastic activity for epirubicin-(C(3)-amide)-[anti-HER2/neu] from 9.9% to 66.9% (90.2% to 33.1% residual survival).	Epirubicin	14-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	193-197
22021909-10	2012	In addition, constitutive TSSC3 expression greatly enhanced the sensitivity of human osteosarcoma cells to the chemotherapeutic drugs cisplatin and epirubicin.	Epirubicin	148-158	pleckstrin homology like domain family A member 2	Homo sapiens	26-31
21920352-9	2011	In conclusion, isomeric geometry and restriction of molecular flexibility of N,N-bis(cyclohexanol)amine aryl esters were crucial for their presentation to and inhibition of Pgp as transport substrates, R123 and epirubicin cooperating with them to this inhibition.	Epirubicin	211-221	ATP binding cassette subfamily B member 1	Homo sapiens	173-176
23110092-10	2012	Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs.	Epirubicin	102-112	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	26-32
23110092-10	2012	Furthermore, knockdown of UGT2B7 in WM115 cells sensitized these cells to treatment by adriamycin and epirubicin indicating that UGT2B7 is involved in resistance to these drugs.	Epirubicin	102-112	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	129-135
22529978-0	2012	GRP78 knockdown enhances apoptosis via the down-regulation of oxidative stress and Akt pathway after epirubicin treatment in colon cancer DLD-1 cells.	Epirubicin	101-111	heat shock protein family A (Hsp70) member 5	Homo sapiens	0-5
22529978-0	2012	GRP78 knockdown enhances apoptosis via the down-regulation of oxidative stress and Akt pathway after epirubicin treatment in colon cancer DLD-1 cells.	Epirubicin	101-111	AKT serine/threonine kinase 1	Homo sapiens	83-86
22529978-3	2012	METHODOLOGY/PRINCIPAL FINDINGS: Treatment with epirubicin in GRP78 knockdown DLD-1 cells enhanced apoptosis and was associated with decreased production of intracellular ROS.	Epirubicin	47-57	heat shock protein family A (Hsp70) member 5	Homo sapiens	61-66
22529978-5	2012	Epirubicin-treated GRP78 knockdown cells resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3beta, as well as downstream targets of beta-catenin expression.	Epirubicin	0-10	heat shock protein family A (Hsp70) member 5	Homo sapiens	19-24
22529978-5	2012	Epirubicin-treated GRP78 knockdown cells resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3beta, as well as downstream targets of beta-catenin expression.	Epirubicin	0-10	AKT serine/threonine kinase 1	Homo sapiens	70-73
22529978-5	2012	Epirubicin-treated GRP78 knockdown cells resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3beta, as well as downstream targets of beta-catenin expression.	Epirubicin	0-10	AKT serine/threonine kinase 1	Homo sapiens	114-117
22529978-5	2012	Epirubicin-treated GRP78 knockdown cells resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3beta, as well as downstream targets of beta-catenin expression.	Epirubicin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	122-131
22529978-5	2012	Epirubicin-treated GRP78 knockdown cells resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3beta, as well as downstream targets of beta-catenin expression.	Epirubicin	0-10	catenin beta 1	Homo sapiens	166-178
22529978-6	2012	Knockdown of Nrf2 with small interfering RNA (siRNA) increased apoptosis in epirubicin-treated GRP78 knockdown cells, which suggested that Nrf2 may be a primary defense mechanism in GRP78 knockdown cells.	Epirubicin	76-86	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
22529978-6	2012	Knockdown of Nrf2 with small interfering RNA (siRNA) increased apoptosis in epirubicin-treated GRP78 knockdown cells, which suggested that Nrf2 may be a primary defense mechanism in GRP78 knockdown cells.	Epirubicin	76-86	heat shock protein family A (Hsp70) member 5	Homo sapiens	95-100
22529978-6	2012	Knockdown of Nrf2 with small interfering RNA (siRNA) increased apoptosis in epirubicin-treated GRP78 knockdown cells, which suggested that Nrf2 may be a primary defense mechanism in GRP78 knockdown cells.	Epirubicin	76-86	NFE2 like bZIP transcription factor 2	Homo sapiens	139-143
22529978-6	2012	Knockdown of Nrf2 with small interfering RNA (siRNA) increased apoptosis in epirubicin-treated GRP78 knockdown cells, which suggested that Nrf2 may be a primary defense mechanism in GRP78 knockdown cells.	Epirubicin	76-86	heat shock protein family A (Hsp70) member 5	Homo sapiens	182-187
22529978-7	2012	We also demonstrated that epirubicin-treated GRP78 knockdown cells could decrease survival pathway signaling through the redox activation of protein phosphatase 2A (PP2A), which is a serine/threonine phosphatase that negatively regulates the Akt pathway.	Epirubicin	26-36	heat shock protein family A (Hsp70) member 5	Homo sapiens	45-50
22529978-7	2012	We also demonstrated that epirubicin-treated GRP78 knockdown cells could decrease survival pathway signaling through the redox activation of protein phosphatase 2A (PP2A), which is a serine/threonine phosphatase that negatively regulates the Akt pathway.	Epirubicin	26-36	protein phosphatase 2 phosphatase activator	Homo sapiens	165-169
22529978-7	2012	We also demonstrated that epirubicin-treated GRP78 knockdown cells could decrease survival pathway signaling through the redox activation of protein phosphatase 2A (PP2A), which is a serine/threonine phosphatase that negatively regulates the Akt pathway.	Epirubicin	26-36	AKT serine/threonine kinase 1	Homo sapiens	242-245
22529978-8	2012	CONCLUSIONS: Our results indicate that epirubicin decreased the intracellular ROS in GRP78 knockdown cells, which decreased survival signaling through both the Akt pathway and the activation of PP2A.	Epirubicin	39-49	heat shock protein family A (Hsp70) member 5	Homo sapiens	85-90
22529978-8	2012	CONCLUSIONS: Our results indicate that epirubicin decreased the intracellular ROS in GRP78 knockdown cells, which decreased survival signaling through both the Akt pathway and the activation of PP2A.	Epirubicin	39-49	AKT serine/threonine kinase 1	Homo sapiens	160-163
22529978-8	2012	CONCLUSIONS: Our results indicate that epirubicin decreased the intracellular ROS in GRP78 knockdown cells, which decreased survival signaling through both the Akt pathway and the activation of PP2A.	Epirubicin	39-49	protein phosphatase 2 phosphatase activator	Homo sapiens	194-198
22529978-9	2012	Together, these mechanisms contributed to the enhanced level of epirubicin-induced apoptosis that was observed in the GRP78 knockdown cells.	Epirubicin	64-74	heat shock protein family A (Hsp70) member 5	Homo sapiens	118-123
22340335-0	2011	Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.	Epirubicin	45-55	BCL2 apoptosis regulator	Homo sapiens	14-19
22340335-4	2011	METHODS: PC3 prostate cancer cell line was cultured and treated with epirubicin and Bcl-2 antisense oligonucleotide alone or in combination.	Epirubicin	69-79	chromobox 8	Homo sapiens	9-12
22340335-9	2011	A marked down-regulation of Bcl-2 mRNA and protein was observed after antisense and epirubicin cotreatment.	Epirubicin	84-94	BCL2 apoptosis regulator	Homo sapiens	28-33
22340335-10	2011	A statistically significantly higher fraction of apoptotic cells was detected by flow-cytometric analysis after epirubicin treatment with prior antisense Bcl-2 transfenction, as compared with mono antisense Bcl-2 or epirubicin treatment.	Epirubicin	112-122	BCL2 apoptosis regulator	Homo sapiens	154-159
21080107-8	2011	Basal-like status and nm23-H1 are independent predictive factors of pCR to neoadjuvant docetaxel plus epirubicin combination chemotherapy in patients with TNBCs.	Epirubicin	102-112	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	22-29
21903448-3	2011	We demonstrated that down-regulation of MRP1 in MC3/5FU, a drug-resistant MEC cell line, by RNA interference increased the drug sensitivity of the cells to 5-fluorouracil, doxorubicin, pharmorubicin, bleomycin-A5, cis-platinum and taxol.	Epirubicin	185-198	ATP binding cassette subfamily C member 1	Homo sapiens	40-44
21838758-12	2011	CFDNA released from epirubicin-treated whole blood significantly elevated thrombin generation in a dose-dependent manner, and involved activation of the contact pathway.	Epirubicin	20-30	coagulation factor II, thrombin	Homo sapiens	74-82
20844986-9	2011	Histological grade and ER/PgR status are independent predictive factors of pCR to neoadjuvant docetaxel plus epirubicin combination chemotherapy in locally advanced breast cancer.	Epirubicin	109-119	estrogen receptor 1	Homo sapiens	23-25
20844986-9	2011	Histological grade and ER/PgR status are independent predictive factors of pCR to neoadjuvant docetaxel plus epirubicin combination chemotherapy in locally advanced breast cancer.	Epirubicin	109-119	progesterone receptor	Homo sapiens	26-29
20872186-7	2011	ER/PgR status and nm23-H1 are independent predictive factors of pCR to neoadjuvant docetaxel plus epirubicin combination chemotherapy in patients with LABC.	Epirubicin	98-108	estrogen receptor 1	Homo sapiens	0-2
20872186-7	2011	ER/PgR status and nm23-H1 are independent predictive factors of pCR to neoadjuvant docetaxel plus epirubicin combination chemotherapy in patients with LABC.	Epirubicin	98-108	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	18-25
21769435-11	2011	These preliminary data indicate that therapy-induced HER4 gene up-regulation may be associated with response to NAC with epirubicine, cyclophosphamide and docetaxel.	Epirubicin	121-132	erb-b2 receptor tyrosine kinase 4	Homo sapiens	53-57
21788566-1	2011	PURPOSE: To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.	Epirubicin	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	163-197
22977612-3	2011	We carried out a phase II placebo (PLA)-controlled randomized trial to assess the possible role of TEL in the prevention of cardiac subclinical damage induced by epirubicin (EPI).	Epirubicin	162-172	ETS variant transcription factor 6	Homo sapiens	99-102
21799462-5	2011	RESULTS: The combined analysis indicated that rs2916733 in microcephalin 1 [combined PFisher min=2.27x10, odds ratio (OR)=2.74 with 95% confidence interval (CI)=1.96-3.83; the nonrisk genotype as reference] was significantly associated with epirubicin-induced leukopenia/neutropenia.	Epirubicin	241-251	microcephalin 1	Homo sapiens	59-74
20929434-1	2011	In the present work, a long-circulating epirubicin hydrochloride (EPI)-containing thermosensitive liposome aiming at antitumor therapy, DPPC/MSPC/DSPG/DSPE-mPEG(2000) (EPI-LTSL), was developed and evaluated.	Epirubicin	40-64	decorin	Rattus norvegicus	146-150
21741827-1	2011	BACKGROUND: The aim of this study was to investigate whether c-myc amplification in human breast cancer is associated with response to neoadjuvant chemotherapy comprising paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC).	Epirubicin	199-209	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	61-66
21441950-4	2011	We show here that the anthracyclines doxorubicin, daunorubicin and epirubicin further increase the amounts of mutant p53 mRNA and protein in cancer cells.	Epirubicin	67-77	tumor protein p53	Homo sapiens	117-120
21514041-0	2011	Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.	Epirubicin	114-124	tumor protein p53	Homo sapiens	29-33
21429547-8	2011	CONCLUSION: Our data show that LAPTM4B-35 attenuated epirubicin-induced apoptosis of GBC-SD cells in vitro through a mitochondria-dependent pathway.	Epirubicin	53-63	lysosomal protein transmembrane 4 beta	Homo sapiens	31-38
21906442-5	2011	The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment.	Epirubicin	97-107	caspase 3	Homo sapiens	25-42
21906442-5	2011	The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment.	Epirubicin	97-107	CASP8 and FADD like apoptosis regulator	Homo sapiens	44-50
21906442-5	2011	The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment.	Epirubicin	97-107	BCL2 apoptosis regulator	Homo sapiens	52-57
21906442-5	2011	The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment.	Epirubicin	97-107	tumor protein p53	Homo sapiens	59-62
21906442-5	2011	The expression levels of caspase-3, -8, -9, c-FLIP, Bcl-2, p53, and p21 in the FLS changed after epirubicin treatment.	Epirubicin	97-107	H3 histone pseudogene 16	Homo sapiens	68-71
21906442-6	2011	CONCLUSION: Epirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2.	Epirubicin	12-22	tumor protein p53	Homo sapiens	108-111
21906442-6	2011	CONCLUSION: Epirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2.	Epirubicin	12-22	H3 histone pseudogene 16	Homo sapiens	113-116
21906442-6	2011	CONCLUSION: Epirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2.	Epirubicin	12-22	CASP8 and FADD like apoptosis regulator	Homo sapiens	118-124
21906442-6	2011	CONCLUSION: Epirubicin may coordinate with AD5-10 in inducing FLS apoptosis through affecting the levels of p53, p21, c-FLIP, and Bcl-2.	Epirubicin	12-22	BCL2 apoptosis regulator	Homo sapiens	130-135
21518729-9	2011	In summary, our data show that ATM and p53 coordinately regulate FOXM1 via E2F to modulate epirubicin response and resistance in breast cancer.	Epirubicin	91-101	ATM serine/threonine kinase	Homo sapiens	31-34
21658222-0	2011	Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.	Epirubicin	67-77	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	10-16
21658222-3	2011	The present study aimed to describe the impact of the UGT2B7(His268Tyr) polymorphism on invasive disease-free survival in breast cancer patients after epirubicin treatment.	Epirubicin	151-161	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	54-60
21658222-9	2011	RESULTS: Among the 205 epirubicin-treated patients, carriers of two UGT2B7(268Tyr) alleles had a mean invasive disease-free survival of 8.6 (95% confidence interval (CI) 7.9 to 9.3) years as compared to 7.5 (95% CI 6.9 to 8.0) years in carriers of at least one UGT2B7(268His) allele (adjusted hazard ratio (HR) = 2.64 (95% CI 1.22 to 5.71); P = 0.014).	Epirubicin	23-33	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	68-74
21658222-9	2011	RESULTS: Among the 205 epirubicin-treated patients, carriers of two UGT2B7(268Tyr) alleles had a mean invasive disease-free survival of 8.6 (95% confidence interval (CI) 7.9 to 9.3) years as compared to 7.5 (95% CI 6.9 to 8.0) years in carriers of at least one UGT2B7(268His) allele (adjusted hazard ratio (HR) = 2.64 (95% CI 1.22 to 5.71); P = 0.014).	Epirubicin	23-33	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	261-267
21658222-10	2011	In addition, the impact of the UGT2B7(His268Tyr) polymorphism became even more pronounced in patients subsequently treated with tamoxifen (adjusted HR = 5.22 (95% CI 1.67 to 26.04); P = 0.015) whereas no such difference in invasive disease-free survival was observed in patients not receiving epirubicin.	Epirubicin	293-303	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	31-37
21658222-11	2011	CONCLUSIONS: Breast cancer patients carrying the UGT2B7(268Tyr/Tyr) genotype may benefit most from adjuvant epirubicin-based chemotherapy.	Epirubicin	108-118	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	49-55
21684102-4	2011	Our data demonstrated that overexpression of TIMP-1 could significantly decrease the sensitivity of MDA-435 breast cancer cells to epirubicin and paclitaxel.	Epirubicin	131-141	TIMP metallopeptidase inhibitor 1	Homo sapiens	45-51
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Epirubicin	61-71	TIMP metallopeptidase inhibitor 1	Homo sapiens	17-23
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Epirubicin	61-71	AKT serine/threonine kinase 1	Homo sapiens	112-115
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Epirubicin	61-71	AKT serine/threonine kinase 1	Homo sapiens	226-229
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Epirubicin	61-71	TIMP metallopeptidase inhibitor 1	Homo sapiens	278-284
21518729-0	2011	ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.	Epirubicin	63-73	ATM serine/threonine kinase	Homo sapiens	0-3
21518729-0	2011	ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.	Epirubicin	63-73	tumor protein p53	Homo sapiens	8-11
21518729-0	2011	ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.	Epirubicin	63-73	forkhead box M1	Homo sapiens	21-26
21518729-1	2011	In this report, we investigated the role and regulation of forkhead box M1 (FOXM1) in breast cancer and epirubicin resistance.	Epirubicin	104-114	forkhead box M1	Homo sapiens	59-74
21518729-2	2011	We generated epirubicin-resistant MCF-7 breast carcinoma (MCF-7-EPI(R)) cells and found FOXM1 protein levels to be higher in MCF-7-EPI(R) than in MCF-7 cells and that FOXM1 expression is downregulated by epirubicin in MCF-7 but not in MCF-7-EPI(R) cells.	Epirubicin	13-23	forkhead box M1	Homo sapiens	88-93
21518729-2	2011	We generated epirubicin-resistant MCF-7 breast carcinoma (MCF-7-EPI(R)) cells and found FOXM1 protein levels to be higher in MCF-7-EPI(R) than in MCF-7 cells and that FOXM1 expression is downregulated by epirubicin in MCF-7 but not in MCF-7-EPI(R) cells.	Epirubicin	13-23	forkhead box M1	Homo sapiens	167-172
21518729-2	2011	We generated epirubicin-resistant MCF-7 breast carcinoma (MCF-7-EPI(R)) cells and found FOXM1 protein levels to be higher in MCF-7-EPI(R) than in MCF-7 cells and that FOXM1 expression is downregulated by epirubicin in MCF-7 but not in MCF-7-EPI(R) cells.	Epirubicin	204-214	forkhead box M1	Homo sapiens	88-93
21518729-3	2011	We also established that there is a loss of p53 function in MCF-7-EPI(R) cells and that epirubicin represses FOXM1 expression at transcription and gene promoter levels through activation of p53 and repression of E2F activity in MCF-7 cells.	Epirubicin	88-98	forkhead box M1	Homo sapiens	109-114
21518729-3	2011	We also established that there is a loss of p53 function in MCF-7-EPI(R) cells and that epirubicin represses FOXM1 expression at transcription and gene promoter levels through activation of p53 and repression of E2F activity in MCF-7 cells.	Epirubicin	88-98	tumor protein p53	Homo sapiens	190-193
21518729-4	2011	Using p53(-/-) mouse embryo fibroblasts, we showed that p53 is important for epirubicin sensitivity.	Epirubicin	77-87	transformation related protein 53, pseudogene	Mus musculus	6-9
21518729-4	2011	Using p53(-/-) mouse embryo fibroblasts, we showed that p53 is important for epirubicin sensitivity.	Epirubicin	77-87	transformation related protein 53, pseudogene	Mus musculus	56-59
21518729-5	2011	Moreover, transient promoter transfection assays showed that epirubicin and its cellular effectors p53 and E2F1 modulate FOXM1 transcription through an E2F-binding site located within the proximal promoter region.	Epirubicin	61-71	tumor protein p53	Homo sapiens	99-102
21518729-5	2011	Moreover, transient promoter transfection assays showed that epirubicin and its cellular effectors p53 and E2F1 modulate FOXM1 transcription through an E2F-binding site located within the proximal promoter region.	Epirubicin	61-71	E2F transcription factor 1	Homo sapiens	107-111
21518729-5	2011	Moreover, transient promoter transfection assays showed that epirubicin and its cellular effectors p53 and E2F1 modulate FOXM1 transcription through an E2F-binding site located within the proximal promoter region.	Epirubicin	61-71	forkhead box M1	Homo sapiens	121-126
21518729-6	2011	Chromatin immunoprecipitation analysis also revealed that epirubicin treatment increases pRB (retinoblastoma protein) and decreases E2F1 recruitment to the FOXM1 promoter region containing the E2F site.	Epirubicin	58-68	RB transcriptional corepressor 1	Homo sapiens	89-92
21518729-9	2011	In summary, our data show that ATM and p53 coordinately regulate FOXM1 via E2F to modulate epirubicin response and resistance in breast cancer.	Epirubicin	91-101	tumor protein p53	Homo sapiens	39-42
21518729-6	2011	Chromatin immunoprecipitation analysis also revealed that epirubicin treatment increases pRB (retinoblastoma protein) and decreases E2F1 recruitment to the FOXM1 promoter region containing the E2F site.	Epirubicin	58-68	E2F transcription factor 1	Homo sapiens	132-136
21518729-6	2011	Chromatin immunoprecipitation analysis also revealed that epirubicin treatment increases pRB (retinoblastoma protein) and decreases E2F1 recruitment to the FOXM1 promoter region containing the E2F site.	Epirubicin	58-68	forkhead box M1	Homo sapiens	156-161
21518729-7	2011	We also found ataxia-telangiectasia mutated (ATM) protein and mRNA to be overexpressed in the resistant MCF-7-EPI(R) cells compared with MCF-7 cells and that epirubicin could activate ATM to promote E2F activity and FOXM1 expression.	Epirubicin	158-168	ATM serine/threonine kinase	Homo sapiens	14-43
21518729-7	2011	We also found ataxia-telangiectasia mutated (ATM) protein and mRNA to be overexpressed in the resistant MCF-7-EPI(R) cells compared with MCF-7 cells and that epirubicin could activate ATM to promote E2F activity and FOXM1 expression.	Epirubicin	158-168	ATM serine/threonine kinase	Homo sapiens	45-48
21518729-7	2011	We also found ataxia-telangiectasia mutated (ATM) protein and mRNA to be overexpressed in the resistant MCF-7-EPI(R) cells compared with MCF-7 cells and that epirubicin could activate ATM to promote E2F activity and FOXM1 expression.	Epirubicin	158-168	ATM serine/threonine kinase	Homo sapiens	184-187
21518729-7	2011	We also found ataxia-telangiectasia mutated (ATM) protein and mRNA to be overexpressed in the resistant MCF-7-EPI(R) cells compared with MCF-7 cells and that epirubicin could activate ATM to promote E2F activity and FOXM1 expression.	Epirubicin	158-168	forkhead box M1	Homo sapiens	216-221
21518729-8	2011	Furthermore, inhibition of ATM in U2OS cells with caffeine or depletion of ATM in MCF-7-EPI(R) with short interfering RNAs can resensitize these resistant cells to epirubicin, resulting in downregulation of E2F1 and FOXM1 expression and cell death.	Epirubicin	164-174	ATM serine/threonine kinase	Homo sapiens	27-30
21518729-8	2011	Furthermore, inhibition of ATM in U2OS cells with caffeine or depletion of ATM in MCF-7-EPI(R) with short interfering RNAs can resensitize these resistant cells to epirubicin, resulting in downregulation of E2F1 and FOXM1 expression and cell death.	Epirubicin	164-174	ATM serine/threonine kinase	Homo sapiens	75-78
21518729-9	2011	In summary, our data show that ATM and p53 coordinately regulate FOXM1 via E2F to modulate epirubicin response and resistance in breast cancer.	Epirubicin	91-101	forkhead box M1	Homo sapiens	65-70
21354366-5	2011	Furthermore, the IC(50) of DOX and epirubicin (EPI) in HepG2 cells, both of which are known to be exported by MDR1, were higher in spheroid compared with monolayer cells, while IC(50) of 5-fluorouracil (5-FU), which is not exported by MDR1 protein, was almost the same in both types of culture.	Epirubicin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	110-114
21354366-5	2011	Furthermore, the IC(50) of DOX and epirubicin (EPI) in HepG2 cells, both of which are known to be exported by MDR1, were higher in spheroid compared with monolayer cells, while IC(50) of 5-fluorouracil (5-FU), which is not exported by MDR1 protein, was almost the same in both types of culture.	Epirubicin	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	235-239
21468584-0	2011	Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts.	Epirubicin	0-10	TNF superfamily member 10	Homo sapiens	20-25
21789023-0	2011	Low-dose epirubicin inhibits ezrin-mediated metastatic behavior of breast cancer cells.	Epirubicin	9-19	ezrin	Homo sapiens	29-34
21789023-6	2011	Low-dose epirubicin inhibited the migration of breast cancer cells in a concentration-dependent manner without promoting cytotoxicity in vitro and decreased the expression of ezrin in a concentration-dependent manner.	Epirubicin	9-19	ezrin	Homo sapiens	175-180
21556366-0	2011	Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.	Epirubicin	125-135	tumor protein p53	Homo sapiens	36-40
21556366-0	2011	Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.	Epirubicin	125-135	MDM2 proto-oncogene	Homo sapiens	55-59
21556366-8	2011	PRINCIPAL FINDINGS: While TP53 and CHEK2 mutations predicted resistance to epirubicin, MDM2 status did not.	Epirubicin	75-85	tumor protein p53	Homo sapiens	26-30
21556366-8	2011	PRINCIPAL FINDINGS: While TP53 and CHEK2 mutations predicted resistance to epirubicin, MDM2 status did not.	Epirubicin	75-85	checkpoint kinase 2	Homo sapiens	35-40
21556366-10	2011	Remarkably, TP53 mutations (p = 0.007) but also MDM2 309TG/GG genotype status (p = 0.012) were associated with a poor disease-specific survival among patients having paclitaxel but not patients having epirubicin first-line.	Epirubicin	201-211	tumor protein p53	Homo sapiens	12-16
21556366-12	2011	CONCLUSION: TP53 and CHEK2 mutations were associated with lack of response to epirubicin monotherapy.	Epirubicin	78-88	tumor protein p53	Homo sapiens	12-16
21556366-12	2011	CONCLUSION: TP53 and CHEK2 mutations were associated with lack of response to epirubicin monotherapy.	Epirubicin	78-88	checkpoint kinase 2	Homo sapiens	21-26
20798686-6	2011	Furthermore, all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy showed miR-448 suppression, an increased SATB1, Twist1 expression and acquisition of mesenchymal phenotypes.	Epirubicin	62-72	microRNA 448	Homo sapiens	142-149
21468584-3	2011	Treatment with epirubicin (1.18 microg/ml, IC50 dose for 24 h) and TRAIL (100 ng/ml for 24 h) led to a marked increase in the inhibition rate of cell proliferation and apoptosis compared to treatment with epirubicin or TRAIL alone (P&lt;0.05).	Epirubicin	15-25	TNF superfamily member 10	Homo sapiens	219-224
21468584-3	2011	Treatment with epirubicin (1.18 microg/ml, IC50 dose for 24 h) and TRAIL (100 ng/ml for 24 h) led to a marked increase in the inhibition rate of cell proliferation and apoptosis compared to treatment with epirubicin or TRAIL alone (P&lt;0.05).	Epirubicin	205-215	TNF superfamily member 10	Homo sapiens	67-72
21468584-4	2011	Moreover, even more notable cleavage of caspase-3 and 8 was detected with the combination of epirubicin and TRAIL.	Epirubicin	93-103	caspase 3	Homo sapiens	40-49
21468584-6	2011	Epirubicin significantly promoted lipid raft DR4 and DR5 aggregation, as well as the localization of DR4 and DR5 in the lipid rafts.	Epirubicin	0-10	TNF receptor superfamily member 10a	Homo sapiens	45-48
21468584-6	2011	Epirubicin significantly promoted lipid raft DR4 and DR5 aggregation, as well as the localization of DR4 and DR5 in the lipid rafts.	Epirubicin	0-10	TNF receptor superfamily member 10b	Homo sapiens	53-56
21468584-6	2011	Epirubicin significantly promoted lipid raft DR4 and DR5 aggregation, as well as the localization of DR4 and DR5 in the lipid rafts.	Epirubicin	0-10	TNF receptor superfamily member 10b	Homo sapiens	109-112
21468584-8	2011	Pretreatment with 50 microg/ml nystatin, a cholesterol-sequestering agent, partially prevented epirubicin-induced lipid raft aggregation and DR4 and DR5 clustering.	Epirubicin	95-105	TNF receptor superfamily member 10a	Homo sapiens	141-144
21468584-8	2011	Pretreatment with 50 microg/ml nystatin, a cholesterol-sequestering agent, partially prevented epirubicin-induced lipid raft aggregation and DR4 and DR5 clustering.	Epirubicin	95-105	TNF receptor superfamily member 10b	Homo sapiens	149-152
21468584-10	2011	Our data demonstrate that epirubicin enhanced TRAIL-induced apoptosis in gastric cancer MGC803 cells, at least partially, through death receptor redistribution in the lipid rafts.	Epirubicin	26-36	TNF superfamily member 10	Homo sapiens	46-51
21487460-0	2011	Transient effectiveness of an oral 5-Fluorouracil derivative, s-1, for epirubicin, cyclophosphamide and Paclitaxel refractory skin metastases from possible occult breast cancer in a male.	Epirubicin	71-81	proteasome 26S subunit, non-ATPase 1	Homo sapiens	62-65
21487460-2	2011	We describe the case of a 76-year-old male showing transient effectiveness with an oral 5-fluorouracil derivative, S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), for epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer.	Epirubicin	188-198	proteasome 26S subunit, non-ATPase 1	Homo sapiens	115-118
21291529-0	2011	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.	Epirubicin	213-223	hypoxia inducible factor 1 subunit alpha	Homo sapiens	62-93
21291529-0	2011	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1alpha and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.	Epirubicin	213-223	vascular endothelial growth factor A	Homo sapiens	98-132
21291529-7	2011	PHD1, PHD2 and PHD3 expression was significantly increased after epirubicin therapy (all P &lt; 0.000) with no significant difference in PHD changes between the treatment arms.	Epirubicin	65-75	egl-9 family hypoxia inducible factor 2	Homo sapiens	0-4
21291529-7	2011	PHD1, PHD2 and PHD3 expression was significantly increased after epirubicin therapy (all P &lt; 0.000) with no significant difference in PHD changes between the treatment arms.	Epirubicin	65-75	egl-9 family hypoxia inducible factor 1	Homo sapiens	6-10
21291529-7	2011	PHD1, PHD2 and PHD3 expression was significantly increased after epirubicin therapy (all P &lt; 0.000) with no significant difference in PHD changes between the treatment arms.	Epirubicin	65-75	egl-9 family hypoxia inducible factor 3	Homo sapiens	15-19
21253829-9	2011	Interestingly, among seven tumors expressing lack of response to epirubicin, two samples harbored alterations in RB1, contrasting none out of 16 tumors with stable disease or an objective response (P = 0.08).	Epirubicin	65-75	RB transcriptional corepressor 1	Homo sapiens	113-116
26229727-0	2011	Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.	Epirubicin	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-25
26229727-1	2011	PURPOSE: Discover the anti-neoplastic efficacy of epirubicin-(C13-imino)-[anti-HER2/neu] against chemotherapeutic-resistant SKBr-3 mammary carcinoma and delineate the capacity of selenium to enhance it"s cytotoxic anti-neoplastic potency.	Epirubicin	50-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-87
26229727-4	2011	The sulfhydryl-reactive epirubicin-(C13-imino)-EMCH intermediate was then combined with thiolated anti-HER2/neu monoclonal immunoglobulin.	Epirubicin	24-34	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
26229727-6	2011	Anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] between the epirubicin-equivalent concentrations of 10-12 M and 10-7 M was determined by vitality staining analysis with and without the presence of selenium (5 muM).	Epirubicin	27-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
26229727-7	2011	RESULTS: Epiribucin-(C13-imino)-[anti-HER2/neu] between epirubicin-equivalent concentrations of 10-8 M to 10-7 M consistently evoked higher anti-neoplastic potency than "free" non-conjugated epirubicin which corresponded with previous investigations utilizing epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-[anti-EGFR].	Epirubicin	56-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
26229727-7	2011	RESULTS: Epiribucin-(C13-imino)-[anti-HER2/neu] between epirubicin-equivalent concentrations of 10-8 M to 10-7 M consistently evoked higher anti-neoplastic potency than "free" non-conjugated epirubicin which corresponded with previous investigations utilizing epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-[anti-EGFR].	Epirubicin	191-201	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
26229727-7	2011	RESULTS: Epiribucin-(C13-imino)-[anti-HER2/neu] between epirubicin-equivalent concentrations of 10-8 M to 10-7 M consistently evoked higher anti-neoplastic potency than "free" non-conjugated epirubicin which corresponded with previous investigations utilizing epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-[anti-EGFR].	Epirubicin	191-201	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
26229727-8	2011	Selenium at 5 mM consistently enhanced the cytotoxic anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] at epirubicin equivalent concentrations (10-12 to 10-7 M).	Epirubicin	80-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113
26229727-8	2011	Selenium at 5 mM consistently enhanced the cytotoxic anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] at epirubicin equivalent concentrations (10-12 to 10-7 M).	Epirubicin	80-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-117
20798686-6	2011	Furthermore, all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy showed miR-448 suppression, an increased SATB1, Twist1 expression and acquisition of mesenchymal phenotypes.	Epirubicin	62-72	SATB homeobox 1	Homo sapiens	176-181
20798686-6	2011	Furthermore, all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy showed miR-448 suppression, an increased SATB1, Twist1 expression and acquisition of mesenchymal phenotypes.	Epirubicin	62-72	twist family bHLH transcription factor 1	Homo sapiens	183-189
20798686-6	2011	Furthermore, all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy showed miR-448 suppression, an increased SATB1, Twist1 expression and acquisition of mesenchymal phenotypes.	Epirubicin	91-101	microRNA 448	Homo sapiens	142-149
20798686-6	2011	Furthermore, all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy showed miR-448 suppression, an increased SATB1, Twist1 expression and acquisition of mesenchymal phenotypes.	Epirubicin	91-101	SATB homeobox 1	Homo sapiens	176-181
20798686-6	2011	Furthermore, all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy showed miR-448 suppression, an increased SATB1, Twist1 expression and acquisition of mesenchymal phenotypes.	Epirubicin	91-101	twist family bHLH transcription factor 1	Homo sapiens	183-189
21362365-2	2011	The metabolism of epirubicin (EPI) and cyclophosphamide (CTX) is mainly mediated by cytochrome P450s (CYPs) and glutathione S-transferases (GSTs).	Epirubicin	18-28	glutathione S-transferase pi 1	Homo sapiens	140-144
21362365-2	2011	The metabolism of epirubicin (EPI) and cyclophosphamide (CTX) is mainly mediated by cytochrome P450s (CYPs) and glutathione S-transferases (GSTs).	Epirubicin	30-33	glutathione S-transferase pi 1	Homo sapiens	140-144
20125118-4	2010	Increased ABCB1 transcript expression coincident with acquisition of resistance to epirubicin or paclitaxel was temporally associated with hypomethylation of the ABCB1 downstream promoter in the absence of gene amplifications or changes in mRNA stability.	Epirubicin	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	10-15
21716682-5	2011	When Tan IIA was used with epirubicin, an increase of BT-20 cells apoptosis was accompanied by the decreasing phosphorylation of Akt.	Epirubicin	27-37	AKT serine/threonine kinase 1	Homo sapiens	129-132
21716682-8	2011	The antagonistic effect of STS on epirubicin-induced cytotoxicity in BT-20 cells occurred concomitantly with the reduced epirubicin uptake and the increased phosphorylation of Akt.	Epirubicin	34-44	AKT serine/threonine kinase 1	Homo sapiens	176-179
21716682-9	2011	STS decreased the uptake of epirubicin in BT-20 cells and blocked epirubicin-induced apoptosis through activation of Akt.	Epirubicin	28-38	AKT serine/threonine kinase 1	Homo sapiens	117-120
21716682-9	2011	STS decreased the uptake of epirubicin in BT-20 cells and blocked epirubicin-induced apoptosis through activation of Akt.	Epirubicin	66-76	AKT serine/threonine kinase 1	Homo sapiens	117-120
22163164-9	2011	Caspase-9 and caspase-3 activity was increased after applying antiresistant epirubicin mitosomes.	Epirubicin	76-86	caspase 9	Homo sapiens	0-9
22163164-9	2011	Caspase-9 and caspase-3 activity was increased after applying antiresistant epirubicin mitosomes.	Epirubicin	76-86	caspase 3	Homo sapiens	14-23
22110895-7	2011	The observation that particular regions of the PML and RARA loci are susceptible to topoII-mediated DNA damage induced by epirubicin and mitoxantrone may underlie the propensity of these agents to cause APL.	Epirubicin	122-132	PML nuclear body scaffold	Homo sapiens	47-50
22110895-7	2011	The observation that particular regions of the PML and RARA loci are susceptible to topoII-mediated DNA damage induced by epirubicin and mitoxantrone may underlie the propensity of these agents to cause APL.	Epirubicin	122-132	retinoic acid receptor alpha	Homo sapiens	55-59
21224703-6	2010	Chemotherapy with EC 6 course consisted of a weekly PTX 4 course (epirubicin, cyclophosphamide-weekly paclitaxel) was performed.	Epirubicin	66-76	pentraxin 4	Homo sapiens	52-57
20967268-3	2010	Increased MX2 cell death was observed upon co-treatment with genipin and different doses of menadione, doxorubicin, and epirubicin.	Epirubicin	120-130	MX dynamin like GTPase 2	Homo sapiens	10-13
21180996-1	2010	OBJECTIVE: To evaluate the immunohistochemical expression of cox-2 before primary chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and its association with initial tumor size, lymph node status, hormone receptors, expression of HER2 and the clinical and pathological response in patients with breast cancer.	Epirubicin	116-126	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	61-66
20680681-4	2010	We investigated to compare the effects of the addition of tamoxifen to epirubicin versus epirubicin alone on VEGF and VEGFR2 expression in breast cancer patients.	Epirubicin	71-81	vascular endothelial growth factor A	Homo sapiens	109-113
20680681-4	2010	We investigated to compare the effects of the addition of tamoxifen to epirubicin versus epirubicin alone on VEGF and VEGFR2 expression in breast cancer patients.	Epirubicin	71-81	kinase insert domain receptor	Homo sapiens	118-124
20680681-5	2010	The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment.	Epirubicin	262-272	vascular endothelial growth factor A	Homo sapiens	18-22
20680681-5	2010	The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment.	Epirubicin	280-290	vascular endothelial growth factor A	Homo sapiens	18-22
20680681-6	2010	Epirubicin alone failed to induce changes in VEGF expression (P = 0.54), while the addition of tamoxifen to epirubicin resulted in a significant reduction in VEGF expression (P &lt; 0.001).	Epirubicin	108-118	vascular endothelial growth factor A	Homo sapiens	158-162
20680681-7	2010	As a consequence, baseline VEGF had a negative prognostic role in patients who received epirubicin alone but not in patients receiving epirubicin plus tamoxifen (interaction test P &lt; 0.05).	Epirubicin	88-98	vascular endothelial growth factor A	Homo sapiens	27-31
20680681-8	2010	VEGFR2 expression increased at residual tumor histology in both treatment arms, with a lesser extent in patients receiving tamoxifen plus epirubicin.	Epirubicin	138-148	kinase insert domain receptor	Homo sapiens	0-6
20207475-3	2010	The MTT assay indicated that over-expression of Beclin1 sensitized CaSki cells to chemotherapeutic drugs (cisplatin, paclitaxel, 5-fluorouracil, and epirubicin) and induced greater degrees of cytotoxicity than vector-only controls.	Epirubicin	149-159	beclin 1	Homo sapiens	48-55
20600880-2	2010	In the present study, we developed a functionalized liposomal nanoconstruct, epirubicin liposomes modified with tamoxifen (TAM) and transferrin (TF), for transporting drug across the BBB and afterwards targeting the brain glioma.	Epirubicin	77-87	transferrin	Rattus norvegicus	132-143
20600880-2	2010	In the present study, we developed a functionalized liposomal nanoconstruct, epirubicin liposomes modified with tamoxifen (TAM) and transferrin (TF), for transporting drug across the BBB and afterwards targeting the brain glioma.	Epirubicin	77-87	transferrin	Rattus norvegicus	145-147
20600880-4	2010	RESULTS: When compared with controls, epirubicin liposomes modified with TAM and TF showed the strongest inhibitory effect to C6 glioma cells or glioma spheroids in vitro, significant transport ability across the BBB model in vitro, an evident effect of targeting the brain tumor cells in vitro, and an extended median survival time in the brain glioma-bearing rats.	Epirubicin	38-48	transferrin	Rattus norvegicus	81-83
20600880-5	2010	CONCLUSION: Epirubicin liposomes modified with TAM and TF significantly improve the therapeutic efficacy of brain glioma in vitro and in animals, hence providing a new strategy for brain tumor chemotherapy.	Epirubicin	12-22	transferrin	Rattus norvegicus	55-57
20687516-10	2010	The results demonstrate up to 4-fold increases in cell death in PARG null-TS cells after treatment with epirubicin or sub-IC(50) doses of cisplatin and cyclophosphamide.	Epirubicin	104-114	poly(ADP-ribose) glycohydrolase	Homo sapiens	64-68
19499189-6	2010	Combination studies with P-gp substrate chemotherapeutic agents, demonstrated that all three TKIs have significant potential to augment cytotoxic activity against P-gp-positive malignancies, however, interestingly, these agents also potentiated the toxicity of epirubicin in non-P-gp resistant parental cells.	Epirubicin	261-271	phosphoglycolate phosphatase	Homo sapiens	163-167
19499189-6	2010	Combination studies with P-gp substrate chemotherapeutic agents, demonstrated that all three TKIs have significant potential to augment cytotoxic activity against P-gp-positive malignancies, however, interestingly, these agents also potentiated the toxicity of epirubicin in non-P-gp resistant parental cells.	Epirubicin	261-271	phosphoglycolate phosphatase	Homo sapiens	163-167
20332474-7	2010	This report suggests that combination therapy with epirubicin and cyclophosphamide followed by trastuzumab and paclitaxel was useful for HER2-positive IBC.	Epirubicin	51-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
19657712-5	2010	The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society has demonstrated that TOP2A-positive and BRCA1-negative subsets evaluated by immunohistochemical staining show a significantly higher pathological complete response when treated with preoperative epirubicin-containing regimens.	Epirubicin	287-297	DNA topoisomerase II alpha	Homo sapiens	113-118
19657712-5	2010	The Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society has demonstrated that TOP2A-positive and BRCA1-negative subsets evaluated by immunohistochemical staining show a significantly higher pathological complete response when treated with preoperative epirubicin-containing regimens.	Epirubicin	287-297	BRCA1 DNA repair associated	Homo sapiens	132-137
20217860-5	2010	The anthracyclines, Doxorubicin (DOX) and epirubicin (EPI) were detected by LIF using a Nd:YAG laser (532 nm) or an argon ion laser (488 nm) for excitation.	Epirubicin	42-52	LIF interleukin 6 family cytokine	Homo sapiens	76-79
19526361-0	2010	Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.	Epirubicin	40-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
19884644-1	2010	Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin.	Epirubicin	214-224	PML nuclear body scaffold	Homo sapiens	90-93
19884644-1	2010	Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin.	Epirubicin	214-224	retinoic acid receptor alpha	Homo sapiens	98-102
19884644-5	2010	Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin.	Epirubicin	61-71	PML nuclear body scaffold	Homo sapiens	40-43
19884644-5	2010	Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin.	Epirubicin	61-71	retinoic acid receptor alpha	Homo sapiens	48-52
19884644-5	2010	Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin.	Epirubicin	164-174	PML nuclear body scaffold	Homo sapiens	40-43
19884644-5	2010	Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin.	Epirubicin	164-174	retinoic acid receptor alpha	Homo sapiens	48-52
20422883-5	2010	RESULTS: 50 microM progesterone increased both the cytotoxic and apoptotic effects of 0.1 microg/ml epirubicin on HepG2 cells at 48 hr culture due to 50 microM progesterone accumulated cells in S phase of the cell cycle and subsequently reduced cyclin D1 expression.	Epirubicin	100-110	cyclin D1	Homo sapiens	245-254
19841470-0	2010	Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.	Epirubicin	128-138	erb-b2 receptor tyrosine kinase 2	Rattus norvegicus	27-32
20437856-1	2010	BACKGROUND: In 1995, we designed and carried out a pilot study on the combination of cisplatin + high dose epirubicin + vinorelbine with granulocyte-colony-stimulating factor support for the induction treatment of unresectable stage IIIAN2 and wet IIIB non-small-cell lung cancer.	Epirubicin	107-117	colony stimulating factor 3	Homo sapiens	137-174
19949674-2	2009	Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was employed to retrieve chemoresponse to 5-fluorouracil (5-FU), doxetaxel, doxorubicin, epirubicin, and paclitaxel in 49 patients.	Epirubicin	156-166	myotubularin related protein 11	Homo sapiens	62-65
20437857-14	2010	CONCLUSIONS: A dose-dense TCF regimen in metastatic gastric cancer is feasible, with activity comparable to previous results achieved with epirubicin-based chemotherapy and TCF q3wk in terms of overall survival and time to progression, and deserves to be further tested in randomized phase III studies.	Epirubicin	139-149	hepatocyte nuclear factor 4 alpha	Homo sapiens	26-29
19949674-4	2009	Estrogen receptor (ER)-negative tumors respond well to doxorubicin (P=0.038), and progesterone receptor (PR)-negative tumors to 5-FU (P=0.039), doxetaxel (P=0.038), doxorubicin (P=0.000), epirubicin (P=0.010), and paclitaxel (P=0.003).	Epirubicin	188-198	estrogen receptor 1	Homo sapiens	0-17
19638344-0	2009	Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library.	Epirubicin	29-39	growth arrest specific 1	Homo sapiens	18-22
19826051-7	2009	Of interest is the finding that epirubicin clearly downregulated ADAM10 expression and MICA shedding in HCC cells; its suppressive effect on MICA shedding was abolished in ADAM10-depleted cells.	Epirubicin	32-42	ADAM metallopeptidase domain 10	Homo sapiens	65-71
19826051-7	2009	Of interest is the finding that epirubicin clearly downregulated ADAM10 expression and MICA shedding in HCC cells; its suppressive effect on MICA shedding was abolished in ADAM10-depleted cells.	Epirubicin	32-42	MHC class I polypeptide-related sequence A	Homo sapiens	87-91
19826051-7	2009	Of interest is the finding that epirubicin clearly downregulated ADAM10 expression and MICA shedding in HCC cells; its suppressive effect on MICA shedding was abolished in ADAM10-depleted cells.	Epirubicin	32-42	MHC class I polypeptide-related sequence A	Homo sapiens	141-145
19826051-7	2009	Of interest is the finding that epirubicin clearly downregulated ADAM10 expression and MICA shedding in HCC cells; its suppressive effect on MICA shedding was abolished in ADAM10-depleted cells.	Epirubicin	32-42	ADAM metallopeptidase domain 10	Homo sapiens	172-178
19826051-8	2009	Epirubicin treatment also enhanced the NKG2D-mediated NK sensitivity of HCC cells.	Epirubicin	0-10	killer cell lectin like receptor K1	Homo sapiens	39-44
19826051-10	2009	Soluble MICA and CD44 levels were downregulated with a significant correlation in patients treated by transarterial chemoembolization using epirubicin.	Epirubicin	140-150	MHC class I polypeptide-related sequence A	Homo sapiens	8-12
19826051-10	2009	Soluble MICA and CD44 levels were downregulated with a significant correlation in patients treated by transarterial chemoembolization using epirubicin.	Epirubicin	140-150	CD44 molecule (Indian blood group)	Homo sapiens	17-21
19783235-0	2009	Validation of an LC-MS/MS method for the determination of epirubicin in human serum of patients undergoing drug eluting microsphere-transarterial chemoembolization (DEM-TACE).	Epirubicin	58-68	ADAM metallopeptidase domain 17	Homo sapiens	169-173
19638344-9	2009	P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) but not MRP-1 were up-regulated, and targeted knockdown of P-gp and BCRP could partially reverse GAS1 suppression-induced epirubicin resistance.	Epirubicin	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
19638344-9	2009	P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) but not MRP-1 were up-regulated, and targeted knockdown of P-gp and BCRP could partially reverse GAS1 suppression-induced epirubicin resistance.	Epirubicin	188-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	134-138
19638344-9	2009	P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) but not MRP-1 were up-regulated, and targeted knockdown of P-gp and BCRP could partially reverse GAS1 suppression-induced epirubicin resistance.	Epirubicin	188-198	growth arrest specific 1	Homo sapiens	163-167
19638344-10	2009	Verapamil, a P-gp inhibitor, could reverse P-gp substrate (epirubicin) but not non-P-gp substrate (5-fluorouracil and cisplatin) resistance in GAS1-suppressed gastric cancer cells.	Epirubicin	59-69	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
19638344-10	2009	Verapamil, a P-gp inhibitor, could reverse P-gp substrate (epirubicin) but not non-P-gp substrate (5-fluorouracil and cisplatin) resistance in GAS1-suppressed gastric cancer cells.	Epirubicin	59-69	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
19728910-12	2009	High expression of ABCG2 protein was correlated to the resistance of colorectal cancer cells to epirubicin (P&lt;0.05).	Epirubicin	96-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	19-24
19638344-6	2009	GAS1 suppression resulted in significant epirubicin resistance and cross-resistance to 5-fluorouracil and cisplatin in various gastric cancer cell lines.	Epirubicin	41-51	growth arrest specific 1	Homo sapiens	0-4
19638344-9	2009	P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) but not MRP-1 were up-regulated, and targeted knockdown of P-gp and BCRP could partially reverse GAS1 suppression-induced epirubicin resistance.	Epirubicin	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
19638344-9	2009	P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) but not MRP-1 were up-regulated, and targeted knockdown of P-gp and BCRP could partially reverse GAS1 suppression-induced epirubicin resistance.	Epirubicin	188-198	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
19638344-9	2009	P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) but not MRP-1 were up-regulated, and targeted knockdown of P-gp and BCRP could partially reverse GAS1 suppression-induced epirubicin resistance.	Epirubicin	188-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	26-30
19638344-9	2009	P-glycoprotein (P-gp) and BCRP (breast cancer resistance protein) but not MRP-1 were up-regulated, and targeted knockdown of P-gp and BCRP could partially reverse GAS1 suppression-induced epirubicin resistance.	Epirubicin	188-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-64
19000447-12	2008	The inhibition rates of 5-fluorouracil (5-FU), VCR, epirubicin (EADM) and OXA on cancer cells were lower in the group with strong expression of bcl-2 than in that with weak expression of bcl-2 (P&lt;0.05).	Epirubicin	52-62	BCL2 apoptosis regulator	Homo sapiens	144-149
19218307-0	2009	Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.	Epirubicin	30-40	colony stimulating factor 3	Homo sapiens	57-62
19480561-1	2009	Immunoconjugates of epirubicin were synthesized with monoclonal antibodies against the epidermal growth factor receptors, HER2/neu and EGFR, by creating a sulfhydryl-reactive epirubicin intermediate applying heterobifunctional succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), which was introduced at alpha-monoamide groups of the epirubicin carbohydrate moiety.	Epirubicin	20-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-130
19480561-1	2009	Immunoconjugates of epirubicin were synthesized with monoclonal antibodies against the epidermal growth factor receptors, HER2/neu and EGFR, by creating a sulfhydryl-reactive epirubicin intermediate applying heterobifunctional succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), which was introduced at alpha-monoamide groups of the epirubicin carbohydrate moiety.	Epirubicin	20-30	epidermal growth factor receptor	Homo sapiens	135-139
19480561-4	2009	Epirubicin-(anti-HER2/neu) and epirubicin-(anti-EGFR) had greater potency against chemotherapeutic-resistant SKBr-3 mammary carcinoma than did epirubicin at epirubicin-equivalent concentrations.	Epirubicin	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-25
19480561-4	2009	Epirubicin-(anti-HER2/neu) and epirubicin-(anti-EGFR) had greater potency against chemotherapeutic-resistant SKBr-3 mammary carcinoma than did epirubicin at epirubicin-equivalent concentrations.	Epirubicin	31-41	epidermal growth factor receptor	Homo sapiens	48-52
19480561-5	2009	Epirubicin-(anti-HER2/neu) was more potent than epirubicin-(anti-EGFR), and a synergistic level of antineoplastic activity was detected with an epirubicin immunoconjugate 50/50 combination.	Epirubicin	48-58	epidermal growth factor receptor	Homo sapiens	65-69
19480561-5	2009	Epirubicin-(anti-HER2/neu) was more potent than epirubicin-(anti-EGFR), and a synergistic level of antineoplastic activity was detected with an epirubicin immunoconjugate 50/50 combination.	Epirubicin	144-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-25
19509181-0	2009	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.	Epirubicin	135-145	aldehyde dehydrogenase 1 family member A1	Homo sapiens	54-78
19781349-0	2009	[Study of the relationship between early growth response gene 1 activity in p38 mitogen-activated protein kinase pathway and epirubicin resistance of human breast carcinoma cells].	Epirubicin	125-135	early growth response 1	Homo sapiens	35-63
19781349-0	2009	[Study of the relationship between early growth response gene 1 activity in p38 mitogen-activated protein kinase pathway and epirubicin resistance of human breast carcinoma cells].	Epirubicin	125-135	mitogen-activated protein kinase 14	Homo sapiens	76-79
19781349-1	2009	OBJECTIVE: To investigate the relationship between activities of early growth response gene 1 (EGR-1) of p38 mitogen-activated protein kinase (MAPK) pathway and in the epirubicin resistance of breast carcinoma cells.	Epirubicin	168-178	early growth response 1	Homo sapiens	65-93
19781349-1	2009	OBJECTIVE: To investigate the relationship between activities of early growth response gene 1 (EGR-1) of p38 mitogen-activated protein kinase (MAPK) pathway and in the epirubicin resistance of breast carcinoma cells.	Epirubicin	168-178	early growth response 1	Homo sapiens	95-100
19781349-1	2009	OBJECTIVE: To investigate the relationship between activities of early growth response gene 1 (EGR-1) of p38 mitogen-activated protein kinase (MAPK) pathway and in the epirubicin resistance of breast carcinoma cells.	Epirubicin	168-178	mitogen-activated protein kinase 14	Homo sapiens	105-108
19781349-18	2009	The activation of EGR-1 mediated by p38MAPK pathway plays a critical role in epirubicin resistance.	Epirubicin	77-87	early growth response 1	Homo sapiens	18-23
19288008-5	2009	We compared the different sensitivity to epirubicin in RT112 and MGH-U1 cell lines with different Id-1 expression.	Epirubicin	41-51	inhibitor of DNA binding 1, HLH protein	Homo sapiens	98-102
19288008-7	2009	The results of cell viability assay showed up-regulation of Id-1 in RT112 leading to increased sensitivity in response to epirubicin, and down-regulation of Id-1 increased cellular sensitivity to epirubicin.	Epirubicin	122-132	inhibitor of DNA binding 1, HLH protein	Homo sapiens	60-64
19288008-7	2009	The results of cell viability assay showed up-regulation of Id-1 in RT112 leading to increased sensitivity in response to epirubicin, and down-regulation of Id-1 increased cellular sensitivity to epirubicin.	Epirubicin	196-206	inhibitor of DNA binding 1, HLH protein	Homo sapiens	157-161
19288008-8	2009	Furthermore, the analysis of apoptosis related protein revealed that up-regulation of Id-1 suppressed epirubicin-induced apoptosis and down-regulation of Id-1 leading to increased epirubicin-induced apoptosis.	Epirubicin	102-112	inhibitor of DNA binding 1, HLH protein	Homo sapiens	86-90
19288008-8	2009	Furthermore, the analysis of apoptosis related protein revealed that up-regulation of Id-1 suppressed epirubicin-induced apoptosis and down-regulation of Id-1 leading to increased epirubicin-induced apoptosis.	Epirubicin	180-190	inhibitor of DNA binding 1, HLH protein	Homo sapiens	86-90
19288008-8	2009	Furthermore, the analysis of apoptosis related protein revealed that up-regulation of Id-1 suppressed epirubicin-induced apoptosis and down-regulation of Id-1 leading to increased epirubicin-induced apoptosis.	Epirubicin	180-190	inhibitor of DNA binding 1, HLH protein	Homo sapiens	154-158
19288008-10	2009	Our results suggest that up-regulation of Id-1 in bladder cancer cells lead to increased cell viability in response to epirubicin by its improved anti-apoptotic role, and down-regulation of Id-1 increases cellular sensitivity to epirubicin by increased anticancer drug-induced apoptosis.	Epirubicin	119-129	inhibitor of DNA binding 1, HLH protein	Homo sapiens	42-46
19288008-10	2009	Our results suggest that up-regulation of Id-1 in bladder cancer cells lead to increased cell viability in response to epirubicin by its improved anti-apoptotic role, and down-regulation of Id-1 increases cellular sensitivity to epirubicin by increased anticancer drug-induced apoptosis.	Epirubicin	229-239	inhibitor of DNA binding 1, HLH protein	Homo sapiens	190-194
18806833-0	2009	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.	Epirubicin	102-112	erythropoietin	Homo sapiens	0-3
18806833-0	2009	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.	Epirubicin	102-112	colony stimulating factor 3	Homo sapiens	24-29
19535243-12	2009	CONCLUSION: Lack of TIMP-1 tumour cell immunoreactivity seems to predict a favourable effect of epirubicin-containing adjuvant therapy in primary breast cancer.	Epirubicin	96-106	TIMP metallopeptidase inhibitor 1	Homo sapiens	20-26
19542717-1	2009	Many patients complain of venous pain or develop phlebitis following treatment with epirubicin hydrochloride(EPI).	Epirubicin	84-108	tissue factor pathway inhibitor	Homo sapiens	109-112
19429229-0	2009	Elevated serum soluble Fas ligand is a promising marker of testicular toxicity induced by epirubicin in rats.	Epirubicin	90-100	Fas ligand	Rattus norvegicus	23-33
19429229-1	2009	To investigate the role of the Fas/Fas ligand (Fas/FasL) system in testicular toxicity induced by epirubicin (Epi) and to correlate the system with the serum levels of soluble Fas and Fas ligand (sFas/sFasL), epirubicin was intraperitoneally administered to male Sprague-Dawley male rats at doses of 1.2mg/kg once a week for 10 weeks, and genital organ weights and histopathology were examined.	Epirubicin	98-108	Fas ligand	Rattus norvegicus	51-55
19622290-9	2009	CONCLUSION: High expression of MDR1, MRP1, ABCG2 proteins in gastric cancer is related with the resistance to epirubicin, which indicates that these MDR genes may play a role in conferring the drug resistance to epirubicin.	Epirubicin	110-120	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
19622290-9	2009	CONCLUSION: High expression of MDR1, MRP1, ABCG2 proteins in gastric cancer is related with the resistance to epirubicin, which indicates that these MDR genes may play a role in conferring the drug resistance to epirubicin.	Epirubicin	110-120	ATP binding cassette subfamily C member 1	Homo sapiens	37-41
19622290-9	2009	CONCLUSION: High expression of MDR1, MRP1, ABCG2 proteins in gastric cancer is related with the resistance to epirubicin, which indicates that these MDR genes may play a role in conferring the drug resistance to epirubicin.	Epirubicin	110-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-48
19622290-9	2009	CONCLUSION: High expression of MDR1, MRP1, ABCG2 proteins in gastric cancer is related with the resistance to epirubicin, which indicates that these MDR genes may play a role in conferring the drug resistance to epirubicin.	Epirubicin	212-222	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
19622290-9	2009	CONCLUSION: High expression of MDR1, MRP1, ABCG2 proteins in gastric cancer is related with the resistance to epirubicin, which indicates that these MDR genes may play a role in conferring the drug resistance to epirubicin.	Epirubicin	212-222	ATP binding cassette subfamily C member 1	Homo sapiens	37-41
19622290-9	2009	CONCLUSION: High expression of MDR1, MRP1, ABCG2 proteins in gastric cancer is related with the resistance to epirubicin, which indicates that these MDR genes may play a role in conferring the drug resistance to epirubicin.	Epirubicin	212-222	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-48
19187077-6	2009	RESULTS: Exposure of defibrinated plasma to either doxorubicin- or epirubicin-treated HUVECs resulted in an increase in plasma thrombin generation.	Epirubicin	67-77	coagulation factor II, thrombin	Homo sapiens	127-135
19187077-7	2009	The procoagulant activity of doxorubicin- and epirubicin-treated HUVECs reflects an increase in tissue factor activity and phosphatidylserine exposure.	Epirubicin	46-56	coagulation factor III, tissue factor	Homo sapiens	96-109
17707098-9	2008	Epirubicin leads to a significant upregulation of stroke volume and cardiac output, which is even more pronounced in the high-level NT-pro-BNP group, while liposomal doxorubicin does not change immediate hemodynamics.	Epirubicin	0-10	natriuretic peptide B	Homo sapiens	139-142
18824363-0	2008	Synergistic interaction between p-glycoprotein modulators and epirubicine on resistant cancer cells.	Epirubicin	62-73	ATP binding cassette subfamily B member 1	Homo sapiens	32-46
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	MDM4 regulator of p53	Homo sapiens	89-118
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	ATP binding cassette subfamily C member 2	Homo sapiens	124-128
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	BCL2 apoptosis regulator	Homo sapiens	204-209
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	BCL2 associated X, apoptosis regulator	Homo sapiens	242-245
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	BCL2 associated X, apoptosis regulator	Homo sapiens	279-282
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	BCL2 apoptosis regulator	Homo sapiens	286-291
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	tumor protein p53	Homo sapiens	321-324
18606222-5	2008	GC and epirubicin significantly reduced mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulated the MDR1 promoter region; suppressed the mRNA expression of Bcl-2; induced the mRNA expression of Bax; and significantly increased the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3.	Epirubicin	7-17	caspase 9	Homo sapiens	326-342
18064460-2	2008	PATIENTS AND METHODS: We investigated in patients with T2-T3 N0-3 ER, PgR &lt;10% and HER2 negative breast cancers the activity both in terms of pathological (pCR) and objective responses of four courses of cisplatin containing chemotherapy (ECF, epirubicin, cisplatin, and fluorouracil as continuous infusion) followed by three courses of weekly paclitaxel.	Epirubicin	247-257	progesterone receptor	Homo sapiens	70-73
18725978-0	2008	CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.	Epirubicin	134-144	checkpoint kinase 2	Homo sapiens	0-5
18725978-0	2008	CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.	Epirubicin	134-144	tumor protein p53	Homo sapiens	69-73
18665163-0	2008	tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.	Epirubicin	77-87	MIA SH3 domain ER export factor 3	Homo sapiens	0-5
18665163-1	2008	tAnGo is a large randomised trial assessing the addition of gemcitabine(G) to paclitaxel(T), following epirubicin(E) and cyclophosphamide(C) in women with invasive higher risk early breast cancer.	Epirubicin	103-113	MIA SH3 domain ER export factor 3	Homo sapiens	0-5
18280644-0	2008	Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.	Epirubicin	100-110	BRCA1 DNA repair associated	Homo sapiens	35-40
18636193-5	2008	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay indicated that overexpression of S100P sensitized OVCAR3 cells for chemotherapeutic drugs (paclitaxel, oxaliplatin, 5-fluorouracil, etoposide and epirubicin) induced cytotoxicity more than vector-only controls.	Epirubicin	211-221	S100 calcium binding protein P	Homo sapiens	98-103
18676329-3	2008	Anthracyclines (daunorubicin, doxorubicin, and epirubicin), mitomycin, and monoclonal antibodies such as trastuzumab have been associated with cardiotoxicities, but other chemotherapeutic agents, such as fluorouracil, cyclophosphamide, interferons, and interleukin-2 and other targeted agents, also can cause this side effect.	Epirubicin	47-57	interleukin 2	Homo sapiens	253-266
18511948-4	2008	Consistently, response to epirubicin was impaired in NQO1(*)2-homozygous breast carcinoma cells in vitro, reflecting both p53-linked and p53-independent roles of NQO1.	Epirubicin	26-36	NAD(P)H quinone dehydrogenase 1	Homo sapiens	53-57
18511948-4	2008	Consistently, response to epirubicin was impaired in NQO1(*)2-homozygous breast carcinoma cells in vitro, reflecting both p53-linked and p53-independent roles of NQO1.	Epirubicin	26-36	tumor protein p53	Homo sapiens	122-125
18511948-4	2008	Consistently, response to epirubicin was impaired in NQO1(*)2-homozygous breast carcinoma cells in vitro, reflecting both p53-linked and p53-independent roles of NQO1.	Epirubicin	26-36	tumor protein p53	Homo sapiens	137-140
18511948-4	2008	Consistently, response to epirubicin was impaired in NQO1(*)2-homozygous breast carcinoma cells in vitro, reflecting both p53-linked and p53-independent roles of NQO1.	Epirubicin	26-36	NAD(P)H quinone dehydrogenase 1	Homo sapiens	162-166
19024543-0	2008	[RNAi-mediated gene silencing of livin synergistic with epirubicin enhance apoptosis of human breast cancer cells].	Epirubicin	56-66	baculoviral IAP repeat containing 7	Homo sapiens	33-38
19024543-5	2008	ZR-75-30 cells transfected with dsRNA targeting livin for 24 h were treated with 50 microg/ml epirubicin for 12 h, flow cytometry was used to detect the apoptosis rate of the cells.	Epirubicin	94-104	baculoviral IAP repeat containing 7	Homo sapiens	48-53
19024543-8	2008	36 h after the treatment of siRNA against livin combined with epirubicin the apoptosis rate was (15.18 +/- 0.05)%, significantly higher than those of the negative control group and blank control group [(2.78 +/- 0.08)% and (2.65 +/- 0.12)% respectively, both P &lt; 0.01].	Epirubicin	62-72	baculoviral IAP repeat containing 7	Homo sapiens	42-47
19024543-9	2008	CONCLUSIONS: Sequence specific siRNA targeting livin synergistic with epirubicin is capable of enhancing the apoptosis rate of human breast cancer cells.	Epirubicin	70-80	baculoviral IAP repeat containing 7	Homo sapiens	47-52
18280644-1	2008	Epirubicin exerts its anti-tumor effect through binding to topoisomerase IIalpha (TOP2A) and inducing DNA double-strand breaks.	Epirubicin	0-10	DNA topoisomerase II alpha	Homo sapiens	82-87
18280644-6	2008	The TOP2A-positive and BRCA1-negative phenotype associates with a favorable response to epirubicin-based regimens.	Epirubicin	88-98	DNA topoisomerase II alpha	Homo sapiens	4-9
18280644-6	2008	The TOP2A-positive and BRCA1-negative phenotype associates with a favorable response to epirubicin-based regimens.	Epirubicin	88-98	BRCA1 DNA repair associated	Homo sapiens	23-28
18461567-2	2008	The simultaneous determination of the anthracyclines, daunorubicin, doxorubicin and epirubicin, was achieved using CE coupled to LIF, with an excitation and emission wavelength of 488 and 560 nm, respectively.	Epirubicin	84-94	LIF interleukin 6 family cytokine	Homo sapiens	129-132
17604344-1	2008	Epirubicin, an antineoplastic drug, is considered to be taken up by tumor cells via a common carrier by facilitated diffusion and is then pumped out in an energy-dependent manner because epirubicin is a substrate for P-glycoprotein (P-gp).	Epirubicin	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	217-231
17604344-1	2008	Epirubicin, an antineoplastic drug, is considered to be taken up by tumor cells via a common carrier by facilitated diffusion and is then pumped out in an energy-dependent manner because epirubicin is a substrate for P-glycoprotein (P-gp).	Epirubicin	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	233-237
17604344-1	2008	Epirubicin, an antineoplastic drug, is considered to be taken up by tumor cells via a common carrier by facilitated diffusion and is then pumped out in an energy-dependent manner because epirubicin is a substrate for P-glycoprotein (P-gp).	Epirubicin	187-197	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	217-231
17604344-1	2008	Epirubicin, an antineoplastic drug, is considered to be taken up by tumor cells via a common carrier by facilitated diffusion and is then pumped out in an energy-dependent manner because epirubicin is a substrate for P-glycoprotein (P-gp).	Epirubicin	187-197	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	233-237
18078328-4	2008	After treatment with SM, coexpression of HER2 and topoisomerase IIalpha (TOP2A) H661 and H69 cells is more sensitive to the TOP2 inhibitor, epirubicin.	Epirubicin	140-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	41-71
18078328-4	2008	After treatment with SM, coexpression of HER2 and topoisomerase IIalpha (TOP2A) H661 and H69 cells is more sensitive to the TOP2 inhibitor, epirubicin.	Epirubicin	140-150	DNA topoisomerase II alpha	Homo sapiens	73-78
18078328-8	2008	The data presented herein suggest that the expression of HER2 did not influence the SM-induced apoptosis of different types of lung cancer cells and that the SM up-regulation of HER2 and TOP2A expressions simultaneously augmented trastuzumab and epirubicin-induced deaths of lung cancer H661 and H69 cells.	Epirubicin	246-256	erb-b2 receptor tyrosine kinase 2	Homo sapiens	178-182
18078328-8	2008	The data presented herein suggest that the expression of HER2 did not influence the SM-induced apoptosis of different types of lung cancer cells and that the SM up-regulation of HER2 and TOP2A expressions simultaneously augmented trastuzumab and epirubicin-induced deaths of lung cancer H661 and H69 cells.	Epirubicin	246-256	DNA topoisomerase II alpha	Homo sapiens	187-192
18758179-2	2008	To develop a combination of epirubicin (EPI) and docetaxel (DTX) in Japan, dose escalation and pharmacokinetic studies were performed in patients with advanced or recurrent breast cancer.	Epirubicin	28-38	tissue factor pathway inhibitor	Homo sapiens	40-43
18270380-0	2008	High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.	Epirubicin	145-155	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-42
18270380-9	2008	CONCLUSION: PST with weekly docetaxel and epirubicin were well-tolerated and very high pathological complete response rate was achieved in HER-2/neu-overexpression tumors.	Epirubicin	42-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	145-148
18465341-1	2008	BACKGROUND: Previous analyses of TOP2A and HER2 in the Danish Breast Cancer Coopererative Group (DBCG) trial 89D suggested that TOP2A amplifications and possible also deletions are predictive markers for the effect of adjuvant epirubicin in patients with primary breast cancer.	Epirubicin	227-237	DNA topoisomerase II alpha	Homo sapiens	128-133
18465341-12	2008	CONCLUSION: In conclusion, this updated analysis of TOP2A aberrations in DBCG trial 89D suggests a differential benefit of adjuvant chemotherapy in patients with primary breast cancer, favoring treatment with epirubicin in patients with TOP2A amplifications, and perhaps deletions.	Epirubicin	209-219	DNA topoisomerase II alpha	Homo sapiens	52-57
18465341-12	2008	CONCLUSION: In conclusion, this updated analysis of TOP2A aberrations in DBCG trial 89D suggests a differential benefit of adjuvant chemotherapy in patients with primary breast cancer, favoring treatment with epirubicin in patients with TOP2A amplifications, and perhaps deletions.	Epirubicin	209-219	DNA topoisomerase II alpha	Homo sapiens	237-242
17876337-1	2007	In advanced breast cancers, TP53 mutation is highly predictive of complete response to high-dose epirubicin/cyclophosphamide chemotherapy.	Epirubicin	97-107	tumor protein p53	Homo sapiens	28-32
17938864-0	2008	RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells.	Epirubicin	136-146	vascular endothelial growth factor C	Homo sapiens	33-69
17938864-0	2008	RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells.	Epirubicin	136-146	vascular endothelial growth factor C	Homo sapiens	71-77
18064393-0	2007	Knockdown of S-phase kinase-associated protein-2 expression in MCF-7 inhibits cell growth and enhances the cytotoxic effects of epirubicin.	Epirubicin	128-138	S-phase kinase associated protein 2	Homo sapiens	13-48
18064393-9	2007	Treatment with Skp2 siRNA followed by treatment with epirubicin further inhibited the proliferation of cancer cell lines, compared with control siRNA followed by epirubicin.	Epirubicin	162-172	S-phase kinase associated protein 2	Homo sapiens	15-19
18064393-10	2007	Therefore, knockdown of Skp2 expression by RNAi inhibits breast cancer cell growth and enhances the effect of epirubicin.	Epirubicin	110-120	S-phase kinase associated protein 2	Homo sapiens	24-28
18465341-1	2008	BACKGROUND: Previous analyses of TOP2A and HER2 in the Danish Breast Cancer Coopererative Group (DBCG) trial 89D suggested that TOP2A amplifications and possible also deletions are predictive markers for the effect of adjuvant epirubicin in patients with primary breast cancer.	Epirubicin	227-237	DNA topoisomerase II alpha	Homo sapiens	33-38
17297610-0	2007	Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.	Epirubicin	55-65	large tumor suppressor kinase 2	Homo sapiens	4-9
17716984-8	2007	CONCLUSION: A dose-intense and dose-dense regimen of cyclophosphamide, epirubicin and 5-fluorouracil was delivered with G-CSF without apparent increase in acute toxicity.	Epirubicin	71-81	colony stimulating factor 3	Homo sapiens	120-125
17914082-10	2007	Significant correlations between the reduction in the SR peak (deltaSR) after 200 mg/m2 of epirubicin and the increase in IL-6 and ROS and decrease in GPx were observed.	Epirubicin	91-101	interleukin 6	Homo sapiens	122-126
17297610-2	2007	This study investigated possible correlations of intra-tumoral LATS1 and LATS2 mRNA levels with response to epirubicin plus cyclophosphamide (EC) or docetaxel (DOC) treatment.	Epirubicin	108-118	large tumor suppressor kinase 2	Homo sapiens	73-78
17639997-7	2007	Therefore, the downregulation of the HER2 and TOP2A expression by SM with epirubicin may partially explain the SM and epirubicin cytotoxicity synergy effect in NSCLC.	Epirubicin	74-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
17639997-7	2007	Therefore, the downregulation of the HER2 and TOP2A expression by SM with epirubicin may partially explain the SM and epirubicin cytotoxicity synergy effect in NSCLC.	Epirubicin	74-84	DNA topoisomerase II alpha	Homo sapiens	46-51
17639997-7	2007	Therefore, the downregulation of the HER2 and TOP2A expression by SM with epirubicin may partially explain the SM and epirubicin cytotoxicity synergy effect in NSCLC.	Epirubicin	118-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
17639997-7	2007	Therefore, the downregulation of the HER2 and TOP2A expression by SM with epirubicin may partially explain the SM and epirubicin cytotoxicity synergy effect in NSCLC.	Epirubicin	118-128	DNA topoisomerase II alpha	Homo sapiens	46-51
17589945-3	2007	TAE was performed with Lipiodol followed by Gelfoam embolization; TACE was performed with Farmorubicin prepared in sterile drip at a dose of 50 mg/m(2), infused over 30 min using a peristaltic pump, and followed by Lipiodol and Gelfoam embolization.	Epirubicin	90-102	ADAM metallopeptidase domain 17	Homo sapiens	66-70
17611656-7	2007	Up-regulation of LFA-3 and ICAM-1 was also observed in ACHN cells treated with two derivatives of ADR, epirubicin and pirarubicin.	Epirubicin	103-113	CD58 molecule	Homo sapiens	17-22
17611656-7	2007	Up-regulation of LFA-3 and ICAM-1 was also observed in ACHN cells treated with two derivatives of ADR, epirubicin and pirarubicin.	Epirubicin	103-113	intercellular adhesion molecule 1	Homo sapiens	27-33
17388661-0	2007	Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.	Epirubicin	78-88	tumor protein p53	Homo sapiens	25-29
17545523-6	2007	CK18 levels were determined in serum from 61 breast cancer patients during docetaxel or cyclophosphamide/epirubicin/5-fluorouracil (CEF) therapy.	Epirubicin	105-115	keratin 18	Homo sapiens	0-4
17198756-1	2007	We have shown that low doses of medroxyprogesterone acetate (MPA- 2.6 microM) and tamoxifen (TAM- 270 nM) could augment the effectiveness of epirubicin in breast tumor cells.	Epirubicin	141-151	guanylate binding protein 4	Mus musculus	61-67
17342096-3	2007	Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC).	Epirubicin	83-93	teratocarcinoma-derived growth factor 1	Homo sapiens	0-6
17342096-3	2007	Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC).	Epirubicin	83-93	ATP binding cassette subfamily B member 1	Homo sapiens	68-71
17342096-3	2007	Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC).	Epirubicin	95-98	teratocarcinoma-derived growth factor 1	Homo sapiens	0-6
17342096-3	2007	Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC).	Epirubicin	95-98	ATP binding cassette subfamily B member 1	Homo sapiens	68-71
17436599-3	2007	These MDR inhibitor compounds and epirubicin were demonstrated to have additive and synergistic antiproliferative effects in checkerboard experiments on human MDR1 gene-transfected mouse lymphoma cells in vitro.	Epirubicin	34-44	ATP binding cassette subfamily B member 1	Homo sapiens	159-163
17762397-15	2007	In untreated metastatic breast cancer patients, the weekly administration of epirubicin and paclitaxel with granulocyte colony-stimulating factor support seems to be extremely tolerable and active, and deserves further investigation into a phase III trial.	Epirubicin	77-87	colony stimulating factor 3	Homo sapiens	108-145
17465239-6	2007	CONCLUSION: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel.	Epirubicin	100-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
17465239-6	2007	CONCLUSION: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel.	Epirubicin	100-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-20
17388661-16	2007	CONCLUSIONS: This study demonstrates that, in noninflammatory breast cancers, TP53 status is a key predictive factor for response to this dose-dense epirubicin-cyclophosphamide regimen and further suggests that the basal subtype is exquisitely sensitive to this association.	Epirubicin	149-159	tumor protein p53	Homo sapiens	78-82
17453364-2	2007	A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity.	Epirubicin	150-160	colony stimulating factor 3	Homo sapiens	113-118
17324279-0	2007	HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.	Epirubicin	181-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
17324279-13	2007	Clinical response is inversely correlated with a risk of death in patients submitted to neoadjuvant chemotherapy and HER2 overexpression is the major prognostic factor in stage II and III breast cancer patients treated with a neoadjuvant docetaxel and epirubicin combination.	Epirubicin	252-262	erb-b2 receptor tyrosine kinase 2	Homo sapiens	117-121
17283126-4	2007	A proteomics screen identified RPB8 as a protein modified after epirubicin treatment in BRCA1-dependent manner.	Epirubicin	64-74	RNA polymerase II, I and III subunit H	Homo sapiens	31-35
17283126-4	2007	A proteomics screen identified RPB8 as a protein modified after epirubicin treatment in BRCA1-dependent manner.	Epirubicin	64-74	BRCA1 DNA repair associated	Homo sapiens	88-93
17255277-10	2007	Additionally, high levels of HAI-2 were a significant predictor for poor clinical complete response to preoperative epirubicin in univariate (P = 0.01) and multivariate analyses (P = 0.016).	Epirubicin	116-126	serine peptidase inhibitor, Kunitz type 2	Homo sapiens	29-34
17200359-1	2007	PURPOSE: Findings from our previously published phase III randomized trial showed a high pathologic complete remission (CR) rate in patients with human epidermal growth factor receptor 2-positive breast cancer after the concurrent administration of trastuzumab and paclitaxel, followed by concurrent trastuzumab and 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) preoperative chemotherapy.	Epirubicin	332-342	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-186
18086299-0	2007	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.	Epirubicin	116-126	CD40 molecule	Homo sapiens	0-4
18086299-0	2007	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.	Epirubicin	116-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-157
17143548-9	2007	In addition, mPEBP4 overexpression inhibits Epirubicin-induced cellular apoptosis.	Epirubicin	44-54	phosphatidylethanolamine binding protein 4	Mus musculus	13-19
16954440-2	2006	CAIX expression was assessed in 183 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin+tamoxifen as primary systemic treatment.	Epirubicin	143-153	carbonic anhydrase 9	Homo sapiens	0-4
17270637-10	2007	CONCLUSIONS: The results of this study have suggested the feasibility and tolerability of the combination of weekly docetaxel and weekly epirubicin, which led to a rapid and long-lasting decrease in prostate-specific antigen levels and a palliative response in patients with advanced hormone-refractory prostate cancer.	Epirubicin	137-147	kallikrein related peptidase 3	Homo sapiens	199-224
16965675-3	2006	This study was to investigate the possibility of using troglitazone, one of TZD, as the sensitizer of epirubicin in the treatment of estrogen receptor (ER) negative breast cancer.	Epirubicin	102-112	estrogen receptor 1	Homo sapiens	133-150
16965675-3	2006	This study was to investigate the possibility of using troglitazone, one of TZD, as the sensitizer of epirubicin in the treatment of estrogen receptor (ER) negative breast cancer.	Epirubicin	102-112	estrogen receptor 1	Homo sapiens	152-154
16965675-12	2006	Co-treatment with troglitazone and epirubicin further downregulated the expression level of Bcl-2 and inhibited cell migration simultaneously.	Epirubicin	35-45	BCL2 apoptosis regulator	Homo sapiens	92-97
16985101-2	2006	An important pathway for epirubicin detoxification is UGT2B7-dependent glucuronidation.	Epirubicin	25-35	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	54-60
16954440-0	2006	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.	Epirubicin	94-104	carbonic anhydrase 9	Homo sapiens	8-29
16954440-1	2006	The purpose of this study is to investigate the role of carbonic anhydrase IX (CAIX) expression in predicting the response to epirubicin and disease-free survival (DFS) in breast cancer patients enrolled in a single institution trial of primary anthracycline and tamoxifen therapy.	Epirubicin	126-136	carbonic anhydrase 9	Homo sapiens	56-77
16954440-1	2006	The purpose of this study is to investigate the role of carbonic anhydrase IX (CAIX) expression in predicting the response to epirubicin and disease-free survival (DFS) in breast cancer patients enrolled in a single institution trial of primary anthracycline and tamoxifen therapy.	Epirubicin	126-136	carbonic anhydrase 9	Homo sapiens	79-83
16781665-0	2006	Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo.	Epirubicin	56-66	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-33
16954440-2	2006	CAIX expression was assessed in 183 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin+tamoxifen as primary systemic treatment.	Epirubicin	161-171	carbonic anhydrase 9	Homo sapiens	0-4
16899602-1	2006	PURPOSE: To investigate the relationship of hypoxia-inducible factor-1alpha (HIF-1alpha) tumor expression in predicting the response to epirubicin and disease-free survival (DFS) in patients with breast cancer enrolled in a single institution trial of primary anthracycline and tamoxifen therapy.	Epirubicin	136-146	hypoxia inducible factor 1 subunit alpha	Homo sapiens	44-75
16899602-2	2006	EXPERIMENTAL DESIGN: The expression of HIF-1alpha was assessed by immunohistochemistry in 187 patients with T(2-4) N(0-1) breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin + tamoxifen as primary systemic treatment.	Epirubicin	205-215	hypoxia inducible factor 1 subunit alpha	Homo sapiens	39-49
16899602-2	2006	EXPERIMENTAL DESIGN: The expression of HIF-1alpha was assessed by immunohistochemistry in 187 patients with T(2-4) N(0-1) breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin + tamoxifen as primary systemic treatment.	Epirubicin	223-233	hypoxia inducible factor 1 subunit alpha	Homo sapiens	39-49